



# **Ethylene Oxide Carcinogenic Dose-Response Assessment**

**CAS Registry Number: 75-21-8**

Prepared by  
Joseph T. Haney, Jr., M.S.  
Allison Jenkins, M.P.H.  
Jessica L. Myers, PhD  
Toxicology, Risk Assessment, and Research Division

**Development Support Document**

**Proposed, June 28, 2019**

TEXAS COMMISSION ON ENVIRONMENTAL QUALITY

## DSD History

Effective Date	Reason
August 16, 2017	Public request for toxicity information
June 28, 2019	DSD proposed for public comment
To be determined, 2019	DSD posted as final

## TABLE OF CONTENTS

DSD HISTORY.....	I
TABLE OF CONTENTS .....	II
LIST OF TABLES .....	III
LIST OF FIGURES .....	V
ACRONYMS AND ABBREVIATIONS .....	VII
CHAPTER 1 KEY FINDINGS, EXECUTIVE SUMMARY, AND SUMMARY TABLES.....	1
EXECUTIVE SUMMARY.....	1
SUMMARY OF KEY POINTS.....	4
CHAPTER 2 MAJOR SOURCES AND USES.....	10
CHAPTER 3 CARCINOGENIC POTENTIAL.....	11
3.1 CARCINOGENIC WEIGHT OF EVIDENCE (WOE).....	11
3.2 RELEVANT DATA.....	11
3.2.1 <i>Epidemiological Studies</i> .....	11
3.2.1.1 NIOSH Cohort.....	11
3.2.1.2 UCC Cohort.....	13
3.2.2 <i>Animal Studies</i> .....	15
3.3 MODE OF ACTION (MOA) AND CARCINOGENIC CLASSIFICATION.....	15
3.3.1 <i>MOA</i> .....	15
3.3.2 <i>Carcinogenic Classification</i> .....	17
3.4 CARCINOGENIC DOSE-RESPONSE ASSESSMENT.....	18
3.4.1 <i>Low-Dose Extrapolation Approach</i> .....	19
3.4.1.1 Consideration of MOA.....	20
3.4.1.2 Consideration of Endogenous Levels, Key Epidemiological Data, and Model Predictions.....	23
3.4.1.2.1 Endogenous Levels .....	23
3.4.1.2.2 Key Epidemiological Data with Additional Context Using Endogenous Data and Model Predictions.....	26
3.4.1.2.2.1 Key Data from the UCC Cohort .....	27
3.4.1.2.2.2 Key Data from the NIOSH Cohort and Endogenous Data .....	27
3.4.1.2.2.3 Lymphoid Cancer in the NIOSH Cohort - Model Predictions Versus Observed.....	41
3.4.1.2.2.4 Implications of Key Epidemiological Findings, Endogenous Data, and Model Predictions for Use of USEPA's Selected Linear Two-Piece Spline Model Assessment and URF.....	47
3.4.1.3 Consideration of Model Fit Criteria.....	48
3.4.1.4 Selection of the Extrapolation Model .....	51
3.4.1.4.1 Conclusions on Use of USEPA's Linear Two-Piece Spline Model.....	51
3.4.1.4.2 Conclusions on Use of an Alternative Model.....	54
3.4.1.5 Relevant Cox Proportional Hazards Model Results .....	55
3.4.1.5.1 Parameter Estimates .....	57
3.4.1.5.1.1 Lymphoid Cancer .....	57
3.4.1.5.1.2 Breast Cancer.....	60
3.4.1.5.2 Risk-Based Air Concentrations and URFs .....	61
3.4.1.5.2.1 Lymphoid Cancer .....	61
3.4.1.5.2.2 Breast Cancer.....	64

3.4.1.6 Selection of Critical Cancer Endpoint and Final URF .....	65
3.4.1.6.1 Critical Cancer Endpoint .....	65
3.4.1.6.2 Final URF and Air Concentrations at 1 in 100,000 Excess Risk .....	66
3.4.2 <i>Evaluating Susceptibility from Early-Life Exposures</i> .....	69
3.4.3 <i>Final EtO URF and <sup>chronic</sup>ESL<sub>nonthreshold(c)</sub></i> .....	69
3.5 LONG-TERM ESL AND VALUE FOR AIR MONITORING EVALUATION .....	69
<b>CHAPTER 4 REFERENCES .....</b>	<b>70</b>
<b>APPENDIX 1 SYSTEMATIC REVIEW AND EVIDENCE INTEGRATION .....</b>	<b>77</b>
A1.1 PROBLEM FORMULATION AND PROTOCOL .....	77
A1.2 SYSTEMATIC LITERATURE REVIEW AND STUDY SELECTION .....	78
A1.3 DATA EXTRACTION .....	82
A1.4 STUDY QUALITY AND RISK OF BIAS (ROB) .....	85
A1.5 EVIDENCE INTEGRATION .....	89
A1.6 CONFIDENCE RATING .....	91
<b>APPENDIX 2 ADDITIONAL ANALYSIS OF KIRMAN AND HAYS (2017) DATA .....</b>	<b>95</b>
<b>APPENDIX 3 REALITY CHECK OF EPIDEMIOLOGICAL EXPOSURE-RESPONSE MODEL RESULTS FOR ETO AND LYMPHOID CANCER MORTALITY .....</b>	<b>98</b>
A3.1 PREDICTED VERSUS OBSERVED NUMBER OF LYMPHOID CANCER DEATHS IN THE NIOSH COHORT .....	99
A3.2 PREDICTED VERSUS OBSERVED NUMBER OF LYMPHOID CANCER DEATHS IN THE NIOSH COHORT BY QUINTILES 102	
A3.3 CALCULATION OF THE EXPECTED NUMBER OF CASE-SPECIFIC DEATHS IN A COHORT USING US BACKGROUND HAZARD RATES .....	105
A3.4 CALCULATING THE EXPECTED NUMBER OF CAUSE-SPECIFIC DEATHS IN A COHORT ASSUMING THAT THE DEATH RATE IN THE COHORT INCREASES WITH CUMULATIVE EXPOSURE .....	107
A3.5 REFERENCES .....	108
<b>APPENDIX 4 HYPOTHETICAL EXAMPLE OF APPEARANCE OF SUPRA-LINEARITY IN THE ABSENCE OF TRULY LOW-DOSE DATA .....</b>	<b>118</b>
<b>APPENDIX 5 CORRECTED P-VALUES AND AKAIKE INFORMATION CRITERION (AIC) FOR THE TWO-PIECE SPLINE MODEL AND OTHER MODELS .....</b>	<b>124</b>
A5.1 LYMPHOID CANCER: .....	124
A5.1.1 <i>Corrected p-value example for the log-linear spline model with knot at 1,600 ppm-days...</i>	124
A5.1.2 <i>Corrected AIC value example for the log-linear spline model with knot at 1,600 ppm-days</i>	125
A5.2 BREAST CANCER INCIDENCE .....	127
A5.2.1 <i>Corrected AIC example for the linear spline model with knot at 5,750 ppm-days.....</i>	127
<b>APPENDIX 6 VISUAL FIT TO THE UNDERLYING NIOSH DATA .....</b>	<b>130</b>

## LIST OF TABLES

Table 1: Chronic Health-Based Screening Values for EtO .....	8
Table 2: Chemical and Physical Properties .....	9

Table 3: Carcinogenic Weight of Evidence.....	11
Table 4: Occupational Exposures Corresponding to Normal Background Endogenous Levels of EtO versus Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort (Valdez-Flores et al. 2010) .....	31
Table 5: Occupational Exposures Corresponding to Normal Background Endogenous Levels of EtO versus Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort (Steenland et al. 2004, 2003) .....	33
Table 6: Cancer Endpoint-Specific Environmental EtO Air Concentrations at 1 in 100,000 Excess Risk based on Maximum Likelihood Estimates (MLE) (Valdez-Flores et al. 2010) <sup>a,b,c</sup> .....	56
Table 7: Lymphoid Cell Lineage Tumor Mortality - NIOSH (male + female) - MLE and Standard Error (SE) of the Estimate for Different EtO Exposure Lags .....	57
Table 8: Lymphoid Cell Lineage Tumor Mortality - NIOSH (male only) - MLE and SE of the Estimate for Different EtO Exposure Lags .....	58
Table 9: Lymphoid Cell Lineage Tumor Mortality - UCC/Dow 2013 update (males) - MLE and SE of the Estimate for Different EtO Exposure Lags.....	59
Table 10: Breast Cancer Mortality - NIOSH (females) - MLE and SE of the Estimate for Different EtO Exposure Lags.....	60
Table 11: Breast Cancer Incidence (with interviews) - NIOSH (females) - MLE and SE of the Estimate <sup>a</sup> ....	61
Table 12: Lymphoid Cell Lineage Tumor Mortality - NIOSH (male + female) - MLE and 95% Lower Confidence Limit (95% LCL) of the Environmental EtO Concentration at 1 in 100,000 Excess Risk.....	61
Table 13: Lymphoid Cell Lineage Tumor Mortality - NIOSH (male only) - MLE and 95% LCL of the Environmental EtO Concentration at 1 in 100,000 Excess Risk .....	62
Table 14: Lymphoid Cell Lineage Tumor Mortality - UCC/DOW 2013 Update (males) - MLE and 95% LCL of the Environmental EtO Concentration at 1 in 100,000 Excess Risk.....	62
Table 15: Breast Cancer Incidence (with interviews) - NIOSH (females) - MLE and 95% LCL of the Environmental EtO Concentration at 1 in 100 Excess Risk <sup>a</sup> .....	65
Table 16: Weighting Factors for the Lymphoid Tumor Analyses for the NIOSH and UCC Cohorts .....	67
Table 17: PECO Statement used by the TCEQ to Develop Toxicity Factors for EtO.....	77
Table 18: Search Strings used in the Literature Review of EtO .....	78
Table 19: SWIFT-Review Tags and Results .....	79
Table 20: Available Reviews and Inhalation Toxicity Values for EtO .....	79
Table 21: Inclusion/Exclusion Criteria used in the Review of EtO .....	80
Table 22: Excluded Human Studies Related to Carcinogenicity .....	82
Table 23: Data Extraction from Epidemiological Studies.....	83
Table 24: Study Quality Domains for Epidemiology Studies (taken from HAWC) .....	85
Table 25: Study Quality Domain Scoring.....	87
Table 26: Study Quality Confidence Rating Scoring.....	87
Table 27: Study Quality and ROB Scoring Visual.....	88
Table 28: Evidence Integration Table for Human Studies .....	89
Table 29: Confidence Scoring Criteria for EtO Carcinogenic Assessment.....	92
Table 30: Confidence in the Toxicity Assessment.....	93
Table 31: USEPA's Selected Model Assessment Statistically Significantly Over-Predicts Lymphoid Cancer Mortalities.....	100

Table 32: USEPA's Selected Model Statistically Significantly Over-Predicts Lymphoid Cancer Mortalities for All Cumulative Exposure Groups .....	104
Table 33: Lymphoid Cancer Mortality Rates in the U.S. Population for Each Calendar Year (1930-1972), Each Race, Each Sex and Each Age Group (number of lymphoid cancer deaths per 100,000) .....	109
Table 34: Lymphoid Cancer Mortality Rates in the U.S. Population for Each Calendar Year (1973-1981), Each Race, Each Sex and Each Age Group (number of lymphoid cancer deaths per 100,000) .....	110
Table 35: Lymphoid Cancer Mortality Rates in the U.S. Population for Each Calendar Year (1982-1990), Each Race, Each Sex and Each Age Group (number of lymphoid cancer deaths per 100,000) .....	112
Table 36: Lymphoid Cancer Mortality Rates in the U.S. Population for Each Calendar Year (1991-1999), Each Race, Each Sex and Each Age Group (number of lymphoid cancer deaths per 100,000) .....	114
Table 37: Lymphoid Cancer Mortality Rates in the U.S. Population for Each Calendar Year (2000-2008), Each Race, Each Sex and Each Age Group (number of lymphoid cancer deaths per 100,000) .....	115
Table 38: Corrected USEPA Table 4-6 - Models Considered for Modeling the EtO Exposure-Response Data for Lymphoid Cancer Mortality in Both Sexes in the NIOSH Cohort for the Derivation of Unit Risk Estimates.....	126
Table 39: Corrected USEPA Table 4-14 - Models Considered for Modeling the EtO Exposure-Response Data for Breast Cancer Incidence in Females in the Subcohort with Interviews from the NIOSH and Health Incidence Study Cohort for the Derivation of Unit Risk Estimates .....	128

## LIST OF FIGURES

Figure 1: Dose-Response Curve Examples .....	19
Figure 2: Occupational Exposures Corresponding to Normal Background Endogenous Levels of EtO versus Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort - Linear Scale.....	35
Figure 3: Occupational Exposures Corresponding to Normal Background Endogenous Levels of EtO versus Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort - Log Scale.....	36
Figure 4: Occupational Exposures Corresponding to USEPA Risk-Based Doses and Normal Background Endogenous Levels of EtO versus Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort - Log Scale .....	37
Figure 5: Occupational Exposures Corresponding to Normal Background Endogenous Levels of EtO versus Lagged Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort - Linear Scale .....	38
Figure 6: Occupational Exposures Corresponding to Normal Background Endogenous Levels of EtO versus Lagged Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort - Log Scale.....	39
Figure 7: Occupational Exposures Corresponding to USEPA Risk-Based Doses and Normal Background Endogenous Levels of EtO versus Lagged Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort - Log Scale .....	40
Figure 8: Statistically Significant Over-Prediction of Lymphoid Cancer Mortalities from EtO Exposure by the USEPA (2016) Selected Model Assessment (upper bound of linear two-piece spline) for the NIOSH Cohort versus Reasonably Accurate Results from the TCEQ Selected Model (upper bound Cox proportional hazards) .....	42

Figure 9: Statistically Significant Over-Prediction of Lymphoid Cancer Mortalities from EtO Exposure by the USEPA (2016) Selected Model Assessment (upper bound of linear two-piece spline) for the NIOSH Cohort versus Reasonably Accurate Results from the TCEQ Selected Model (upper bound Cox proportional hazards) - Quintile 2 .....	43
Figure 10: Statistically Significant Over-Prediction of Lymphoid Cancer Mortalities from EtO Exposure by the USEPA (2016) Selected Model Assessment (upper bound of linear two-piece spline) for the NIOSH Cohort versus Reasonably Accurate Results from the TCEQ Selected Model (upper bound Cox proportional hazards) - Quintile 3 .....	44
Figure 11: Statistically Significant Over-Prediction of Lymphoid Cancer Mortalities from EtO Exposure by the USEPA (2016) Selected Model Assessment (upper bound of linear two-piece spline) for the NIOSH Cohort versus Reasonably Accurate Results from the TCEQ Selected Model (upper bound Cox proportional hazards) - Quintile 4 .....	45
Figure 12: Statistically Significant Over-Prediction of Lymphoid Cancer Mortalities from EtO Exposure by the USEPA (2016) Selected Model Assessment (upper bound of linear two-piece spline) for the NIOSH Cohort versus Reasonably Accurate Results from the TCEQ Selected Model (upper bound Cox proportional hazards) - Quintile 5 .....	46
Figure 13: USEPA's Selected Model Statistically Significantly Over-Predicts Lymphoid Cancer Mortalities .....	102
Figure 14: Seemingly Supra-linear Dose-Response for Lymphoid Cancer .....	118
Figure 15: Hypothetical Sublinear Dose-Response at Truly Low Doses Plotted with Available High-Dose Data for Lymphoid Cancer .....	119
Figure 16: Hypothetical Sublinear Dose-Response at Truly Low Doses Plotted with Available High-Dose Data for Lymphoid Cancer – Expanded Low-Dose View .....	120
Figure 17: Seemingly Supra-linear Dose-Response from Removal of Hypothetical Low-Dose Data for Lymphoid Cancer .....	121
Figure 18: Seemingly Supra-linear Dose-Response from Removal of Hypothetical Low-Dose Data .....	122
Figure 19: USEPA (2016) Figure 4-3 .....	130
Figure 20: Lymphoid Cancer Death Categorical Rate Ratios (RRs) and Various Fitted Models for 15-Year Lagged Occupational Doses $\leq 150,000$ ppm $\times$ days (NIOSH cohort) .....	132
Figure 21: Lymphoid Cancer Death Categorical RRs and Various Fitted Models for 15-Year Lagged Occupational Doses $\leq 40,000$ ppm $\times$ days (NIOSH cohort) .....	132
Figure 22: Lymphoid Cancer Death Categorical RRs and the Cox Proportional Hazards and Two-Piece Spline ("knot" at 1,600 ppm $\times$ days) Fitted Models for 15-Year Lagged Occupational Doses $\leq 150,000$ ppm $\times$ days (NIOSH cohort) .....	133

## Acronyms and Abbreviations

Acronyms and Abbreviations	Definitions
AMCV	air monitoring comparison value
°C	degrees Celsius
CES	critical effect size
DNA	deoxyribonucleic acid
DSD	development support document
ESL	effects screening level
<sup>chronic</sup> ESL <sub>nonthreshold(c)</sub>	chronic health-based effects screening level for nonthreshold dose response cancer effect
EtO	ethylene oxide
HEV	hemoglobin N-(2-hydroxyethyl)-valine
IARC	International Agency for Research on Cancer
LCL	lower confidence limit
LHN	lymphohematopoietic neoplasms
MW	molecular weight
µg	microgram
µg/m <sup>3</sup>	micrograms per cubic meter
mg	milligrams
mg/m <sup>3</sup>	milligrams per cubic meter
MLE	maximum likelihood estimate
mm Hg	millimeters of mercury
MOA	mode of action
n	number
N/A	Not applicable
NATA	National Air Toxics Assessment
NIOSH	National Institute for Occupational Safety and Health
NHL	non-Hodgkin's lymphoma



OSHA	Occupational Safety and Health Administration
PEL	permissible exposure level
POD	point of departure
ppb	parts per billion
ppm	parts per million
RR	risk ratio
SAB	Science Advisory Board
SAS	Statistical Analysis System
SCE	sister chromatid exchange
SD	standard deviation
SE	standard error
SIR	standardized incidence ratio
SMR	standardized mortality ratio
TCEQ	Texas Commission on Environmental Quality
TD	Toxicology Division
UCC	Union Carbide Corporation
URF	unit risk factor
USEPA	United States Environmental Protection Agency
USFDA	US Food & Drug Administration
WHO	World Health Organization
WV	West Virginia

## Chapter 1 Key Findings, Executive Summary, and Summary Tables

### *Executive Summary*

- Ethylene oxide (EtO) is a chemical with many industrial applications and is particularly useful as a sterilant for medical devices.
- Because EtO is emitted in Texas and has been determined to be a carcinogen, the TCEQ undertook a carcinogenic dose-response assessment and derivation of a unit risk factor (URF) and an effect screening level (ESL) for this chemical.
- Review of the EtO literature demonstrated that EtO operates by a direct-acting mutagenic mode of action (MOA) and suggests that the EtO cancer dose-response should be no more than linear overall with sublinearity expected by both the TCEQ and USEPA (2016) at endogenous levels and below.
- In addition, EtO is produced endogenously, and an ambient air concentration of  $\approx 1.3$  ppb would be required to increase the internal dose of EtO by 1 standard deviation. Therefore, ambient EtO concentrations significantly less than 1 ppb (e.g., USEPA's acceptable air concentrations of 0.0001-0.01 ppb) would not be expected to produce biologically meaningful internal doses considering the range of normal endogenously-produced background EtO levels.
- Consistent with TCEQ guidelines (TCEQ 2015), recently derived toxicity factors and guideline air levels were reviewed to determine if there is a toxicity factor or guideline air level that is suitable for adoption by the TCEQ. As such, the USEPA's recently completed Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide (USEPA 2016) was reviewed. The USEPA derived a URF of  $9.1E-3$  per ppb (lymphoid and breast cancer, ADAF adjusted), which corresponds to a 1 in 100,000 excess cancer risk air concentration of 0.001 ppb.
- The human data available for deriving an EtO toxicity factor are from two very high exposure occupational cohorts (Union Carbide Corporation (UCC) and National Institute for Occupational Safety and Health (NIOSH)) that provide no information about the shape of the dose-response curve at low (i.e., environmentally-relevant) EtO concentrations. The TCEQ agrees with USEPA's determination that in the low-dose range a sublinear dose-response is "highly plausible," based on the MOA and information about endogenous production of EtO.
- In contrast to their determination that the low-dose region of the EtO dose-response curve is highly plausibly sublinear, USEPA ultimately chose to model EtO-induced lymphoid cancer with an overall supra-linear two-piece spline model that has a very steep linear slope in the low-dose region.

- The TCEQ evaluated USEPA's URF and overall supra-linear (i.e., linear two-piece spline) modeling choice in the context of the available observed data to determine the validity of the modeling and URF:
  - Endogenous Levels of EtO – USEPA's URF estimates that ambient concentrations of EtO > 0.01 ppb would produce an unacceptable increased cancer risk of greater than 1 in 10,000. This estimated ambient EtO concentration corresponds to an internal dose that is over 30 times lower than the 1<sup>st</sup> percentile of normal endogenous background levels (non-smokers), which is highly unlikely to be biologically meaningful and is inconsistent with the assessment of excess risk.
  - Population-Level Lymphoid Cancer Risk – Using measured concentrations of a biomarker of internal EtO exposure (an EtO-specific protein adduct in blood), it can be estimated that the mean amounts of background EtO levels would be equivalent to ambient concentrations of EtO of 1.9 ppb in non-smokers and 18.8 ppb in smokers. Accordingly, at measured background levels of EtO, the USEPA's URF for lymphoid cancer (7.1E-03 per ppb, ADAF adjusted) would predict a population-wide lymphoid cancer incidence rate of ≈3.8% (in the absence of any exogenous EtO ambient air exposure or other potential causes of lymphoid cancer). By contrast, the USEPA-cited lymphoid cancer background incidence rate (which would have many contributing factors, not just a single chemical) is 3%, demonstrating that USEPA's URF overestimates observable lymphoid cancer risk based on endogenous/background levels of EtO alone.
  - Lymphoid Cancer Risk from Cohort Studies – The UCC cohort shows no statistically significant increased risk of lymphoid cancer with EtO exposure. The NIOSH cohort shows statistically significant increased risk of lymphoid cancer mortality at relatively high cumulative exposures. These data are not consistent with USEPA's selected model assessment (i.e., upper bound on the linear two-piece spline model) because that model assessment would predict statistically increased risks at even the lowest EtO cumulative exposures (see below).
  - Model Fit with Observed Data – USEPA conducted their EtO cancer dose-response modeling using the NIOSH cohort data. To verify that USEPA's final selected model assessment (i.e., upper bound on the linear two-piece spline model) properly fit the original data, it was used to predict the expected number of lymphoid cancer deaths based on the same NIOSH individual exposure data as USEPA used for modeling. *Whereas 53 lymphoid cancer deaths were observed in this cohort of 17,530 workers, USEPA's selected dose-response model assessment predicted 141 (95% confidence interval (CI) of 108, 188) lymphoid cancer deaths in this same cohort. Similarly, USEPA's final selected model assessment statistically significantly over-predicts lymphoid cancer deaths in every cumulative exposure quintile and indicates that statistically increased lymphoid cancer mortality should have occurred in every exposure quintile (including the*

lowest), when in fact this did not occur. This demonstrates unequivocally that USEPA's selected model assessment cannot be validated by the data that was used to derive it, and this model is not appropriate to use for estimates of population risk.

- The TCEQ determined that USEPA's use of an overall supra-linear dose-response model (i.e., the upper bound of the linear two-piece spline model) to derive their URF: 1) is not justified by the MOA data (which support a no-more-than linear dose-response); 2) is not consistent with predicted population risk from endogenous EtO for lymphoid cancer; and 3) statistically significantly over-estimates the number of lymphoid cancer deaths in the cohort from which the dose-response model was derived. **Therefore, the TCEQ found that USEPA's EtO inhalation URF is not adequately supported by scientific data and the TCEQ did not adopt it for this evaluation.**
- The TCEQ conducted a systematic review for studies that could inform the derivation of a cancer URF for inhalation exposures to EtO. This review identified key epidemiological data from two cohorts of occupationally-exposed workers, and Cox proportional hazards modeling was conducted to model the EtO-cancer dose-response.
- The TCEQ ultimately chose lymphoid cancer mortality as the critical cancer endpoint, using a 15-year EtO exposure lag with results for NIOSH males being more conservative, to calculate a **URF of 2.5E-6 per ppb (1.4E-6 per ug/m<sup>3</sup>)** and a <sup>chronic</sup>ESL<sub>nonthreshold(c)</sub> of **4 ppb (7 ug/m<sup>3</sup>)** at an excess cancer risk level of 1 in 100,000.
- As with USEPA's URF, the TCEQ's URF was evaluated in the context of the available observed data to determine the validity of the modeling and URF:
  - Endogenous Levels of EtO – Compared to endogenous EtO levels, the TCEQ's ESL of 4 ppb would produce an internal exposure equivalent to between the 90<sup>th</sup>-95<sup>th</sup> percentile of the normal endogenous range and could biologically plausibly be associated with excess risk above and distinguishable from normal endogenous EtO contributions to background risk.
  - Population-Level Lymphoid Cancer Risk - At measured endogenous levels of EtO, the TCEQ's URF would predict a population-wide lymphoid cancer rate that is lower than the background population lymphoid cancer rate (unlike USEPA's URF).
  - Lymphoid Cancer Risk from Cohort Studies – The standard Cox proportional hazards model of lymphoid cancer mortality did not show a relationship with EtO exposure that was statistically significantly different from zero. Therefore, by assuming a significant positive slope in the EtO-cancer association, the TCEQ is making a conservative decision to assume that EtO is causing lymphoid cancer in the exposed workers in the NIOSH cohort. Adding to this conservatism is the TCEQ's decision to use an upper confidence limit on the slope.

- Model Fit with Observed Data – To verify that the TCEQ’s model properly fit the original data, the expected number of lymphoid cancer deaths based on the individual exposure estimates for the NIOSH cohort (also used by USEPA) were calculated. Whereas *53 lymphoid cancer deaths were observed* in this cohort of 17,530 workers, *the TCEQ’s selected dose-response assessment (i.e., upper bound of the Cox proportional hazard model) predicted 59 (95% CI of 45, 78) lymphoid cancer deaths*. Similarly, TCEQ’s selected assessment neither significantly over- or under-estimated lymphoid cancer deaths for any exposure quintile. This demonstrates that the TCEQ’s model selection provides a superior fit to the observed number of lymphoid cancer deaths in the NIOSH cohort.
- The TCEQ determined that the use of Cox proportional hazards models to derive a URF for inhalation EtO cancer risk: 1) is justified by the MOA data showing EtO to be a direct-acting carcinogen whose effects, particularly at doses near the endogenous range, would be buffered by cellular repair mechanisms; 2) is consistent with population background risk considering background endogenous EtO levels (i.e., does not overestimate population risk for lymphoid cancer mortality); and 3) accurately estimates the number of lymphoid cancer deaths in the cohort from which the dose-response model was derived. **Therefore, the TCEQ’s EtO URF has a sound scientific basis and will be adopted for review of air concentration data and for use in air permit reviews.**

### Summary of Key Points

In 2016, the USEPA derived an inhalation URF for EtO (9.1E-03 per ppb or 5.0E-03 per  $\mu\text{g}/\text{m}^3$ ; p. 4-91 of USEPA 2016) based on an overall supra-linear two-piece spline model (USEPA 2016). The URF is primarily driven by USEPA’s dose-response assessment of lymphoid cancer in the NIOSH cohort. Despite extensive review by the USEPA Science Advisory Board (SAB) and extensive public comments on the science, in this Development Support Document (DSD) the TCEQ is able to demonstrate that *the model assessment ultimately selected by USEPA (i.e., the upper bound of the linear two-piece spline model with the “knot” at 1,600 ppm  $\times$  days, 15-year exposure lag) statistically significantly over-estimates the actual number of lymphoid cancer mortalities observed in the NIOSH cohort; predicting 141 (95% CI of 108, 188) if USEPA’s model were accurate versus the 53 actually observed (Figure 8). By contrast, the model assessment selected by the TCEQ (i.e., the upper bound of the Cox proportional hazards model, 15-year exposure lag) based on relevant considerations discussed herein predicts 59 lymphoid cancer mortalities versus the 53 actually observed. Furthermore, the USEPA’s model assessment statistically significantly over-predicts lymphoid cancer mortality in every NIOSH cumulative exposure group, whereas the TCEQ’s model assessment neither statistically over- or under-predicts for any cumulative exposure group (Figures 9-12).*

Supra-linear models are generally not biologically plausible and tend to grossly overestimate low-dose risks. Therefore, sufficient mechanistic or biological data are required to support the application of a supra-linear model (i.e., the steep lower-dose component) for low-dose extrapolation (TCEQ 2015). USEPA (2016) provides no solid mechanistic or biological foundation for adopting an overall supra-linear dose-response model, particularly its steep slope in the range of interest (e.g., typical environmental levels). In fact, *USEPA acknowledges the lack of mechanistic data to support the biological plausibility of a supra-linear dose-response*, stating “the EPA is not aware of a mechanistic explanation” and citing “insufficient information to elucidate a basis” (pp. I-29 and I-34 of USEPA 2016). Indeed, all the relevant considerations (e.g., MOA, normal endogenous background levels) discussed in various sections of this DSD consistently support the conclusion that there is a lack of data to adequately support the application of a supra-linear model with its steep low-dose slope to extrapolate to significantly lower (e.g., ambient air) EtO doses. Moreover, the available dose-response data from the NIOSH cohort (e.g., Steenland et al. 2004) are not informative as to the shape of the dose-response curve across doses of true interest (e.g., in the range of typical environmental concentrations), which USEPA acknowledged (p. I-14 of USEPA 2016; see Section 3.4.1.4.1). Workers were exposed to extraordinarily high concentrations of EtO, with exposure means  $\approx 1,000,000$ - $2,000,000$  times higher than central tendency environmental exposures (animal carcinogenicity data are at even higher mean concentrations) and daily job exposures ranging from  $\approx 15,000$ - $32,000,000$  times higher than central tendency environmental exposures. High-dose carcinogenicity data alone are incapable of informing truly low-dose risk, no matter how extensive the analyses or peer review (i.e., other relevant information such as mechanism/MOA must be duly considered). Indeed, USEPA acknowledges that “the actual exposure-response relationship at low exposure levels is unknown” (pp. 4-61 and 4-74 of USEPA 2016). *USEPA (2016) should not have based a URF on a supra-linear model (i.e., its lower-dose component) without a robust mechanistic justification for expecting its steep low-dose slope at truly low doses nor should the USEPA have used it to make a large low-dose extrapolation across an area (i.e., the endogenous range) where the agency in fact considers sublinearity “highly plausible.”*

However, USEPA did ultimately derive a URF based on a supra-linear model (i.e., the lower-dose slope of the linear two-piece spline model), which necessarily leads to the following implausible conclusions when considering endogenous levels of EtO:

- *The air concentration at the maximum acceptable excess risk (0.01 ppb at  $1E-04$  risk) corresponds to an internal dose that is over 30 times lower than even the 1<sup>st</sup> percentile of normal endogenous background levels (see Section 3.4.1.2.2);*
- *Expressed in other terms, based on USEPA (2016) and data on normal endogenous background levels, air concentrations corresponding to more than  $\approx 0.5\%$  percent of mean normal endogenous background levels in nonsmokers would be considered to be associated with unacceptable risk; and*

- *The predicted lymphoid cancer incidence based on mean background levels alone is greater than the population background rate cited by USEPA (see Section 3.4.1.2.1).*

The statistically significant overestimation of risk, *driven by a lymphoid cancer model for which there is inadequate statistical evidence that the slope is even greater than zero in the NIOSH (or UCC) cohort* (Appendix 5), undermines accurate risk communication and can lead to unintended societal consequences.

Consistent with the discussion above, the TCEQ has derived an inhalation URF for EtO because currently available information indicates that the existing USEPA URF results in biologically implausible risk estimates at environmentally-relevant air concentrations where use of the steep low-dose slope from an overall supra-linear two-piece spline model is not justified. For example:

- *The air concentrations corresponding to the USEPA acceptable excess risk range (1 in a million to 1 in 10,000 based on the USEPA 2016 URF) are orders of magnitude below those corresponding to the normal endogenous background range (see Figure 7), making minuscule contributions to internal exposure that are not biologically meaningful as resulting total exposures are indistinguishable from normal endogenous background;*
- *Statistically significant increases in critical cancer endpoints observed in the NIOSH cohort occur at carcinogenic cumulative exposures that are orders of magnitude above endogenous levels (below which USEPA extrapolates orders of magnitude), and USEPA had no truly low-dose data to inform the shape/slope of the dose-response over the normal endogenous background range much less near typical environmental or risk-based air concentrations, which are even lower;*
- *The biological implausibility of an overall supra-linear model for extrapolating risk down to endogenous levels (and lower environmental and risk-based levels) is in fact supported by USEPA stating, “EPA considers it highly plausible that the dose-response relationship over the endogenous range is sublinear”; contrary to USEPA’s expectation, the USEPA (2016) URF is based on a supra-linear model (i.e., the steep lower-dose linear component) that was used to extrapolate over the endogenous range and even below; and*
- *Consequently, when USEPA’s URF is used in conjunction with population-weighted mean background levels in nonsmokers and smokers, a background lymphoid cancer incidence greater than the USEPA-cited background incidence is predicted based on background levels alone (see Section 3.4.1.2.1), which suggests a scientifically unreasonable URF.*

Moreover, USEPA may not have adequately explored the potential contributions of ethylene to EtO risk, stating “only ~3% of exogenous ethylene was converted to EtO in workers exposed to

0.3 ppm” and that “exogenous ethylene exposure is unlikely to contribute significantly to the effects associated with exposure to exogenous EtO in humans” (p. 3-30 of USEPA 2016). *However, based on USEPA’s URF, mean environmental concentrations of ethylene in many areas would in fact result in unacceptable excess risk estimates when multiplied by 0.03 to account for the USEPA-cited endogenous conversion of 3% of exogenous ethylene to EtO.* More specifically, greater than a  $1\text{E-}04$  excess risk would be estimated by USEPA’s EtO URF at long-term ethylene air concentrations greater than 0.37 ppb. Interestingly, mean ethylene concentrations reported in human breath (e.g., 23 ppb in Fenske and Paulson 1999, baseline mean of 29-32 ppb reported in Bratu 2019) exceed this  $1\text{E-}04$  excess risk concentration by over 60-fold. These and other considerations are discussed in more detail within this DSD. *The TCEQ concludes that available information (e.g., mechanistic, biological) does not adequately support use of a supra-linear model (i.e., the steep lower-dose slope of the linear two-piece spline model) for extrapolation to truly low (e.g., environmental) air concentrations.* Consequently, the TCEQ conducted a systematic review of the EtO human cancer literature and derived an appropriate URF based on mechanistic and biological information using models that were consistent with the available data.

**The TCEQ URF for EtO based on lymphoid cancer is  $2.5\text{E-}06$  per ppb ( $1.4\text{E-}06$  per  $\mu\text{g}/\text{m}^3$ ) and results in a risk-based air concentration of 4 ppb at the no significant excess risk level of 1 in 100,000** (TCEQ 2015). The internal dose from continuous exposure to this EtO air concentration would correspond to the upper end of the endogenous range (i.e., between the 90<sup>th</sup> and 95<sup>th</sup> percentile), which is more biologically plausibly consistent with the assessment of excess (i.e., above and distinguishable from EtO background) risk. *The TCEQ-selected dose-response assessment (i.e., upper bound of the Cox proportional hazards model, 15-year exposure lag) accurately predicts the underlying cohort dose-response data (Figures 8-12).*

Table 1 provides a summary of the risk-based value from a chronic, carcinogenic evaluation of EtO for use in air permitting and air monitoring. Please refer to Section 1.6.2 of the *TCEQ Guidelines to Develop Toxicity Factors* (TCEQ 2015) for an explanation of the various values used for review of ambient air monitoring data and air permitting. Table 2 provides summary information and the physical/chemical data of EtO.



**Table 1: Chronic Health-Based Screening Values for EtO**

Screening Level Type	Duration	Value 1 ( $\mu\text{g}/\text{m}^3$ )	Value 2 (ppb)	Usage	Flags	Surrogated/ RPF	Critical Effect(s)	Notes
chronic <sup>a</sup> ESL <sub>nonthreshold(c)</sub>	70 yr	7	4	P,M,R	A,S,D	--	Lymphoid cancer in occupationally-exposed workers	--

Bold values used for air permit reviews; values have been rounded to one significant digit.

<sup>a</sup> Based on the URF of  $1.4\text{E-}06$  ( $\mu\text{g}/\text{m}^3$ )<sup>-1</sup> or  $2.5\text{E-}06$  (ppb)<sup>-1</sup> and a no significant risk level of 1 in 100,000 excess cancer risk.

Usage:

P = Used in Air Permitting

M = Used to Evaluate Air Monitoring Data

R = Used to Calculate Remediation Cleanup Levels

N = Usage Not Defined


Flags:

A = AMCV report

S = ESL Summary Report

D = ESL Detail Report

**Table 2: Chemical and Physical Properties**

Parameter	Value	Reference
Molecular Formula	C <sub>2</sub> H <sub>4</sub> O	ATSDR 1990
Chemical Structure		ChemSpider 2019
CAS Registry Number	75-21-8	ATSDR 1990
Molecular Weight	44.05	ATSDR 1990
Physical State at 25°C	Gas	ATSDR 1990
Color/Form	Colorless gas	ATSDR 1990
Odor	Sweet, olefinic	ATSDR 1990
Synonyms	Ethylene oxide; oxirane; epoxyethane	ATSDR 1990
Solubility in water	1x10 <sup>6</sup> mg/L	ATSDR 1990
Log K <sub>ow</sub>	-0.22	ATSDR 1990
Vapor Pressure	1.095x10 <sup>3</sup> mmHg	ATSDR 1990
Melting Point	-111°C	ATSDR 1990
Boiling Point	11°C	ATSDR 1990
Conversion Factors	1 ppm = 1.83 mg/m <sup>3</sup> 1 mg/m <sup>3</sup> = 0.55 ppm	ATSDR 1990

## Chapter 2 Major Sources and Uses

EtO is used as a chemical intermediate in the manufacture of ethylene glycol (antifreeze), polyester, detergents, polyurethane foam, solvents, medicine, adhesives, and other products. The conversion of EtO to ethylene glycols represents a major use for ethylene glycol in the US (IARC 2012). Relatively small amounts of EtO are used in sterilization of surgical equipment and plastic, as a fumigant, and as a sterilant for food (spices) and cosmetics (IARC 2012). In 2018, ethylene oxide was being produced in the US at 15 facilities in 11 locations by 9 companies. In the US, EtO is primarily produced in Texas and Louisiana ("Ethylene Oxide Frequently Asked Questions," 2018).

After the release of USEPA's 2014 National Air Toxics Assessment (NATA), the USEPA began to evaluate facilities that emit EtO. The 2014 NATA estimated that EtO significantly contributes to potential elevated cancer risks in some census tracts across the US; risk that is largely driven by the USEPA's recently-derived URF. Because of concerns related to cancer risk from EtO emissions raised by NATA, at least two EtO sterilizing facilities have closed or will close in 2019. In order to prevent shortages of critical medical equipment, the US Food & Drug Administration (USFDA) has been working with medical device manufacturers to find alternative locations and methods for sterilization. According to the USFDA, EtO is the likely sterilant for medical devices made from certain polymers (plastic or resin), metals, or glass, or that have multiple layers of packaging or hard-to-reach places (e.g., catheters). Approximately fifty percent of all sterile medical devices in the US are sterilized with EtO ("Ethylene Oxide Sterilization," 2019).

Sources of EtO emissions into the air include, but are not limited to, industrial emissions or venting with other gases. Other sources of EtO air emissions include its use as a sterilizer of medical equipment and its release from commodity-fumigated materials. The general population may be exposed to EtO through breathing ambient air containing EtO, smoking tobacco products, and breathing secondhand cigarette smoke ("Ethylene Oxide. 75-21-8"). Certain occupational groups (e.g., workers in EtO manufacturing or workers that use EtO to produce solvents, antifreeze, textiles, detergents, and polyurethane foam, sterilization technicians, and agricultural workers involved in fumigation) may be exposed in the workplace (IARC 2012).

EtO is also produced endogenously in the body due to oxidation of ethylene, which is generated by intestinal bacteria, lipid peroxidation of unsaturated fats, methionine, and hemoglobin. Recent analyses indicate that endogenous levels of EtO are significant relative to (i.e., higher than) doses corresponding to recently-derived regulatory values (USEPA 2016) and typical environmental exposures (Kirman and Hays 2017).

## Chapter 3 Carcinogenic Potential

### 3.1 Carcinogenic Weight of Evidence (WOE)

EtO has been evaluated for carcinogenic potential by the International Agency for Research on Cancer (IARC), the US Environmental Protection Agency (USEPA), and the World Health Organization (WHO). These agencies' carcinogenic classifications for EtO are provided in Table 3 below.

**Table 3: Carcinogenic Weight of Evidence**

Group	Classification
IARC (2012)	Group I: Carcinogenic to humans
USEPA (2016)	Carcinogenic to humans
WHO (2003)	Highly likely to be carcinogenic to humans

Generally, the TCEQ only performs carcinogenic dose-response assessments for chemicals considered by the TCEQ either to be "Carcinogenic to Humans" or "Likely to Be Carcinogenic to Humans" (TCEQ 2015). For the purposes of this DSD, the TCEQ has adopted the USEPA (2016) carcinogenic classification for EtO, which is discussed further in Section 3.3.2.

### 3.2 Relevant Data

#### 3.2.1 Epidemiological Studies

Based on the systematic review conducted by the TCEQ (Appendix A) as well as review of USEPA (2016) and other dose-response assessments (e.g., Valdez-Flores et al. 2010, Kirman et al. 2004), the assessment of excess cancer risk in the NIOSH and/or UCC cohorts provides the best basis for a carcinogenic assessment of EtO. These studies are summarized below.

##### 3.2.1.1 NIOSH Cohort

Much of the following study summary is based on information from Section 4.1 of USEPA (2016).

The NIOSH retrospective cohort study of 17,530 workers in 13 sterilizing facilities (most recent follow-up by Steenland et al. 2004, 2003) provides adequate data for deriving quantitative cancer risk estimates (unit risk estimates or URFs) for EtO in humans. Briefly, the following are positive study attributes:

- Exposure estimates were derived for the individual workers using a comprehensive exposure assessment (although there are associated uncertainties);
- The cohort was large and diverse (e.g., 55% female); and
- There was little reported exposure to chemicals other than EtO.

EtO exposure estimates, including estimates for early exposures for which no measurements were available, were determined using a regression model that estimated exposures for each individual as a function of facility, exposure category, and time period. The regression model was based on extensive personal monitoring data from 18 facilities from 1976 to 1985 as well as information on factors influencing exposure, such as engineering controls (Hornung et al. 1994). Uncertainties are inevitably associated with historical exposure reconstruction. In this case, USEPA acknowledges that EtO measurement data were not available for most of the time that the cohort was exposed, errors in retrospective exposure assignments are inevitable, and that the exposure estimates are a primary source of uncertainty in the URF estimates (pp. 4-64 and 4-65 of USEPA 2016). Accordingly, to the TCEQ there appears to be appreciable uncertainty stemming from the lack of EtO exposure data prior to the time air monitoring data collection began when exposures for much of the cohort would have been relatively high and significantly contributed to cumulative exposure estimates (ppm-days, both unlagged and lagged), which appear likely to be biased low although a detailed discussion is beyond the scope of this DSD (e.g., Bogen et al. 2019, Li et al. 2019). The USEPA SAB agreed that these exposure estimates are likely of lower reliability (because there were no exposure measurement data that could be included in the exposure model prior to 1979) and actual EtO exposures were likely to have been higher than reflected in the estimates (p. I-41 of USEPA 2016). However, for the later monitoring data the regression model was able to account for 85% of the variation in average EtO exposure levels when evaluated against independent test data from the same set of data. The investigators estimated the cumulative exposure (ppm × days) for each individual worker by multiplying the estimated exposure (ppm) for each job (exposure category) held by the worker by the number of days spent in that job and summing over all the jobs held by the worker.

The TCEQ notes that this worker population was exposed to extraordinarily high concentrations of EtO. For example, Tables IV and V of Hornung et al. (1994) provide measured and estimated worker exposure means of 3.5-4.6 ppm, which are  $\approx 1,000,000$ - $2,000,000$  times higher than central tendency environmental levels (i.e., background and environmental exposure means  $\approx 0.0024$ - $0.0034$  ppb per USEPA 2016). Animal carcinogenicity studies were conducted at even higher EtO exposure concentrations (10-100 ppm; see Section 3.2 of USEPA 2016). On any given day, estimated exposure for a job could have ranged from 50-77,000 ppb (pp. D-4 and D-37 of USEPA 2016), which is remarkably  $\approx 15,000$ - $32,000,000$  times higher than central tendency environmental levels of EtO. Consequently, when USEPA (2016) discusses model fit in the “low-dose” region, the low-dose region for these workers provides no information about the shape

of the dose-response at environmental levels. High-dose carcinogenicity data alone are incapable of informing truly low-dose risk, no matter how extensive the analyses or peer review (i.e., other relevant information must be duly considered).

In regard to study findings, Steenland et al. (2004) present follow-up results for the cohort mortality study previously discussed by Steenland et al. (1991) and Stayner et al. (1993). Positive findings in the current follow-up include statistically increased (lympho)hematopoietic cancer mortality in males of the highest EtO exposure group (see Tables 4, 6, and 7 of the study) and statistically increased breast cancer mortality in females of the highest EtO exposure group (see Tables 5 and 8 of the study). Steenland et al. (2003) present results of a breast cancer incidence study of a subcohort of 7,576 women from the NIOSH cohort that showed statistically increased odds ratios for the highest exposure group (see Tables 4 and 5 of the study).

### **3.2.1.2 UCC Cohort**

Swaen et al. (2009) redefined and updated the UCC cohort of male workers employed in industrial facilities where EtO was produced or used. Previous studies of the UCC cohort were published by Greenberg et al. (1990) and Teta et al. (1993). All 2,063 men were employed between 1940 and the end of 1988 and were observed for mortality through 2003. Workers from EtO departments at the Kanawha Valley, WV sites hired after 1988 were determined to have no appreciable EtO exposure and were, therefore, not added to the cohort. Cause-specific standardized mortality ratios (SMRs) were calculated. Internal analyses were made by applying Cox proportional hazards models to the data.

The exposure assessment for this update relies on the qualitative categorization of EtO producing and using departments by exposure level developed by Greenberg et al. (1990), and on quantitative estimates of average intensity by these department categories and by time period (1925-1988) developed by Teta et al. (1993). Time period cut points were chosen as follows: 1925, the start-up of EtO production in the Kanawha Valley; 1940, start of cohort observation and first period with published estimates of exposure; 1957, chlorohydrin process for EtO production completely shut-down; and 1974, the period when airborne exposures declined substantially due to process and exposure controls. The combination of the average exposure for the four different time periods and the three classifications of departments into low, medium, and high exposure departments created the exposure matrix. Cumulative EtO exposure (ppm-years) for each study subject was then estimated by multiplying the estimated time-period and department-specific exposure concentrations by duration in months for each individual's assignments to EtO departments and summing the products over all assignments up through December 1988 (Swaen et al. 2009). The average cumulative EtO exposure was 67.16 ppm-years ( $\approx 16,118$  ppm-days, as  $67.16 \text{ ppm-years} \times 240 \text{ days/year}$ ), about twice that of the NIOSH cohort. As of Swaen et al. (2009), the average follow-up period for the UCC cohort

was 10 years longer (36.5 versus 25.8 years) and the percent deceased was 3-fold greater than the NIOSH cohort (51% versus 16%). However, the number of expected cancer deaths for the UCC cohort (a measure of study power) was between 2-3 times less because of the significantly smaller cohort size in both number and person-years (e.g., 75,306 versus 450,906 person-years). Nevertheless, this is an important cohort that contributes to the human EtO carcinogenicity database. For example, the long follow-up period and relatively high cumulative exposure estimates are advantageous for the identification of potential long-term carcinogenic effects.

As mentioned above, uncertainties are inevitably associated with historical exposure reconstruction. In addition to finding fault with the cohort for being smaller and limited to males, USEPA (2016) characterizes the EtO exposure assessment for the UCC cohort as more uncertain than that for the NIOSH cohort (e.g., greater likelihood for exposure misclassification, use of surrogate exposure data; see Section 4.1 of USEPA 2016). However, the NIOSH cohort appears to have unemphasized yet significant uncertainties of its own; most notably, the lack of exposure data prior to the mid-70's when exposures were likely to have been significant and would have increased cumulative exposure estimates for much of the cohort (e.g., Bogen et al. 2019). Ultimately, the TCEQ finds that these cohorts provide the best basis for a regulatory dose-response assessment for EtO, and cohort-specific results will be appropriately weighed based on relevant statistical criteria.

Regarding study findings, Swaen et al. (2009) report that no indications were found for excess cancer risks from EtO exposures, including the lymphohematopoietic malignancies (e.g., 11 leukemia deaths occurred and 11.8 were expected, 12 non-Hodgkin's lymphoma deaths occurred and 11.5 were expected). Cox proportional hazards modeling for all cause, leukemia, and lymphoid malignancies mortality revealed no trends or associations with cumulative EtO exposure. In recognition of exposure estimate uncertainty, it is also important to note that no statistically significantly elevated SMRs were found in the analysis by hire date, and there were no statistically significant increases in the longest duration category and no suggested trends by duration (all surrogates of exposure). Study authors concluded that the cohort showed no long-term carcinogenic effects associated with EtO exposure.

*Similarly, an as of yet unpublished update of the UCC cohort through 2013 (submitted as Bender et al.) concludes that examination of mortality from all causes of death, all cancers, leukemia, non-Hodgkin's lymphoma, and lymphoid malignancies revealed no evidence for an exposure-related response; EtO exposure in this cohort was not associated with an observable increase in lymphohematopoietic cancer mortality (personal communication with study co-author Ciriaco Valdez-Flores). The average cumulative dose of EtO (67 ppm-years) is reported to be around two times that for the NIOSH cohort, with a ≈63% longer follow-up period (≈41 years) and a similar number of lymphoid cancer deaths in males (27 in NIOSH versus 25 in UCC) despite the*

number of person-years for males in the NIOSH cohort (189,868 person-years) being significantly greater than that in the UCC cohort (83,524 person-years).

### 3.2.2 Animal Studies

Human (i.e., epidemiological) data are available for a carcinogenic assessment of EtO and are preferred over animal data for toxicity factor (i.e., URF) development (TCEQ 2015). Therefore, animal carcinogenicity data are not discussed herein. See Section 4.2 of USEPA (2016) for relevant information.

### 3.3 Mode of Action (MOA) and Carcinogenic Classification

The TCEQ has adopted the overall USEPA (2016) EtO MOA analysis and carcinogenic classification determinations for the purposes of this DSD (note that this does not necessarily mean that the TCEQ necessarily fully concurs with every USEPA statement or characterization). As such, summary information was essentially derived directly from Sections 3.4.3 and 3.5.1 of USEPA (2016) and is presented below, with references to USEPA (2016) document sections removed [*emphasis added*]. The references for the studies supporting the information below can be found in the aforementioned sections of USEPA (2016).

#### 3.3.1 MOA

In this section, the evidence for a mutagenic MOA for EtO carcinogenicity is analyzed under the MOA framework in the USEPA's 2005 Guidelines for Carcinogen Risk Assessment (USEPA 2005a).

The hypothesis is that EtO carcinogenicity has a mutagenic MOA. This hypothesized MOA is presumed to apply to all the tumor types. The key events in the hypothesized mutagenic MOA are: (1) DNA adduct formation by EtO, which is a direct-acting alkylating agent; (2) the resulting heritable genetic damage, including DNA mutations, particularly in oncogenes and tumor suppressor genes, as well as chromosomal alterations; and (3) the clonal expansion of mutated cells during later stages of cancer development; eventually resulting in (4) tumor formation. Mutagenicity is a well-established cause of carcinogenicity.

*Is the hypothesized MOA sufficiently supported in the test animals?*

Consistent with the USEPA's 2005 Guidelines for Carcinogen Risk Assessment (USEPA 2005a), this MOA analysis for a mutagenic MOA is organized around the Hill "criteria" (or considerations) developed for the analysis of epidemiological studies (Hill 1965). These considerations are denoted in underlined italics in the discussion below.

Numerous studies have demonstrated that EtO forms protein and DNA adducts, in mice and rats, and there is incontrovertible evidence that EtO is mutagenic and genotoxic. The evidence



for causal associations between the key events and tumor formation has strength and consistency. Increases in the frequency of gene mutations in reporter genes have been observed in the lung, T-lymphocytes, bone marrow, and testes of transgenic mice and in T-lymphocytes of rats exposed to EtO via inhalation at concentrations similar to those inducing tumors in the rodent carcinogenesis bioassays. In addition, in the lung, uterine, mammary gland and Harderian gland tumors from EtO-exposed mice in those bioassays, dramatic shifts toward guanine and adenine mutations have been observed in the mutational spectra of the proto-oncogenes *Hras* and *Kras*, as well as the tumor suppressor *Trp53*, consistent with the propensity of EtO to form DNA adducts on purine bases.

Inhalation studies in laboratory animals have also demonstrated that EtO exposure levels in the range of those used in the rodent bioassays induce sister chromatid exchanges (SCEs) in several species and consistently induce chromosomal aberrations in mice. In rats, although SCEs are consistently observed in the available studies, the results for micronuclei formation and chromosomal aberrations following subchronic (up to 4-week) inhalation exposures to EtO at the same exposure levels as those used in the rodent bioassays have been nonpositive; however, IARC (2008) has noted analytical limitations with some of these analyses. In addition, Donner et al. (2010) demonstrated a clear duration effect in mice, with chromosomal aberrations being induced at those same EtO exposure levels only following longer exposure durations ( $\geq 12$  weeks).

Specificity is not expected for a multisite mutagen and carcinogen such as EtO (USEPA 2005a). A temporal relationship is clearly evident, with DNA adducts, point mutations, and chromosomal effects observed in acute and subchronic assays.

Dose-response relationships have been observed between EtO exposure *in vivo* and DNA adducts, SCEs, and *Hprt* and *Trp53* mutations. A mutagenic MOA for EtO carcinogenicity also clearly comports with notions of biological plausibility and coherence because *EtO is a direct-acting alkylating agent. Such agents are generally capable of forming DNA adducts, which in turn have the potential to cause genetic damage, including mutations; and mutagenicity, in its turn, is a well-established cause of carcinogenicity. This chain of key events is consistent with current understanding of the biology of cancer.*

In addition to the clear evidence supporting a mutagenic MOA in test animals, there are no other compelling hypothesized MOAs for EtO carcinogenicity. For example, there is no evidence of cytotoxicity or other cellular dysfunction indicative of regenerative proliferation, and little-to-no evidence supporting some other toxicity-related MOA, such as oxidative stress.

*Is the hypothesized MOA relevant to humans?*

The evidence discussed above demonstrates that EtO is a systemic mutagen in test animals; thus, there is the presumption that it would also be a mutagen in humans. Moreover, human evidence directly supports a mutagenic MOA for EtO carcinogenicity. Several studies of humans have reported exposure-response relationships between hemoglobin adduct levels and EtO exposure levels (e.g., van Sittert et al. 1993, Schulte et al. 1992), demonstrating the ability of EtO to bind covalently in systemic human cells, as it does in rodent cells. DNA adducts in EtO-exposed humans have not been well studied, and the evidence of increased DNA adducts is limited. EtO has yielded positive results in *in vitro* mutagenicity studies of human cells. Although the studies of point mutations in EtO-exposed humans are few and insensitive and the evidence for mutations is limited, there is clear evidence from a number of human studies that EtO causes chromosomal aberrations, SCEs, and micronucleus formation in peripheral blood lymphocytes, with some evidence of positive relationships with exposure concentration and duration.

USEPA (2016) indicates that there is strong evidence that EtO causes cancer in humans, including some of the cancer types observed in rodent studies (i.e., lymphohematopoietic cancers have been observed in both rats and mice and mammary carcinomas have been observed in female mice), providing further weight to the relevance of genotoxicity to the development of cancer in humans. USEPA (2016) concludes that *the weight of evidence supports a mutagenic MOA for EtO carcinogenicity*. Although oxidative stress or other processes might contribute to the development of EtO-induced cancers, the TCEQ agrees that the available evidence best supports a mutagenic MOA as the primary process mediating EtO-induced carcinogenicity (USEPA 2016).

### 3.3.2 Carcinogenic Classification

Regarding carcinogenic classification under USEPA (2005a), while USEPA (2016) states that there is substantial evidence that EtO exposure is causally associated with lymphohematopoietic cancers and female breast cancer in human studies, the agency acknowledges that *the evidence is not strong enough to be conclusive*. Of the seven relevant Hill “criteria” (or considerations) for causality (Hill 1965), temporality, coherence, biological plausibility, and analogy are readily satisfied, and the other three criteria (consistency, biological gradient, and strength of association) are satisfied to varying degrees. For example, there is “some evidence of dose-response relationships”, but “there is *little strength* in the associations, as reflected by the modest magnitude of most of the RR [relative risk] estimates.” See Section 3.5.1 of USEPA (2016) for additional discussion on these criteria. USEPA (2016) ultimately concludes that *the overall epidemiological evidence for causal associations between EtO exposure and lymphohematopoietic cancer as well as female breast cancer is strong but less than conclusive, with epidemiology study evidence for other cancer types (e.g., stomach cancer and pancreatic cancer) also being inadequate*.

USEPA (2016) further concludes that the laboratory animal evidence for EtO carcinogenicity is “sufficient” based on findings of tumors at multiple sites, by both oral and inhalation routes of exposure, and in both sexes of both rats and mice. Tumor types resulting from inhalation exposure included mononuclear cell leukemia in male and female rats and malignant lymphoma and mammary carcinoma in female mice, suggesting some site concordance with the lymphohematopoietic and breast cancers observed in humans, also exposed by inhalation. Lastly, USEPA concludes that the evidence of EtO genotoxicity and mutagenicity is unequivocal (see Section 3.5.1 of USEPA 23016 for details), ultimately classifying EtO as “*carcinogenic to humans*” under USEPA (2005a).

The TCEQ agrees that since the epidemiological evidence is less than convincing, additional lines of evidence are required for the EtO carcinogenic classification. USEPA (2016) cites the following lines of evidence to support the “*carcinogenic to humans*” classification: (1) there is strong, although less than conclusive on its own, evidence of cancer in humans associated with EtO exposure via inhalation, specifically, evidence of lymphohematopoietic cancers and female breast cancer in EtO-exposed workers; (2) there is extensive evidence of EtO-induced carcinogenicity in laboratory animals, including lymphohematopoietic cancers in rats and mice and mammary carcinomas in mice following inhalation exposure; (3) EtO is a direct-acting alkylating agent whose mutagenic and genotoxic capabilities have been well established in a variety of experimental systems, and a mutagenic mode of carcinogenic action has been identified in animals involving the key precursor events of DNA adduct formation and subsequent DNA damage, including point mutations and chromosomal effects; and (4) there is strong evidence that the key precursor events are anticipated to occur in humans and progress to tumors, including evidence of chromosome damage, such as chromosomal aberrations, SCEs, and micronuclei in EtO-exposed workers. In supporting a “*carcinogenic to humans (Group 1)*” designation, IARC (2012) draws conclusions similar to those of USEPA (2016), citing *limited evidence* in humans, *sufficient evidence* in experimental animals, and *strong evidence* supportive of a genotoxic MOA for carcinogenicity.

As mentioned in Section 3.3, the TCEQ has adopted the USEPA (2016) EtO carcinogenic classification (*carcinogenic to humans*) for purposes of this DSD.


### **3.4 Carcinogenic Dose-Response Assessment**

Per TCEQ guidelines (TCEQ 2015), when toxicity factors or guideline air levels are identified in the scientific literature or databases, they are reviewed to determine whether the approaches used to develop the toxicity factors or guideline levels are similar to the procedures used by the TCEQ. If so, after careful consideration the TCEQ may elect to adopt the published toxicity factor or guideline level. In the present case, the scientific literature search identified USEPA (2016) and Valdez-Flores et al. (2010) as representing two relatively recent carcinogenic dose-response assessments for EtO for consideration under TCEQ guidelines (TCEQ 2015). In Sections

3.4.1.1 and 3.4.1.2 below, the TCEQ reviews the available data for MOA, endogenous EtO levels, key epidemiological data, and model predictions to determine whether to adopt the USEPA (2016) EtO inhalation URF. After making the adoption determination, the TCEQ continues with an original assessment to derive an EtO inhalation URF based on TCEQ guidelines and best principles.

### 3.4.1 Low-Dose Extrapolation Approach

Use of MOA information to inform the dose-response assessment is a main focus of the TCEQ (2015) and USEPA (2005a,b) guidelines. Consequently, examining the MOA (as well as dose-response) for cancer endpoints with statistically significant increases (e.g., endpoint-specific SMRs) is an important initial step in cancer dose-response assessment. Generally, the MOA and other information may support one of the following low-dose extrapolation approaches: (1) nonthreshold (typically a linear extrapolation to zero); (2) threshold (typically identifying a point of departure (POD) and applying uncertainty factors); or (3) both (TCEQ 2015). Thus, to the extent that an MOA for a chemical is understood, it informs the low-dose extrapolation procedure for that chemical. Examples of different shapes of dose-response curves are shown in Figure 1.



**Figure 1: Dose-Response Curve Examples**

One of the potential non-threshold dose-response curves shown in Figure 1 is supra-linear, with a steep low-dose slope. Section 7.7.7.3 of TCEQ (2015) addresses the potential use of a supra-linear dose-response model specifically, and indicates [*emphasis added*]:

As indicated by Crump and Allen (1985), linear exposure-response models are “considered conservative in the sense that other biologically plausible dose-response models would generally imply lower risks.” *Some researchers have published dose-response models that are inherently supra-linear at low exposures.* The increase of the hazard rate or relative risk of a supra-linear exposure-response model is faster at lower exposures than at higher exposures. *These types of models are generally not biologically plausible and tend to grossly exaggerate the estimation of risks at low exposures.*

The TCEQ guidelines (2015) go on to state... “Using supra-linear exposure-response models can only be justified if there is sufficient biological or mechanistic data to support their application.” Another way to state this more specifically might be [added]... “Using the initial steep slope starting at zero dose in supra-linear exposure-response models can only be justified if there is sufficient biological or mechanistic data to support their application.”

In this evaluation, the TCEQ concludes that the low-dose extrapolation of EtO-induced carcinogenic effects should be based on a model that is no more than linear, and arguably sublinear at endogenous levels and below. This conclusion is based on data relevant to the MOA, data on normal background endogenous EtO levels, key epidemiological study data (e.g., overall results for the UCC and NIOSH cohorts, doses associated with statistically increased cancer), and an evaluation of the ability of a model (or lack thereof) to reasonably predict the underlying dose-response data. *In contrast, USEPA (2016) used an overall supra-linear two-piece spline model for EtO carcinogenesis. This model assumed a non-threshold steep linear relationship between EtO and cancer formation at lower concentrations, with a high-concentration linear relationship that had a much shallower slope (i.e., an overall supra-linear relationship; similar to that depicted in Figure 1). In the present case, the TCEQ finds insufficient data to justify the supra-linear modeling approach (i.e., use of the steep lower-dose slope starting at zero dose from the linear two-piece spline model) ultimately adopted by USEPA (2016).* Even ignoring critical deterministic considerations (e.g., the lack of mechanistic data to justify use of an overall supra-linear model), as a much lesser secondary matter, the appropriate consideration of model fit criteria (e.g., for lymphoid cancer mortality in the NIOSH cohort) still does not support use of a supra-linear model over more conventional models (e.g., the likelihood of the linear two-piece spline model for lymphoid cancer mortality is not different from the likelihood of the null model at the 5% significance level, visual examination of model fits to the actual underlying data, etc.). These considerations are discussed in more detail below.

#### **3.4.1.1 Consideration of MOA**

MOA information is discussed in Section 3.3.1, which supports a likely mutagenic MOA for EtO carcinogenicity. *MOA information can suggest the likely shape of the dose-response curve at*

*lower doses (USEPA 2005a).* That is, toxicological principles can inform expectations about low-dose risk when truly low-dose data are unavailable. In this case, in the key epidemiological cohort (NIOSH) used by USEPA (2016), estimated mean worker exposures to EtO were  $\approx 1,000,000$ - $2,000,000$  times higher than central tendency ambient environmental EtO levels (see Section 3.2.1.1). Consideration of a direct acting DNA-reactive chemical in conjunction with normal detoxification processes and baseline levels of DNA repair enzymes that have evolved to efficiently detoxify and/or repair significant levels of endogenous EtO and associated adducts (in the endogenous range) suggests a no more than linear low-dose response component near the endogenous range with a transition to a higher dose-response slope at some point above the endogenous range where the body can no longer effectively detoxify EtO and/or repair the resulting damage. Thus, across a range of doses from truly low (e.g., ambient air, endogenous) to high (e.g., high occupational exposures), the expected dose-response could be characterized as appearing sublinear in the low-dose range and/or sublinear overall across doses (see Figure 1). In contrast to the sublinear response associated with impaired detoxification and/or DNA repair for direct acting chemicals such as EtO, supra-linear responses are associated with an MOA that involves the saturation of metabolic activation where fewer electrophiles are formed per unit dose at higher exposures, which is not the case for EtO (Swenberg et al. 2008).

Kirman and Hays (2017) expressed this conclusion similarly. That is, based on relevant considerations, an overall sublinear (not supra-linear) dose-response would be expected over the range of possible exposures to EtO, from those that result in total body burdens (endogenous + exogenous) within the normal endogenous level range to those that result in a total body burden significantly greater than the normal range where the normally effective detoxification/repair processes are overwhelmed. This conclusion is reasonably consistent with that of the USEPA [*emphasis added*], “EPA considers it *highly plausible that the dose-response relationship over the endogenous range is sublinear* (e.g., that the baseline levels of DNA repair enzymes and other protective systems evolved to deal with endogenous DNA damage would work more effectively for lower levels of endogenous adducts), that is, that the slope of the dose-response relationship for risk per adduct would increase as the level of endogenous adducts increases.” Figures 4 and 7 in Section 3.4.1.2.2 show that *EtO exposures corresponding to 1E-06 to 1E-04 excess risk based on USEPA (2016) are well below those corresponding to normal endogenous background levels*, inevitably leading to the expectation of sublinearity (or no excess risk) at such low doses based on the discussions above. In contrast to an overall linear or sublinear model, *using an overall supra-linear dose-response model (i.e., the steep low-dose component) to extrapolate risk down to an exposure lower than the point where a transition to a sublinear dose-response would be expected is not scientifically defensible and would be expected to grossly exaggerate truly low-dose risk (e.g., at endogenous levels and below).* That is, a steep slope from one portion of an overall supra-linear dose-response model should not be applied to a portion of the dose-response that admittedly is highly likely to have a shallow/sublinear slope.

Lastly, in addition to USEPA citing direct mutagenic activity as mechanistic justification for default linear extrapolation from high-to-low doses (pp. 4-22 and 4-37 of USEPA 2016) while still considering it “highly plausible that the dose-response relationship over the endogenous range is sublinear,” *it is also critical to note that USEPA acknowledges the lack of mechanistic data to support the biological plausibility of an overall supra-linear dose-response, stating “the EPA is not aware of a mechanistic explanation” in response to questions from the USEPA SAB (p. I-29 of USEPA 2016).*

In summary:

- An overall sublinear dose-response is expected for endogenous, direct-acting chemicals like EtO (i.e., an overall more-than-/supra-linear dose-response is not expected).
- USEPA acknowledges that it is *highly plausible* that the EtO dose-response relationship over the endogenous range is *sublinear*, and since the exposures corresponding to 1E-06 to 1E-04 excess risk based on USEPA (2016) are *well below* those corresponding to normal endogenous background levels (see Figures 4 and 7 in Section 3.4.1.2.2), a sublinear dose-response would be expected at such low doses (if any biologically meaningful response is to be expected).
- Consequently, *it is not scientifically defensible and likely grossly exaggerates EtO low-dose risk to use a supra-linear dose-response model (i.e., the steep low-dose slope) to extrapolate risk below the point where a transition to a sublinear dose-response is expected or “highly plausible” (e.g., at endogenous levels and below).*
- As body burdens progressively increase to significantly higher levels than the normal endogenous range, excess risk is expected to increase as the normally relatively effective detoxification/repair processes are progressively overwhelmed at higher and higher doses, *making higher-than-endogenous risk increasingly discernable from background risk consistent with the assessment of “excess” (i.e., above background) risk.*

USEPA should not have used an overall supra-linear model (i.e., the linear two-piece spline model) to derive a URF for EtO without a robust mechanistic justification for expecting supra-linearity (i.e., the steep lower-dose slope component) at truly low doses or used it to make a large low-dose extrapolation through and below an area (i.e., the endogenous range) where the agency actually considers sublinearity as “highly plausible.” The NIOSH data are, in fact, not inconsistent with such expectations at low doses of EtO as there are no truly low-dose data available from the cohort (Section 3.2.1.1).

### **3.4.1.2 Consideration of Endogenous Levels, Key Epidemiological Data, and Model Predictions**

#### **3.4.1.2.1 Endogenous Levels**

The analysis of Kirman and Hays (2017) documents endogenous EtO levels normally found within the body expressed in terms of exogenous EtO exposures. Such information can provide support for a given risk assessment approach for chemicals such as EtO that have both endogenous and exogenous exposure pathways. Hemoglobin N-(2-hydroxyethyl)-valine (HEV) adducts are caused by the reaction of EtO with hemoglobin in erythrocytes and provide a biomarker/molecular dosimeter of internal EtO dose that can be correlated with exogenous (i.e., ambient air) EtO exposure. USEPA (2005a) indicates that it may be informative to use such biomarkers of internal exposure for dose-response assessment or to provide insight into the potential shape of the dose-response curve at doses below those at which tumors are induced experimentally. As EtO is widely distributed in the body, the levels of HEV in erythrocytes are expected to be proportional to levels of HEV in other tissues (including target tissues), which are further expected to be proportional to tissue exposures to free EtO (Kirman and Hays 2017). Kirman and Hays (2017) conducted a meta-analysis from the published literature characterizing the distribution of HEV adducts in EtO-unexposed (i.e., the background endogenous distribution) and exposed populations (smokers, workers). The relationship between exposure and HEV adducts is linear with  $R^2=0.998$  (see Figure 3 of the study). In the meta-analysis for unexposed populations ( $n=661$ ), the weighted mean of background endogenous HEV (random effects model) was 21.1 pmol/g Hb with a standard deviation (SD) of 14.6 pmol/g Hb. The fixed effects model produced very similar results (see Table 3 of the study).

The TCEQ further evaluated the unexposed population data ( $n=661$ ) and determined that an increase in the mean HEV of  $\geq 0.861$  pmol/g Hb would be statistically significant ( $p \leq 0.05$ , Appendix 2). This HEV increase would correspond to continuous environmental air concentrations of  $\approx \geq 0.08$  ppb. While continuous exposure of this unexposed population to EtO concentrations  $\geq 0.08$  ppb would be expected to cause a statistically significant increase in HEV ( $\geq 0.861$  pmol/g Hb), there is no basis to conclude that such a change would be biologically significant. For example, the addition of 0.861 pmol/g Hb represents less than 5% of the mean and such a deviation appears to be well within the range of normal endogenous variation (e.g.,  $SD = 14.6$  pmol/g Hb; 5<sup>th</sup> to 95<sup>th</sup> percentile range = 6.1-48.7 pmol/g Hb; Table 4 of Kirman and Hays 2017). A statistically significant change that lacks biological significance is not considered an adverse response (TCEQ 2015).

A 1 SD change from the mean is considered as a critical effect size (CES) for potentially adverse continuous endpoints (TCEQ 2015) in the absence of a CES that distinguishes between levels of change that should be considered biologically significant or adverse and those that should not (i.e., absent a commonly accepted bright line demarcation). That being said, DNA and/or



protein (e.g., HEV) adducts are not usually used by environmental regulatory agencies to derive regulatory values because such adducts do not clearly meet the typical regulatory definition of “adverse effect” (i.e., a biochemical change, functional impairment, or pathologic lesion that affects the performance of the whole organism or reduces an organism's ability to respond to an additional environmental challenge). Rather, protein adducts such as HEV may simply be viewed as biomarkers of internal exposure that can be related back to external exposure levels in the present case. Accordingly, applying this 1 SD CES approach to continuous endpoint changes, particularly normal endogenous background levels, that do not clearly meet the typical regulatory definition of “adverse” may be considered conservative. Nevertheless, this analysis provides some needed context in this case. With that in mind, the continuous EtO exposure corresponding to an increase of 1 SD in HEV (14.6 pmol/g Hb) is  $\approx 1.3$  ppb (Table 4 of Kirman and Hays 2017). This does not provide a basis for expecting a biologically-significant/meaningful increase in internal exposure with continuous exposure to  $< 1$  ppb EtO because a  $> 1$  ppb continuous exposure is required to produce a 1 SD increase in HEV levels (which this example is conservatively considering as both statistically significant and potentially biologically significant). *Rather, these considerations suggest that inhalation exposure to sub-ppb EtO air concentrations (particularly parts per trillion (ppt) concentrations such as 0.1-10 ppt) is of little biological importance compared to normal endogenous background levels.* Considering EtO as a mutagenic carcinogen, this is generally consistent with the conclusions of Swenberg et al. (2008) that:

- 1) At low exposures, the likelihood that a mutation will arise from exogenous adducts becomes *de minimus* as compared to the large molecular dose normally formed endogenously (e.g., *Hprt* mutations were not statistically increased compared to background in mice exposed even up to 10 ppm EtO; high exposure to  $\geq 50$  ppm EtO was required to produce statistically significant increases over background; see Figure 9 of the study); and
- 2) The biologic effects of *de minimus* exposures below endogenous amounts are lost in the noise of the background (e.g., carcinogenesis is driven by endogenous DNA damage when the dose-response for mutations due to external EtO exposure comes into the normal background frequency due to endogenous production).

Put another way by Kirman and Hays (2017), pragmatically speaking, the considerable variation in endogenous EtO exposure creates a signal-to-noise issue when exogenous exposures fall well below those consistent with endogenous exposures, and in such cases small exogenous exposures may not contribute to total exposure or to potential effects in a biologically meaningful way.

Lastly, endogenous/background level data can be used for a reality check on the USEPA (2016) lymphoid cancer URF. Use of the EtO air concentration corresponding to the mean of normal

endogenous background levels in the unexposed population (1.9 ppb) in conjunction with the USEPA (2016) age-dependent adjustment factor (ADAF)-adjusted URF for lymphoid cancer (7.1E-03 per ppb) suggests a background incidence of  $\approx 1.35\%$  in nonsmokers due to endogenous EtO alone, which remarkably would be almost half (46%) of the lymphoid cancer background incidence of 3% (p. 4-95 of USEPA 2016). However, the smoking population must also be considered. Use of the EtO air concentration corresponding to the mean background in smokers (18.8 ppb at an HEV of 205.4 pmol/g Hb; Tables 2 and 4 of Kirman and Hays 2017) with the lymphoid cancer URF suggests an incidence of lymphoid cancer in smokers of  $\approx 13.3\%$  due to EtO alone. *Weighting the URF-estimated lymphoid cancer incidence for smokers (13.3%) at 20.9% of the population (for 2005 since current cancer rates would reflect contributions from past smoking, generally consistent with the USEPA 2016 exposure lag period of 15 years) with that for nonsmokers (1.35%) results in a population estimate of  $\approx 3.85\%$  due to background EtO levels in the U.S. population alone (e.g., without contributions from EtO in ambient air, contributions from the endogenous conversion of ethylene to EtO, known chemical leukemogens, or other risks factors such as genetic predispositions), which is higher than the lymphoid cancer background incidence of 3% cited by USEPA (p. 4-95 of USEPA 2016). This reality check suggests a scientifically unreasonable URF.*

In regard to the endogenous conversion of exogenous ethylene to EtO, USEPA may not have adequately explored the potential contributions of ethylene exposure to EtO risk, stating “only  $\approx 3\%$  of exogenous ethylene was converted to EtO in workers exposed to 0.3 ppm” and that “exogenous ethylene exposure is unlikely to contribute significantly to the effects associated with exposure to exogenous EtO in humans” (p. 3-30 of USEPA 2016). *However, based on USEPA’s URF, mean environmental concentrations of ethylene in many areas would in fact result in unacceptable excess risk estimates when multiplied by 0.03 to account for the USEPA-cited endogenous conversion of 3% of exogenous ethylene to EtO.* More specifically, greater than a  $1\text{E-}04$  excess risk would be estimated by USEPA’s EtO URF at long-term ethylene air concentrations greater than 0.37 ppb (i.e.,  $0.37 \text{ ppb ethylene} \times 0.03 \text{ converted-to-EtO} = 0.011 \text{ ppb EtO} \times 9.1\text{E-}03 \text{ per ppb} = 1.0\text{E-}04$ ). For additional context, this concentration is not only exceeded by ambient levels in many areas, but also by the indoor mean range (0.82-3.3 ppb) and personal exposure mean range (3.1-3.6) provided by Health Canada (2016). Interestingly, mean ethylene concentrations reported in human breath (e.g., 23 ppb in Fenske and Paulson 1999, 29-32 ppb reported in Bratu 2019) exceed this  $1\text{E-}04$  excess risk concentration (0.37 ppb ethylene based on USEPA 2016) by over 60-fold.

Data on normal endogenous background levels of EtO are also used in the next section, in conjunction with relevant epidemiological data.

#### 3.4.1.2.2 Key Epidemiological Data with Additional Context Using Endogenous Data and Model Predictions

Key epidemiological findings were reviewed for consistency with expectations for an overall supra-linear dose-response for EtO-induced carcinogenicity. *If the underlying dose-response for EtO-induced cancer in humans were supra-linear with a steep low-dose slope beginning at zero dose, statistically significant increases in critical cancer endpoints would be expected beginning in the lower occupational exposure groups.* That is, if exogenous EtO had a steep dose-response slope (i.e., were a potent carcinogen) starting in the true low-dose region, such as near the range of endogenous levels (as modeled in USEPA 2016), then statistically increased cancer mortality rates would be expected at the “low” worker doses evaluated for large cohorts (NIOSH, UCC), particularly considering that even “low” historical worker exposures have been significantly higher than environmental EtO concentrations (statistically confirmed; see Section 3.4.1.2.2.3). For example, in regard to the NIOSH cohort, Tables IV and V of Hornung et al. (1994) provide measured and estimated worker EtO exposure means (3.5-4.6 ppm) that are  $\approx 1,000,000$ - $2,000,000$  times higher than central tendency environmental levels ( $\approx 0.0024$ - $0.0034$  ppb per USEPA 2016). Remarkably, estimated daily EtO exposure for a job could have ranged from  $\approx 15,000$ - $32,000,000$  times the central tendency environmental levels (see Section 3.2.1.1). Mean NIOSH cohort exposure levels of 3.5-4.6 ppm, for example, are over 1,800-2,400 times higher than mean normal endogenous background and about 500-700 times higher than even the 99<sup>th</sup> percentile of normal endogenous background (Table 4 of Kirman and Hays 2017). For the UCC cohort, the average cumulative EtO exposure was twice as high as that for the NIOSH cohort (although the study power is less; see Section 3.2.1.2). *Thus, considering significantly elevated historical occupational exposures, if EtO-induced cancer had a steep dose-response slope (i.e., were a potent carcinogen) in the true low-dose region (as modeled in USEPA 2016), then the epidemiological evidence for cancer in workers induced by this direct-acting mutagenic carcinogen would be expected to be conclusive, for both males and females, but is not.* For example, regarding the epidemiological evidence, USEPA (2016) states that while there is “some evidence of dose-response relationships”, “there is *little strength* in the associations.” This certainly would not be expected for a potent low-dose human carcinogen with a steep low-dose slope (as part of the overall supra-linear dose-response) when there was significantly elevated historical occupational exposure, but nevertheless is why USEPA (2016) and the TCEQ must partially rely on animal data for a finding of “carcinogenic to humans.” Below, key epidemiological data, alone and in conjunction with data on normal endogenous background levels, are further reviewed to determine if this information is supportive of adoption of a supra-linear dose-response (i.e., the steep low-dose component) for low-dose extrapolation of carcinogenic risk for EtO.

#### **3.4.1.2.2.1 Key Data from the UCC Cohort**

Multiple analyses of epidemiological data from the UCC cohort have shown no long-term carcinogenic effects associated with EtO exposure. Swaen et al. (2009) reported no indications of excess cancer risk, including for the lymphohematopoietic malignancies. There were no trends or associations with cumulative exposure for all cause, leukemia, or lymphoid malignancy mortality. Additionally, no statistically significantly elevated SMRs were found in the analysis by hire date, there were no statistically significant increases in the longest duration category, and no suggested trends by duration (all surrogates of exposure). *Likewise, an update of the UCC cohort through 2013 (unpublished as of the date of this DSD) concludes that examination of mortality from all causes of death, all cancers, leukemia, non-Hodgkin's lymphoma, and lymphoid malignancies revealed no evidence for an exposure-related response. EtO exposure in this cohort (with average cumulative dose of  $\approx 67$  ppm-years and average follow-up of  $\approx 41$  years) was not associated with an observable increase in lymphohematopoietic cancer mortality* (personal communication with study co-author Ciriaco Valdez-Flores). These UCC study results in highly-exposed workers are not consistent with EtO-induced carcinogenicity, much less a supra-linear dose-response with a steep low-dose component (e.g., USEPA's linear two-piece spline model).

#### **3.4.1.2.2.2 Key Data from the NIOSH Cohort and Endogenous Data**

Regarding key epidemiological data, this section primarily focuses on statistically significant cancer endpoint increases with EtO exposure in the most sensitive sex (male or female) in the NIOSH cohort, although combined results (male + female) are also discussed. Tables 4 and 5 contain the lowest male or female dose group with a statistically significant increase for each critical cancer endpoint in the cohort based on evaluations by Valdez-Flores et al. (2010) and Steenland et al. (2004, 2003), respectively. Columns 1 and 4 of Table 4 show that based on the analyses in Valdez-Flores et al. (2010), critical cancer endpoints in the NIOSH cohort (i.e., lymphohematopoietic, lymphoid, non-Hodgkin's lymphoma) were only statistically increased in males, and only in the highest (5<sup>th</sup>) EtO exposure quantile. Breast cancer in females was not statistically increased even in the highest exposure group (5<sup>th</sup> quantile). The upper ends of the exposure intervals for these highest (5<sup>th</sup>) quantiles are open ended, and even the lower ends of the exposure intervals are extraordinarily high. *It is remarkable that although workers were exposed to EtO air concentrations  $\approx 15,000$ - $32,000,000$  times higher than central tendency environmental levels, critical cancer endpoints such as lymphoid cancer mortality were only statistically increased in the highest male exposure group. Such high occupational exposures being required to produce statistically significant increases in a large cohort is not consistent with a steep dose-response slope beginning at zero dose in the low-dose region of a supra-linear dose-response (e.g., in the range of endogenously- or environmentally-relevant doses).* Importantly, Table 4 also utilizes data from Kirman and Hays (2017) to calculate environmental EtO exposures (ppm-days) corresponding to the normal endogenous background range (column 2), and then converts those environmental exposures to equivalent occupational exposures

(column 3) for comparison to the occupational carcinogenic doses (ppm-days) for critical cancer endpoints (i.e., occupational doses associated with statistically increased cancer). The comparisons provided in column 5 of Table 4 show that across statistically increased cancer endpoints (excludes breast cancer), the lowest carcinogenic doses for EtO (ppm-days, unlagged) in either sex are:

- $\approx 500$ -800 times higher than the mean endogenous background EtO dose in the unexposed population;
- $\approx 600$ -900 times higher than the median endogenous background EtO dose in the unexposed population;
- $\approx 1,600$ -2,700 times higher than the 5<sup>th</sup> percentile of normal endogenous background EtO doses in the unexposed population; and
- $\approx 200$ -300 times higher than even the 95<sup>th</sup> percentile of normal endogenous background EtO doses in the unexposed population.

The bottom of Table 4 shows that on average, the lower ends of the carcinogenic doses for the most sensitive sex across endpoints are  $\approx 600$  higher than the mean endogenous background EtO dose in the unexposed population,  $\approx 700$  higher than the median endogenous background EtO dose,  $\approx 2,100$  higher than the 5<sup>th</sup> percentile of normal endogenous background EtO doses, and  $\approx 300$  times higher than the 95<sup>th</sup> percentile of normal endogenous background EtO doses in the unexposed population (Table 4).

Similarly, columns 1 and 4 of Table 5 show that based on the analyses in Steenland et al. (2004, 2003), certain critical cancer endpoints in the NIOSH cohort (i.e., all hematopoietic, lymphoid, non-Hodgkin's lymphoma) were only statistically increased in males, while breast cancer incidence was only statistically increased in females, and only in the highest EtO exposure quantiles for each of these cancer endpoints. The upper ends of the exposure intervals for these highest quantiles are open ended, and even the lower ends of the exposure intervals for these significantly lagged exposures (typically 15 years) are still remarkably high. High occupational EtO exposures being required to produce statistically significant increases in a large cohort is not consistent with the steep low-dose slope of a supra-linear dose-response starting at zero dose (e.g., across much lower and more environmentally-relevant exposures). The comparisons provided in column 5 of Table 5 show that on average, these lagged carcinogenic doses are:

- $\approx 90$  times higher than the mean endogenous background EtO dose in the unexposed population;
- $\approx 100$  times higher than the median endogenous background EtO dose in the unexposed population;

- $\approx 300$  times higher than the 5<sup>th</sup> percentile of normal endogenous background EtO doses in the unexposed population; and
- $\approx 40$  times higher than even the 95<sup>th</sup> percentile of normal endogenous background EtO doses in the unexposed population.

These differences are appreciable considering that the occupational exposures used for these comparisons have been reduced by lagging the exposure 10-15 years, and by using the lowest end of the carcinogenic dose range for each endpoint.

Based on the data in Tables 4 and 5 (as well as data from the cited source studies), Figures 2, 3, 4 and Figures 5, 6, 7 (Figures 3 and 6 in particular, with a log scale for the x- and y-axis) help demonstrate the significant difference between EtO doses corresponding to the normal endogenous background range (5<sup>th</sup>-95<sup>th</sup> percentile) and those associated with (and not associated with) statistically significant increases in the most sensitive sex for critical cancer endpoints in the NIOSH cohort (Valdez-Flores et al. 2010, Steenland et al. 2004, 2003). Figures 4 and 7 help to put into perspective the large differences between occupational EtO doses (ppm-days) and doses corresponding to 1E-06 to 1E-04 excess risk based on USEPA (2016) (i.e., 0.0001-0.01 ppb environmental converted to occupational ppm-days), those corresponding to normal endogenous background levels, and those associated with statistically significant increases in risk. *EtO doses at 1E-06 to 1E-04 excess risk based on USEPA (2016) are orders of magnitude below both those corresponding to normal endogenous background levels and those associated with statistically significant cancer increases in the NIOSH cohort.* Additionally, as shown in Figure 7, although USEPA considers it “highly plausible that the dose-response relationship over the endogenous range is *sublinear*,” USEPA (2016) applied remarkably steep *supra-linear* model low-dose slopes for lymphoid and breast cancer (see Figures 4-9 and 4-10 of USEPA 2016) in the very region where sublinearity is expected (i.e.,  $\leq$  the normal endogenous background range). One consequence is that the EtO air concentration at even the maximum acceptable excess risk (0.01 ppb at 1E-04 risk) is over 30 and 50 times lower than air concentrations corresponding to the 1<sup>st</sup> and 5<sup>th</sup> percentile of normal endogenous background levels, respectively (e.g., 0.56 ppb at the 5<sup>th</sup> percentile (Table 4 of Kirman and Hays 2017) / 0.01 ppb at 1E-04 risk = 56-fold higher). Put another way, the USEPA considers EtO air concentrations corresponding to more than  $\approx 0.5\%$  percent of mean normal endogenous in nonsmokers to be associated with unacceptable risk (i.e., 0.01 ppb/1.9 ppb corresponding to the mean endogenous in nonsmokers (Table 4 of Kirman and Hays 2017)  $\times 100 = 0.53\%$ ).

In regard to combined (male + female) results, although there were no statistically significant increases in mortality in female workers alone for any critical cancer endpoint in any cumulative EtO exposure group of the NIOSH cohort, combining data from male and female workers results in statistically significant increases for lymphohematopoietic and lymphoid cancer mortality at lower cumulative exposures than when evaluated on a sex-specific basis. For example, although

Steenland et al. (2004, 2003) is the source for Table 5, USEPA (2016) had additional analyses conducted for males + females (15-year exposure lag) that showed statistically increased lymphohematopoietic cancer mortality beginning at  $\approx 2,440$  ppm-days (midpoint of the 3<sup>rd</sup> EtO exposure quintile), and increased lymphoid cancer mortality at  $\approx 2,440$  ppm-days (midpoint of the 3<sup>rd</sup> quintile) and  $\geq 13,500$  ppm-days (lower end of 5<sup>th</sup> quintile) (Table 4-2 of USEPA 2016). Similarly, Valdez-Flores et al. (2010) conducted analyses for males + females (no exposure lag) that showed statistically increased lymphoid cancer mortality at  $\approx 2,300$  ppm-days (2<sup>nd</sup> EtO exposure quintile midpoint) and  $\geq 47,559$  ppm-days (5<sup>th</sup> quintile lower end) (Table S.9 of the study). While an explanation of the differences in results for the most sensitive sex versus combined analyses is beyond the scope of this DSD, it is noted that the lower end of these lagged/unlagged carcinogenic EtO doses for NIOSH males + females is  $\approx 50$  times higher than lower percentile normal endogenous doses,  $\approx 10$ -20 times higher than median and upper percentile endogenous doses, and  $> 26,000$ -37,000 times higher than that associated with typical environmental EtO levels (i.e., background and environmental means of  $0.0044$ - $0.0062$   $\mu\text{g}/\text{m}^3$  (USEPA 2016) =  $0.0024$ - $0.0034$  ppb  $\times 70$  years  $\times 365$  days/year =  $61.32$ - $86.87$  ppb-days =  $0.06132$ - $0.08687$  ppm-days).

In summary, high occupational EtO exposure being necessary to produce statistical increases in cancer in the NIOSH cohort, especially in conjunction with null results reported from the UCC cohort (with follow-up through 2013), is not supportive of the steep slope of an overall supra-linear dose-response beginning just above zero dose (e.g., at lower and more environmentally-relevant exposures). *More specifically, risk at endogenous background level doses of EtO (and below) is not expected to be consistent with the lower steep slope portion of an overall supra-linear model (e.g., USEPA's linear two-piece spline model) considering: (1) carcinogenic EtO doses based on the NIOSH study are orders of magnitude higher than normal background endogenous doses in the unexposed population (Tables 4 and 5); (2) USEPA's expectation of sublinearity in the endogenous range, which the TCEQ generally agrees with based on MOA considerations (see Section 3.4.1.1); and (3) the overall study results for both the NIOSH and UCC cohorts in workers exposed to extraordinarily high air concentrations/doses of EtO (e.g., negative findings from the UCC cohort; no statistically increased cancer in the lower NIOSH exposure groups that were still subjected to extraordinarily high air concentrations/doses).* In regard to the steep low-dose slope of an overall supra-linear dose-response being inconsistent with cohort findings on EtO-induced carcinogenicity, **the next section demonstrates the statistically significant over-estimation of risk from EtO exposure for the NIOSH cohort by USEPA's selected model assessment (i.e., the upper bound on the linear two-piece spline model) for both total lymphoid cancer mortalities in the cohort as well as for every exposure quintile.**

**Table 4: Occupational Exposures Corresponding to Normal Background Endogenous Levels of EtO versus Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort (Valdez-Flores et al. 2010)**

Statistically Increased Cancer Mortality Endpoint in NIOSH Cohort (sex-specific)	Environmental Exposures Corresponding to Normal Background Endogenous EtO Levels (ppm-days) <sup>a</sup>	Occupational Exposures Equivalent to Environmental Exposures Corresponding to Endogenous EtO Levels (ppm-days) <sup>b</sup>	Occupational Exposure Interval for Lowest Quantile with Statistically Elevated Risk (ppm-days) <sup>c</sup>	Carcinogenic Dose Compared to Normal Endogenous EtO Background Levels
Lymphohematopoietic (statistically increased in males, not females) <sup>d</sup>	48.5 (mean) 40.9 (median) 14.3 (5 <sup>th</sup> percentile) 115.0 (95 <sup>th</sup> percentile)	147.7 124.3 43.5 349.7	≥70,223.59 (highest (5 <sup>th</sup> ) quantile)	≥475.6 times ≥564.8 times ≥1,613.6 times ≥200.8 times
Lymphoid Tumors (statistically increased in males, not females) <sup>d</sup>	48.5 (mean) 40.9 (median) 14.3 (5 <sup>th</sup> percentile) 115.0 (95 <sup>th</sup> percentile)	147.7 124.3 43.5 349.7	≥88,348.10 (highest (5 <sup>th</sup> ) quantile)	≥598.3 times ≥710.5 times ≥2,030.0 times ≥252.6 times
Non-Hodgkin's Lymphoma (statistically increased in males, not females) <sup>d</sup>	48.5 (mean) 40.9 (median) 14.3 (5 <sup>th</sup> percentile) 115.0 (95 <sup>th</sup> percentile)	147.7 124.3 43.5 349.7	≥117,018.15 (highest (5 <sup>th</sup> ) quantile)	≥792.5 times ≥941.1 times ≥2,688.8 times ≥334.6 times
Breast Cancer ( <i>not statistically increased</i> in females)	48.5 (mean) 40.9 (median) 14.3 (5 <sup>th</sup> percentile) 115.0 (95 <sup>th</sup> percentile)	147.7 124.3 43.5 349.7	≥14,959.26 (highest (5 <sup>th</sup> ) quantile)	≥101.3 times ≥120.3 times ≥343.9 times ≥42.8 times
Carcinogenic Dose <sup>e</sup> Average Magnitude of Exceedance Over Normal Background Levels at the Endogenous:			mean median 5th percentile 95th percentile	≥622.1 times ≥738.8 times ≥2,110.8 times ≥262.7 times



<sup>a</sup> Environmental exposure (ppm-days) corresponding to normal endogenous = continuous air concentrations of 0.0019, 0.0016, and 0.00056-0.0045 ppm corresponding to the mean, median, and 5<sup>th</sup>-95<sup>th</sup> percentile range for normal endogenous HEV levels in the unexposed (Table 4 of Kirman and Hays 2017) × 70 years × 365 days/year.

<sup>b</sup> Occupational exposure equivalent to environmental (ppm-days) = environmental (ppm-days) × 20 m<sup>3</sup>/10 m<sup>3</sup> × 365 days/240 days (i.e., a multiplicative factor of ≈3.042; unrounded values used for calculations); see footnote “2” to Table S.12 of Valdez-Flores et al. (2010).

<sup>c</sup> Table S.9 of Valdez-Flores et al. (2010): Rate ratio analyses and Cox proportional hazards model for cumulative exposure for each combination of endpoint, sex, and study; note that breast cancer was not statistically increased in the rate ratio analysis of Valdez-Flores et al. (2010).

<sup>d</sup> Not statistically elevated in females, only males, so male + female combined results not provided as any risk is driven by the dose-response in males (e.g., statistically significant increases for lymphoid tumors and non-Hodgkin’s lymphoma in males + females combined but not in females alone, only males).

<sup>e</sup> These comparisons exclude breast cancer as it was not statistically increased in the rate ratio analyses of Valdez-Flores et al. (2010).

**Table 5: Occupational Exposures Corresponding to Normal Background Endogenous Levels of EtO versus Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort (Steenland et al. 2004, 2003)**


Statistically Increased Cancer Endpoint in NIOSH Cohort (sex-specific)	Environmental Exposures Corresponding to Normal Background Endogenous EtO Levels (ppm-days) <sup>a</sup>	Occupational Exposures Equivalent to Environmental Exposures Corresponding to Endogenous EtO Levels (ppm-days) <sup>b</sup>	Occupational Exposure Interval for Lowest Quantile with Statistically Elevated Risk (ppm-days) <sup>c</sup>	Carcinogenic Dose Compared to Normal Endogenous EtO Background Levels
All Hematopoietic (statistically increased in males, not females) <sup>d</sup>	48.5 (mean) 40.9 (median) 14.3 (5 <sup>th</sup> percentile) 115.0 (95 <sup>th</sup> percentile)	147.7 124.3 43.5 349.7	≥13,500 (highest (4 <sup>th</sup> ) quantile, 15-yr lag)	≥91.4 times ≥108.6 times ≥310.3 times ≥38.6 times
Lymphoid Cell Line Tumors (statistically increased in males, not females) <sup>d</sup>	48.5 (mean) 40.9 (median) 14.3 (5 <sup>th</sup> percentile) 115.0 (95 <sup>th</sup> percentile)	147.7 124.3 43.5 349.7	≥13,500 (highest (4 <sup>th</sup> ) quantile, 15-yr lag)	≥91.4 times ≥108.6 times ≥310.3 times ≥38.6 times
Non-Hodgkin's Lymphoma (statistically increased in males, not females) <sup>d</sup>	48.5 (mean) 40.9 (median) 14.3 (5 <sup>th</sup> percentile) 115.0 (95 <sup>th</sup> percentile)	147.7 124.3 43.5 349.7	≥13,500 (highest (4 <sup>th</sup> ) quantile, 10-yr lag)	≥91.4 times ≥108.6 times ≥310.3 times ≥38.6 times
Breast Cancer (incidence in females)	48.5 (mean) 40.9 (median) 14.3 (5 <sup>th</sup> percentile) 115.0 (95 <sup>th</sup> percentile)	147.7 124.3 43.5 349.7	>14,620 (highest (5 <sup>th</sup> ) quantile, 15-yr lag)	>99.0 times >117.6 times >335.9 times >41.8 times
<b>Carcinogenic Dose Average Magnitude of Exceedance Over Normal Background Levels at the Endogenous:</b>			<b>mean median 5th percentile 95th percentile</b>	<b>≥93.3 times ≥110.9 times ≥316.7 times ≥39.4 times</b>

<sup>a</sup> Environmental exposure (ppm-days) corresponding to normal endogenous = continuous air concentrations of 0.0019, 0.0016, and 0.00056-0.0045 ppm corresponding to the mean, median, and 5<sup>th</sup>-95<sup>th</sup> percentile range for normal endogenous HEV levels in the unexposed (Table 4 of Kirman and Hays 2017) × 70 years × 365 days/year.


<sup>b</sup> Occupational exposure equivalent to environmental (ppm-days) = environmental (ppm-days) × 20 m<sup>3</sup>/10 m<sup>3</sup> × 365 days/240 days (i.e., a multiplicative factor of ≈3.042; unrounded values used for calculations); see footnote “2” to Table S.12 of Valdez-Flores et al. (2010).

<sup>c</sup> Tables 4, 6, and 7 of Steenland et al. (2004) and Table 4 of Steenland et al. (2003).


<sup>d</sup> Not statistically elevated in females or females + males, only males.




**Figure 2: Occupational Exposures Corresponding to Normal Background Endogenous Levels of EtO versus Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort - Linear Scale**




**Figure 3: Occupational Exposures Corresponding to Normal Background Endogenous Levels of EtO versus Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort - Log Scale**



**Figure 4: Occupational Exposures Corresponding to USEPA Risk-Based Doses and Normal Background Endogenous Levels of EtO versus Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort - Log Scale**




**Figure 5: Occupational Exposures Corresponding to Normal Background Endogenous Levels of EtO versus Lagged Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort - Linear Scale**



**Figure 6: Occupational Exposures Corresponding to Normal Background Endogenous Levels of EtO versus Lagged Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort - Log Scale**






**Figure 7: Occupational Exposures Corresponding to USEPA Risk-Based Doses and Normal Background Endogenous Levels of EtO versus Lagged Exposures Associated with Statistically Significant Increases in Critical Cancer Endpoints in the NIOSH Cohort - Log Scale**

#### **3.4.1.2.2.3 Lymphoid Cancer in the NIOSH Cohort - Model Predictions Versus Observed**

To ground-truth USEPA and other EtO dose-response models (e.g., USEPA's selected assessment of the upper bound on the linear two-piece spline model), the various models were used to estimate the number of lymphoid cancer deaths predicted to occur at the EtO exposure levels estimated for the NIOSH cohort compared to the number of cancer deaths that were actually observed in that cohort (details in Appendix 3). This model ground-truthing exercise demonstrated that *statistically significant increases in lymphoid cancer mortality would have been observed in every cumulative exposure group beginning in the lowest EtO exposure group of the NIOSH cohort if the model assessment selected by USEPA (i.e., the upper bound of the linear two-piece spline model with the "knot" at 1,600 ppm × days, 15-year exposure lag) were realistic (Table 32 of Appendix 3). In addition, USEPA's selected model assessment predicts that a total of 141 lymphoid cancer deaths (95% CI of 108 to 188) would be expected with the EtO exposure levels estimated for the NIOSH cohort (Table 31 of Appendix 3). However, only 53 total deaths from lymphoid cancers were actually observed, demonstrating that USEPA's selected model assessment statistically significantly over-estimates risk.* By contrast, the model assessment ultimately selected by the TCEQ (i.e., the upper bound on the Cox proportional hazards model, 15-year exposure lag; see Section 3.4.1.4.2) is reasonably accurate, predicting 59 lymphoid cancer mortalities from EtO exposure compared to the 53 actually observed (Figure 8).

For quintile-specific results (Table 32 of Appendix 3), the model analysis demonstrated that *for every cumulative EtO exposure group, the linear two-piece spline model assessment utilized by USEPA (2016) statistically significantly over-predicts the 11 lymphoid cancer mortalities that actually occurred in each quintile.* Further, the predictions by the model assessment selected by USEPA (2016) demonstrate that *if the model were realistic, then statistically significant lymphoid cancer increases would have occurred in every cumulative EtO exposure quintile beginning in the lowest (i.e., the lower ends of the 95% CIs range from 17-20 lymphoid cancer mortalities, compared to the 9 lymphoid cancer mortalities in the controls).* These predictions by USEPA's selected model assessment are not borne out by the observed cohort data. On the other hand, the log-linear (Cox proportional hazards) model that is ultimately chosen by the TCEQ (see Section 3.4.1.4.2) does not significantly over- or under-predict the lymphoid cancer deaths observed in any NIOSH cumulative EtO exposure group (Figures 9-12).

In accordance with the discussions above, *the application of the model assessment selected by USEPA (i.e., the upper bound of the linear two-piece spline model with the "knot" at 1,600 ppm × days, 15-year exposure lag) results in statistically erroneous over-predictions of lymphoid cancer risk for the very cohort the model is supposed to fit.* The model is erroneous for the cohort as a whole and every cumulative exposure group, and the URF derived from it lacks the scientific credibility required for regulatory agency use for this and other reasons described in other sections of this DSD (i.e., the lack of mechanistic justification and other considerations).



**Figure 8: Statistically Significant Over-Prediction of Lymphoid Cancer Mortalities from EtO Exposure by the USEPA (2016) Selected Model Assessment (upper bound of linear two-piece spline) for the NIOSH Cohort versus Reasonably Accurate Results from the TCEQ Selected Model (upper bound Cox proportional hazards)**






Figure 9: Statistically Significant Over-Prediction of Lymphoid Cancer Mortalities from EtO Exposure by the USEPA (2016) Selected Model Assessment (upper bound of linear two-piece spline) for the NIOSH Cohort versus Reasonably Accurate Results from the TCEQ Selected Model (upper bound Cox proportional hazards) - Quintile 2



**Figure 10: Statistically Significant Over-Prediction of Lymphoid Cancer Mortalities from EtO Exposure by the USEPA (2016) Selected Model Assessment (upper bound of linear two-piece spline) for the NIOSH Cohort versus Reasonably Accurate Results from the TCEQ Selected Model (upper bound Cox proportional hazards) - Quintile 3**



**Figure 11: Statistically Significant Over-Prediction of Lymphoid Cancer Mortalities from EtO Exposure by the USEPA (2016) Selected Model Assessment (upper bound of linear two-piece spline) for the NIOSH Cohort versus Reasonably Accurate Results from the TCEQ Selected Model (upper bound Cox proportional hazards) - Quintile 4**




Figure 12: Statistically Significant Over-Prediction of Lymphoid Cancer Mortalities from EtO Exposure by the USEPA (2016) Selected Model Assessment (upper bound of linear two-piece spline) for the NIOSH Cohort versus Reasonably Accurate Results from the TCEQ Selected Model (upper bound Cox proportional hazards) - Quintile 5

#### **3.4.1.2.2.4 Implications of Key Epidemiological Findings, Endogenous Data, and Model Predictions for Use of USEPA's Selected Linear Two-Piece Spline Model Assessment and URF**

In summary, the consideration of key epidemiological data such as findings for the UCC and NIOSH cohorts, the carcinogenic doses associated with critical cancer endpoints in the NIOSH study, doses corresponding to normal background endogenous levels, as well as demonstrations of statistically significant over-prediction by USEPA's selected linear two-spline model assessment for lymphoid cancer (the primary URF driver) is not supportive of a supra-linear EtO dose-response (i.e., the steep low-dose slope portion), particularly for low-dose extrapolation (e.g., within or below the range of normal endogenous and ambient levels). Regarding the endogenous range, USEPA (2016) considers it *"highly plausible that the dose-response relationship over the endogenous range is sublinear."* Despite this, as shown in Figure 7, USEPA (2016) actually applied exceptionally steep low-dose slopes from overall supra-linear models for lymphoid and breast cancer in the very low-dose region where a sublinear dose-response is expected (i.e., the endogenous range and even lower). The TCEQ contends that USEPA's choice and application of an overall supra-linear EtO dose-response relationship is therefore internally inconsistent (i.e., self-contradictory). Moreover, the TCEQ has determined that USEPA's use of a supra-linear dose-response (i.e., in particular the steep low-dose slope portion) for low-dose extrapolation is contrary to other considerations discussed above and is not scientifically defensible. *Among other considerations, as part of the scientific weight of evidence, the demonstration of the statistically significant over-estimation of lymphoid cancer risk by the model assessment selected by USEPA (i.e., the upper bound of the linear two-piece spline model with the "knot" at 1,600 ppm × days, 15-year exposure lag), compared to the observed number of lymphoid cancer deaths in the cohort, indicates that this model is not appropriate for deriving the EtO URF.*

[As a peripherally-related topic, the inability to observe sublinearity in the NIOSH cohort might be explained by the lack of dose-response data at low air concentrations (e.g., a few ppb) that would allow total internal exposures (endogenous + exogenous) to remain in/near the normal endogenous range. See Figures 3 and 6, keeping in mind that the exogenous exposures corresponding to the normal background endogenous range would themselves produce internal exposures equal to endogenous exposures, over and above them (and that occupational exposures in Figure 6 have been artificially reduced by lagging exposure 10-15 years). Thus, the available dose-response data appear predominated by exposures above the area in the dose-response expected to be sublinear (i.e., within/near/below the normal endogenous range). In such a case, if the available data are at doses sufficiently high to be in the area of the dose-response where disproportionally increased risk occurs, then the dose-response observed based on the data available might be expected to appear supra-linear overall. Other than providing a hypothetical example in Appendix 4, the TCEQ has not evaluated this possibility further as it is somewhat beyond the scope of this DSD.]



### 3.4.1.3 Consideration of Model Fit Criteria

Although some models have a biological or mechanistic basis (e.g., Michaelis-Menten model of enzyme kinetics, CIIT biologically-based model for formaldehyde), many models used for dose-response assessment do not (e.g., often only to the extent that low-dose linearity is viewed as consistent with a mutagenic MOA). Thus, model fit is a much lesser consideration compared to the consideration of any data that may (or may not) adequately support use of a supra-linear model (TCEQ 2015). For example, *neither USEPA nor TCEQ can cite mechanistic data for EtO that sufficiently support use of a supra-linear model, particularly in the context of concerns about the steepness of the linear two-piece spline model slope over the low-dose region* (e.g., USEPA 2016 considers *sublinearity* “highly plausible” over the endogenous range). In fact, relevant considerations support that the steep low-dose of a supra-linear model should not be used over the low-dose region in this case (see Sections 3.4.1.1 and 3.4.1.2). However, model fit is nevertheless a topic of interest for EtO and therefore the topic is discussed, albeit not as a deterministic consideration. This section focuses on lymphoid cancer because it was the primary driver of the USEPA (2016) URF, although model fit for breast cancer incidence is also considered. In TCEQ’s evaluation of dose-response models that provide the most appropriate fit to the EtO cohort data, the agency also evaluated USEPA’s application of model fit criteria to determine if appropriate for use by the TCEQ.

There are two important overarching issues with USEPA’s consideration of model fit and ultimate selection of the linear two-piece spline model that the TCEQ must duly consider. The first concerns the statistical optimization of “knot” values for the two-piece spline modeling approach. USEPA (2016) indicates that for this approach, the splines were “fit” to the EtO cancer exposure-response data, and that the knot was generally selected by evaluating different knots in increments (e.g., 100, 500, or 1,000 ppm × days) of cumulative exposure and then by choosing the one that resulted in the best (i.e., largest) model likelihood (pp. 4-13, 4-26, 4-36, and 4-45 of USEPA 2016). Thus, from the process described, it is readily apparent that:

- The “knot” was an iteratively fit model parameter and not simply “preselected” (p. 4-52 of USEPA 2016); and
- The knot values, *being statistically estimated/optimized based on the NIOSH data*, clearly do not conform to the USEPA SAB’s notion of potentially fixing some model parameters *not estimated from the data* in the interest of parsimony (see p. 12 of SAB 2015).

“Preselected” is a somewhat ambiguous term that does not adequately characterize and obfuscates how the knot value was statistically fit. This is an important procedural/methodological issue as it appears that under USEPA’s interpretation, multiple model parameters could be statistically estimated/optimized upstream of a final dose-response model, yet none of the fitted parameters would ultimately count as an estimated (*k*) parameter

as they were “preselected” based on prior model-fitting exercises. In the present case, the knot values were determined through model fitting with NIOSH data (e.g., maximization of the likelihood of the model for best fit to the lymphoid cancer data), and thus are obviously estimated parameters ( $k$ ) in the analysis. That is, for the spline models, the parameters ( $k$ ) estimated by USEPA were clearly: (1) the “knot” value; (2) the slope above the knot; and (3) the slope below the knot ( $k=3$ ). However, USEPA (2016) did not account for statistically estimating the optimized knot value. Thus, it appears the degrees of freedom ( $df$ ) were inappropriately enlarged for the spline models (i.e.,  $df = \text{data points modeled } (n) - k$ ), which was not inconsequential. Among other consequences, this:

- Inappropriately decreased the p-value for adequate statistical fit, incorrectly implying that the linear two-piece spline model with a knot at 1,600 ppm × days for lymphoid cancer fit the data statistically better than other models in Table 4-6 of USEPA (2016); and
- Inappropriately decreased the Akaike information criterion (AIC) for the spline models, which did not allow for an appropriate comparison of model fit among models for either lymphoid cancer or breast cancer incidence.

Thus, this appears to amount to an unfortunate statistical misevaluation of model fit in USEPA (2016). Appendix D of USEPA (2016), a revised report of Dr. Kyle Steenland submitted in 2010 under contract with USEPA, acknowledges this  $df/p$ -value issue but then argues for the log-linear two-piece spline model (not ultimately selected by USEPA) not based on statistical fit criteria, but rather conformance with the categorical and cubic spline models in the low-exposure region and the nearly linear exposure-response relationship in that region (p. D-13 of USEPA 2016). In regard to the linear two-piece spline model ultimately selected by USEPA (2016), Section 3.4.1.2.3 demonstrates how it statistically significantly over-estimates risk for every cumulative exposure group, including the lowest (see Figures 9-12).

In regard to the first bullet above, an example in Appendix 5 demonstrates that a p-value of 0.15 is the correct p-value for the likelihood ratio test (not 0.07 as in Table 4-6 of USEPA 2016) when appropriately using  $k=3$  for the log-linear two-piece spline model with a knot at 1,600 ppm × days (lymphoid cancer). Similarly, for the linear two-piece spline model with a knot at 1,600 ppm × days (lymphoid cancer) ultimately selected in USEPA (2016), the correct p-value is 0.14 (not 0.07 as in Table 4-6 of USEPA 2016). *Thus, the correct p-values indicate that the likelihoods of these two-piece spline models (linear and log-linear) with knots at 1,600 ppm × days are not different from the likelihood of the null model at the 5% significance level (i.e., the fitted two-piece spline models do not explain the variability in the data statistically significantly better than the null model). The same is true for all two-piece spline models in Table 4-6 of USEPA (2016) when appropriately using  $k=3$  (p-value range of 0.11-0.15), putting the two-piece spline models and the log-linear (standard Cox regression) model on equal ground in this regard*

*(Appendix 5), although the linear two-piece spline assessment selected in USEPA (2016) statistically significantly over-predicts lymphoid cancer risk whereas the TCEQ's log-linear model does not over- or under-predict risk (see Section 3.4.1.2.2.3, Figure 8, and Appendix 3).*

Regarding the second bullet, the USEPA SAB does not comment on or examine this specific AIC issue in Appendix H of USEPA (2016). *The SAB does recommend less reliance on the AIC (e.g., pp. I-2 and I-9 of USEPA 2016), particularly its naïve use without other scientific considerations (pp. I-17 and I-18 of USEPA 2016), and discusses the true fixing of some model parameters (as opposed to statistical fitting/estimating parameter values from the data as USEPA did) in a more general discussion of model parsimony (p. I-16 of USEPA 2016).* However, Appendix 5 of this DSD contains an example showing that an AIC of 464.6 is the correct AIC value (not 462.6 as in Table 4-6 of USEPA 2016) when appropriately using  $k=3$  for the log-linear two-piece spline model with a knot at 1,600 ppm  $\times$  days (lymphoid cancer). Similarly, for the linear two-piece spline model with a knot at 1,600 ppm  $\times$  days (lymphoid cancer) ultimately selected in USEPA (2016), the correct AIC is 464.5 (not 462.1 as in Table 4-6 of USEPA 2016). *Consequently, not only does the linear two-piece spline model for lymphoid cancer ultimately selected by USEPA (2016) not explain the variability in the data statistically significantly better than the null model, but the correct AIC value (464.5) is higher than those for all log-linear (Cox regression) and linear models in Table 4-6 of USEPA (2016).* Again, as a related issue, *USEPA's selected model assessment for lymphoid cancer mortality statistically significantly over-estimates risk (e.g., Figure 8 and Figures 9-12).* Appendix 5 also contains an example showing that an AIC of 1,956.360 is the correct AIC value (not 1,954.360 as in Table 4-14 of USEPA 2016) when appropriately using  $k=8$  for the linear two-piece spline model with a knot at 5,750 ppm  $\times$  days (breast cancer incidence) ultimately selected in USEPA (2016). Thus, the correct AIC for the linear two-piece spline model (1,956.360) is higher than or similar to AIC values for the log-linear (Cox regression) and linear models in Table 4-14 of USEPA (2016), with the same being true for the AIC value (1,956.485) for the log-linear two-piece spline model. These two-piece spline model AIC values (for breast cancer incidence) are very similar to the AIC for the standard Cox regression model (1,956.675), which also has a p-value  $<0.5$ , putting them on par with each other in this regard (Appendix 5).

As visual fit to the data was also used as a criterion for model selection (e.g., pp. 4-66 and 4-100 of USEPA 2016), the second issue concerns the apparent unintentional visual misrepresentation of model fit in Figures 4-3 and 4-8 of USEPA (2016). Most simply, no true visual comparison of model fit to the data can be made based on Figures 4-3 and 4-8 (pp. 4-21 and 4-51 of USEPA 2016) since the data shown are not the data to which the models shown were fit. The actual data underlying model fits shown are the individual data, not the less refined categorical data shown in the figures. *Thus, because the model fits shown in Figures 4-3 and 4-8 are those to the individual data (and not the categorical data depicted), the figures do not actually show model fit to the modelled data at all.* For lymphoid cancer, objective examination of the model fits to

the underlying data reveals no readily apparent superior fit by any particular model (Appendix 6). Unfortunately, the NIOSH breast cancer incidence data are not publicly available, and to the TCEQ's knowledge no graph similar to that in Appendix 6 for lymphoid cancer has been produced to enable an appropriate visual examination of model fits to the actual underlying breast cancer incidence data.

The above statistical and visual fit considerations do not constitute the type of strong data (e.g., robust mechanistic understanding and justification) needed to justify a supra-linear dose-response model (i.e., the steep lower-dose slope component of USEPA's linear two-piece spline model) for low-dose extrapolation for EtO (TCEQ 2015). In summary:

- 1) Correct p-values for the two-spline models for lymphoid cancer mortality are *within the range* of those for the linear and log-linear (Cox regression) models, although correct AIC values for the two-spline models are *slightly higher* than those for the linear and log-linear (Cox regression) models;
- 2) Correct AIC values for the two-spline models for breast cancer incidence (1,956.360-1,956.485) are *higher than or similar to* those for the linear and log-linear (Cox regression) models, with p-values for Cox regression models also <0.05;
- 3) *Thus, even outside of the lack of the critical deterministic (e.g., mechanistic) data needed to support use of an overall supra-linear model, as a peripheral matter there appears to be no strong statistical indication of a need to adopt a non-conventional, supra-linear model over a more standard model; and*
- 4) As might be expected based on 1 and 2, visual examination of the model fits to the underlying data for lymphoid cancer reveals no readily apparent superior fit by any particular model.

These circumstances do not support deviation from more standard/conventional dose-response models (e.g., Cox proportional hazards model).

#### **3.4.1.4 Selection of the Extrapolation Model**

##### **3.4.1.4.1 Conclusions on Use of USEPA's Linear Two-Piece Spline Model**

The following summarizes the TCEQ's conclusions about the USEPA's linear two-piece spline model for use in the derivation of a URF for EtO. The TCEQ (2015) guidelines require sufficient mechanistic or biological data to support the application of a supra-linear model (i.e., its steep slope beginning at zero dose). *However, adoption of an overall supra-linear model (i.e., the steep lower-dose component) for EtO low-dose extrapolation is not justified based on mechanistic data or supported by other considerations described above (e.g., key epidemiological data, model ground-truthing).* For example, the model assessment ultimately

selected by USEPA (i.e., the upper bound of the linear two-piece spline model with the “knot” at 1,600 ppm × days, 15-year exposure lag) has been demonstrated to statistically significantly over-estimate the total number of lymphoid cancer mortalities observed for the NIOSH cohort as a whole (e.g., predicting 141 compared to the 53 actually observed) as well as for every cumulative exposure group (Appendix 3).

*The TCEQ’s conclusion* that relevant considerations do not provide a sufficient scientific basis for the application of an overall supra-linear model (i.e., its steep low-dose slope) for low-dose extrapolation *is consistent with USEPA (2016) acknowledging that reasons (biological, mechanistic, or otherwise) supporting a supra-linear dose-response are unknown, stating to the SAB “the EPA is not aware of a mechanistic explanation” (p. 1-29 of USEPA 2016; also see pp. 1-34 and 4-71).* In fact, considerations herein suggest that sub-ppb EtO exposure concentrations (e.g., 0.0001-0.01 ppb) may not be consistent with the production of excess (i.e., above background) risk. By contrast, progressively higher EtO air concentrations that produce total internal exposures (endogenous + exogenous) progressively higher than the normal endogenous range are considered more likely to be associated with excess (i.e., above background) risk as the body’s normal detoxification and repair processes for endogenous EtO become progressively more likely to be less efficient and/or overwhelmed. For example, a continuous EtO air exposure concentration that itself produces an internal dose above the normal endogenous range is considered most likely to be associated with excess risk (e.g.,  $\geq$   $\approx$ 4.6-7 ppb; Table 4 of Kirman and Hays 2017), followed by EtO air concentrations that themselves produce internal doses similar to the upper end of the normal endogenous range (e.g., continuous exposure concentrations of 3.5-6.9 ppb would be expected to produce internal doses approximating the 90<sup>th</sup> to 99<sup>th</sup> percentile of the normal endogenous range; Table 4 of Kirman and Hays 2017).

*USEPA provides no robust biological or mechanistic basis for adopting an overall supra-linear EtO dose-response (i.e., the linear two-piece spline model).* In fact, biological/mechanistic considerations by USEPA (2016) are essentially limited to:

- 1) Choosing between two “knot” values for the two-piece spline models, wherein the agency simply indicates that a knot at...
  - a. 1,600 ppm × days (compared to 100 ppm × days) results in a more “biologically realistic” exposure-response for lymphoid cancer as it results in a more gradual rise in low-dose risk and a more plausible rise at higher exposures (p. 4-16 of USEPA 2016); and
  - b. 5,750 ppm × days results in a more “biologically realistic” general model shape for breast cancer incidence (p. 4-52 of USEPA 2016).

- 2) Considering “biologically plausible” exposure lag periods (e.g., pp. D-6 and D-38 of USEPA 2016), although the USEPA SAB did not find USEPA’s biological argument to be strong even for this limited purpose (p. I-1 of USEPA 2016).
- 3) Citing direct mutagenic activity as mechanistic justification for typical default linear low-dose extrapolation (pp. 4-22, 4-37, 4-54, 4-61, 4-74, 4-94, C-30, and I-31 of USEPA 2016).

In acknowledging the lack of mechanistic data for EtO to support the biological plausibility of a supra-linear dose-response, USEPA cites “*insufficient information to elucidate a basis*” (p. I-34 of USEPA 2016). USEPA further indicates that “it is unclear how the available biological data can be used to guide general model selection” (p. I-31 of USEPA 2016). In addition to USEPA’s acknowledgment of a lack of a mechanistic and/or biological justification, all the considerations discussed by the TCEQ in various sections above (e.g., MOA, reality checks of model predictions) consistently support the conclusion that there is a lack of data to adequately support the application of the steep low-dose slope of a supra-linear model to extrapolate to significantly lower doses. *The statistical demonstration of the significant over-estimation of lymphoid cancer mortality by the model assessment selected by USEPA (i.e., the upper bound of the linear two-piece spline model with the “knot” at 1,600 ppm × days, 15-year exposure lag) is of particular interest and does not lend scientific credibility to the associated USEPA (2016) EtO URF.*

Without a solid mechanistic basis, USEPA (2016) is primarily left with the “appearance” of supra-linearity based on a less than accurate representation of model fit. The TCEQ considers model fit criteria as a matter secondary to consideration of the critical deterministic (e.g., mechanistic) data needed to support adoption of a supra-linear model (TCEQ 2015). Regardless, *when appropriately considering statistical and visual model fit, the TCEQ finds no strong (much less compelling) statistical or visual indications of a need to adopt a non-conventional, supra-linear model over a more standard model* (see Section 3.4.1.3 and Appendix 6). Moreover, *the underlying key epidemiological data cannot support the application of a supra-linear model (i.e., the steep low-dose slope) for extrapolation to low environmental EtO doses since the data are not informative as to the shape of the dose-response curve at the truly low doses of interest* (e.g., in the range of typical environmental concentrations). The TCEQ’s conclusions about model fit and that the key epidemiological data are not informative as to the shape of the dose-response curve at the low environmental EtO doses of regulatory interest are consistent with USEPA acknowledging that the model and low-dose extrapolation (as well as exposure estimation) are primary sources of uncertainty and “*the actual exposure-response relationship at low exposure levels is unknown*” (pp. 4-61 and 4-74 of USEPA 2016).

High-dose carcinogenicity data alone are incapable of informing truly low-dose risk, no matter how extensive the analyses or peer review (i.e., other relevant information such as mechanism/MOA must be duly considered). *USEPA (2016) should not have based a URF on a*

*supra-linear model (i.e., its lower-dose component) without a robust mechanistic justification for expecting the associated steep low-dose slope component to be applicable at truly low doses or used it to make a large low-dose extrapolation across the endogenous range (and below) considering that the agency actually considers sublinearity as “highly plausible” in this range.* The key study used by USEPA does not provide EtO dose-response data anywhere near environmental levels/doses. USEPA (2005a) recognizes that the relatively small exposure range observed in many epidemiologic studies makes it difficult to discern the shape of the exposure- or dose-response curve, which in the present case concerns the range being limited to only very high exposures. USEPA (2016) acknowledges that *points of departure are substantially above typical EtO environmental levels, resulting in uncertainty in risk at environmental levels* (p. I-14 of USEPA 2016). For example, the agency cites a POD for breast cancer incidence (12  $\mu\text{g}/\text{m}^3$  or 6.6 ppb) that is almost 3,000 times higher than the cited average background level (0.0044  $\mu\text{g}/\text{m}^3$  or 0.0024 ppb) and further acknowledges that the two lowest deciles have RRs < 1 and thus “are not by themselves consistent with the unit risk estimate.” *Based on the considerations discussed in this DSD (e.g., MOA, normal endogenous levels, model reality checks), the TCEQ finds the assessment to follow to be much more biologically and scientifically reasonable.*

In summary, *robust mechanistic and/or biological data adequate to justify use of an overall supra-linear model (i.e., the application of the steep lower-dose slope for low-dose extrapolation) do not exist for EtO in this case.* In fact, relevant considerations strongly suggest that use of such a model (e.g., USEPA’s linear two-piece spline model) for low-dose extrapolation is inappropriate (see the discussions above). As the adoption of supra-linear modeling results (i.e., the steep slope beginning at zero dose for low-dose extrapolation) is scientifically unjustified, the corresponding analyses in USEPA (2016) are considered no further in this DSD for potential adoption by the TCEQ.

#### **3.4.1.4.2 Conclusions on Use of an Alternative Model**

Based on the considerations discussed above (e.g., MOA, model ground-truthing), *the TCEQ has determined that a low-dose extrapolation model for EtO carcinogenicity that is no more than linear overall is both reasonable and justified*, especially if such extrapolations result in EtO air concentrations (e.g., at 1E-05 excess risk) corresponding to internal exposures within the normal endogenous background range where USEPA (2016) states that a sublinear dose-response is highly plausible. *The Cox proportional hazards model is one such model that has been used previously by the TCEQ* (e.g., in the 1,3-butadiene carcinogenic assessment; TCEQ 2008) and was considered by USEPA (2016). In their assessment of EtO carcinogenicity, Valdez-Flores et al. (2010) also use the Cox proportional hazards model with a default lifetime value of 70 years, consistent with TCEQ guidelines (TCEQ 2015). Additionally, USEPA (2016) describes the Cox proportional hazards model as sublinear at low doses, which would conform to dose-response shape expectations (unlike a strictly linear low-dose model) if risk-based EtO air concentrations (e.g., at 1E-05 excess risk) ultimately correspond to doses in or below the

normal endogenous range. *Based on the considerations discussed above, the TCEQ selects the Cox proportional hazards model for the carcinogenicity assessment of EtO.* Additional discussion of the Cox proportional hazards model relative to other models considered by USEPA (2016) and the TCEQ for lymphoid cancer mortality and breast cancer incidence can be found in Appendix 5. *Lastly, information in Section 3.4.1.2.2.3 and Appendix 3 demonstrates that the Cox proportional hazards model adopted by the TCEQ neither significantly over- or under-predicts lymphoid cancer mortality for the NIOSH cohort as a whole or for any cumulative exposure group.*

#### **3.4.1.5 Relevant Cox Proportional Hazards Model Results**

In accordance with the section above, Cox proportional hazards modeling results were reviewed. For example, Table 6 provides maximum likelihood estimate (MLE) results from Valdez-Flores et al. (2010) for various potential cancer endpoints. *This DSD considers the same critical cancer endpoints as USEPA (2016), namely lymphoid and breast cancer.* The TCEQ will ultimately evaluate excess risk results for biological plausibility and scientific reasonableness in the context of relevant information such as normal endogenous levels, associated predicted background rate, etc.



**Table 6: Cancer Endpoint-Specific Environmental EtO Air Concentrations at 1 in 100,000 Excess Risk based on Maximum Likelihood Estimates (MLE) (Valdez-Flores et al. 2010)<sup>a,b,c</sup>**

Cancer Endpoint	1E-05 Air Level based on MLE for NIOSH: Males (ppb)	1E-05 Air Level based on MLE for NIOSH + UCC: Males (ppb)	1E-05 Air Level based on MLE for NIOSH: Females (ppb)	1E-05 Air Level based on MLE for NIOSH: Males + Females (ppb)	1E-05 Air Level based on MLE for NIOSH + UCC: Males + Females (ppb)
Lymphoid Tumors <sup>d</sup>	6	10	-ns	8	15
Breast Cancer <sup>d,e</sup>	-ns	-ns	7	17	17
Lymphohematopoietic Tissue <sup>f</sup>	6	10	-ns	9	19
Non-Hodgkin's Lymphoma	12	17	-ns	15	23
Lymphocytic Leukemia	13	16	-ns	19	24
Leukemia	18	23	-SS	78	92
Central Nervous System	-ns	-SS	28	-ns	-ns
Malignant Brain	-ns	-ns	19	-ns	-ns
Pancreatic	-ns	-ns	12	-ns	-ns

<sup>a</sup> Environmental air concentration = occupational concentration × 240 days/365 days × 10 m<sup>3</sup>/20 m<sup>3</sup>; no occupational exposure lag.

<sup>b</sup> USEPA (2005) age-dependent adjustment factors incorporated.

<sup>c</sup> An EtO air concentration (ppb) value in a cell indicates that the estimated slope was positive for mortality with cumulative ethylene oxide exposure for the cancer endpoint in the NIOSH cohort, though none were statistically significantly positive, while the slopes for other endpoints in the NIOSH cohort were negative (denoted by "-ns") and some even statistically significantly negative (denoted by "-SS").

<sup>d</sup> Cancer endpoint used by USEPA (2016), includes non-Hodgkin's lymphoma, multiple myeloma, and lymphocytic leukemia as developed in Steenland et al. (2004).

<sup>e</sup> One male breast cancer mortality in the NIOSH cohort; none in the UCC cohort.

<sup>f</sup> Includes leukemia (and specifically myeloid and lymphocytic leukemia), non-Hodgkin's lymphoma, and multiple myeloma.

The results in Table 6 do not incorporate any exposure lag, while USEPA (2016) ultimately utilizes an exposure lag of 15 years. Therefore, in preparing this DSD, the TCEQ contracted with the first author on the Valdez-Flores et al. (2010) study to provide exposure-lagged results for lymphoid and breast cancer mortality that had been previously developed in the course of his research.

### 3.4.1.5.1 Parameter Estimates

#### 3.4.1.5.1.1 Lymphoid Cancer

Tables 7, 8, and 9 contain log-linear (Cox regression) model results for lymphoid cancer mortality in the NIOSH (male + female), NIOSH (male only), and UCC (male only) cohorts, respectively, at various EtO exposure lags. The UCC results are based on an update of the cohort through 2013 that is not yet published.

**Table 7: Lymphoid Cell Lineage Tumor Mortality - NIOSH (male + female) - MLE and Standard Error (SE) of the Estimate for Different EtO Exposure Lags**

Lag (years)	MLE	(SE)	Deviance <sup>a</sup> : -2 × Ln(Likelihood) (p-value vs null) <sup>b</sup>	Likelihood Ratio Test Statistic: Deviance (null model) – Deviance (model) (p-value vs zero lag) <sup>c</sup>
0	3.48×10 <sup>-6</sup>	(1.83×10 <sup>-6</sup> )	726.188 (0.1088)	2.571 (n/a)
5	3.45×10 <sup>-6</sup>	(1.95×10 <sup>-6</sup> )	726.495 (0.3224)	2.264 (1.0000)
10	3.11×10 <sup>-6</sup>	(2.23×10 <sup>-6</sup> )	727.308 (0.4841)	1.451 (1.0000)
15 <sup>d</sup>	2.81×10 <sup>-6</sup>	(2.65×10 <sup>-6</sup> )	727.899 (0.6505)	0.860 (1.0000)
20	1.67×10 <sup>-6</sup>	(3.87×10 <sup>-6</sup> )	728.598 (0.9227)	0.161 (1.0000)
25	1.48×10 <sup>-6</sup>	(5.19×10 <sup>-6</sup> )	728.687 (0.9646)	0.072 (1.0000)
30	2.03×10 <sup>-6</sup>	(6.74×10 <sup>-6</sup> )	728.680 (0.9613)	0.079 (1.0000)

<sup>a</sup> Deviance is -2 × Logarithm of the Likelihood. -2 × Ln (Likelihood) = 728.759 when beta = 0 (null model). The decrease in the deviance at a specific exposure lag (compared with the deviance at 0-years lag) has to be at least 3.84 for the improvement in the deviance to be statistically significant at the 5% significance level. The decrease in the deviance at a non-zero exposure lag (compared with the deviance for the null model) has to be at least 5.99 for the improvement in the deviance to be statistically significant at the 5% significance level.

<sup>b</sup> p-value vs null compares the maximum likelihood of the model fit to the maximum likelihood of the null model. A small p-value indicates that the model with the specified lag fits the data better than the null model.

<sup>c</sup> p-value vs zero lag compares the maximum likelihood of the model fit with the specified lag to the maximum likelihood of the model with zero lag. A small p-value indicates that the model with the specified lag fits the data better than the model with zero lag.

<sup>d</sup> Exposure lag ultimately used by USEPA (2016).

**Table 8: Lymphoid Cell Lineage Tumor Mortality - NIOSH (male only) - MLE and SE of the Estimate for Different EtO Exposure Lags**

Lag (years)	MLE	(SE)	Deviance <sup>a</sup> : -2 × Ln(Likelihood) (p-value vs null) <sup>b</sup>	Likelihood Ratio Test Statistic:  Deviance (null model) – Deviance (model) (p-value vs zero lag) <sup>c</sup>
0	3.89×10 <sup>-6</sup>	(1.77×10 <sup>-6</sup> )	354.312 (0.0696)	3.293 (n/a)
5	3.85×10 <sup>-6</sup>	(1.89×10 <sup>-6</sup> )	354.761 (0.2412)	2.844 (1.0000)
10	3.47×10 <sup>-6</sup>	(2.17×10 <sup>-6</sup> )	355.795 (0.4045)	1.810 (1.0000)
15 <sup>d</sup>	3.12×10 <sup>-6</sup>	(2.61×10 <sup>-6</sup> )	356.553 (0.5910)	1.052 (1.0000)
20	1.63×10 <sup>-6</sup>	(4.08×10 <sup>-6</sup> )	357.467 (0.9333)	0.138 (1.0000)
25	6.50×10 <sup>-7</sup>	(6.06×10 <sup>-6</sup> )	357.594 (0.9945)	0.011 (1.0000)
30	1.70×10 <sup>-6</sup>	(8.66×10 <sup>-6</sup> )	357.604 (0.9995)	0.001 (1.0000)

<sup>a</sup> Deviance is -2 × Logarithm of the Likelihood. -2 × Ln (Likelihood) = 357.605 when beta = 0 (null model). The decrease in the deviance at a specific exposure lag (compared with the deviance at 0-years lag) has to be at least 3.84 for the improvement in the deviance to be statistically significant at the 5% significance level. The decrease in the deviance at a non-zero exposure lag (compared with the deviance for the null model) has to be at least 5.99 for the improvement in the deviance to be statistically significant at the 5% significance level.

<sup>b</sup> p-value vs null compares the maximum likelihood of the model fit to the maximum likelihood of the null model. A small p-value indicates that the model with the specified lag fits the data better than the null model.

<sup>c</sup> p-value vs zero lag compares the maximum likelihood of the model fit with the specified lag to the maximum likelihood of the model with zero lag. A small p-value indicates that the model with the specified lag fits the data better than the model with zero lag.

<sup>d</sup> Exposure lag ultimately used by USEPA (2016).

**Table 9: Lymphoid Cell Lineage Tumor Mortality - UCC/Dow 2013 update (males) - MLE and SE of the Estimate for Different EtO Exposure Lags**

Lag (years)	MLE	(SE)	Deviance <sup>a</sup> : -2 × Ln (Likelihood) (p-value vs null) <sup>b</sup>	Likelihood Ratio Test Statistic: Deviance (null model) – Deviance (model) (p-value vs zero lag) <sup>c</sup>
0	-1.42×10 <sup>-5</sup>	(9.17×10 <sup>-6</sup> )	299.443 (0.0592)	3.559 (n/a)
5	-1.50×10 <sup>-5</sup>	(9.44×10 <sup>-6</sup> )	299.216 (0.1506)	3.786 (0.6338)
10	-1.58×10 <sup>-5</sup>	(9.74×10 <sup>-6</sup> )	299.021 (0.1366)	3.981 (0.5159)
15 <sup>d</sup>	-1.60×10 <sup>-5</sup>	(9.94×10 <sup>-6</sup> )	299.059 (0.1392)	3.943 (0.5355)
20	-1.52×10 <sup>-5</sup>	(9.91×10 <sup>-6</sup> )	299.497 (0.1733)	3.505 (1.0000)
25	-1.53×10 <sup>-5</sup>	(1.03×10 <sup>-5</sup> )	299.744 (0.1961)	3.258 (1.0000)
30	-1.51×10 <sup>-5</sup>	(1.07×10 <sup>-5</sup> )	300.156 (0.2410)	2.846 (1.0000)

<sup>a</sup> Deviance is -2 × Logarithm of the Likelihood. -2 × Ln (Likelihood) = 303.002 when beta = 0 (null model). The decrease in the deviance at a specific exposure lag (compared with the deviance at 0-years lag) has to be at least 3.84 for the improvement in the deviance to be statistically significant at the 5% significance level. The decrease in the deviance at a non-zero exposure lag (compared with the deviance for the null model) has to be at least 5.99 for the improvement in the deviance to be statistically significant at the 5% significance level.

<sup>b</sup> p-value vs null compares the maximum likelihood of the model fit to the maximum likelihood of the null model. A small p-value indicates that the model with the specified lag fits the data better than the null model.

<sup>c</sup> p-value vs zero lag compares the maximum likelihood of the model fit with the specified lag to the maximum likelihood of the model with zero lag. A small p-value indicates that the model with the specified lag fits the data better than the model with zero lag.

<sup>d</sup> Exposure lag ultimately used by USEPA (2016).

In regard to Tables 7, 8, and 9, none of the EtO exposure lags result in a model that fits the NIOSH and UCC lymphoid cancer data statistically significantly better than the log-linear (Cox regression) model with no lag (at the 5% significance level). Aside from this statistical consideration, which does not give rise to a preference for any particular exposure lag duration, from a biological perspective it is reasonable to include an exposure lag of some duration to account for a latency period between exposure and cancer. *For this reason, as well as consistency with USEPA (2016), the TCEQ will also utilize an exposure lag of 15 years.*

### 3.4.1.5.1.2 Breast Cancer

Table 10 contains log-linear (standard Cox regression) model results for breast cancer mortality (female only) in the NIOSH cohort at various exposure lags.

**Table 10: Breast Cancer Mortality - NIOSH (females) - MLE and SE of the Estimate for Different EtO Exposure Lags**

Lag (years)	MLE	(SE)	Deviance <sup>a</sup> : -2 × Ln (Likelihood) (p-value vs null) <sup>b</sup>	Likelihood Ratio Test Statistic:  Deviance (null model) – Deviance (model) (p-value vs zero lag) <sup>c</sup>
0	1.88×10 <sup>-6</sup>	(4.49×10 <sup>-6</sup> )	1570.156 (0.6873)	0.162 (n/a)
5	2.89×10 <sup>-6</sup>	(4.56×10 <sup>-6</sup> )	1569.958 (0.8353)	0.360 (0.6563)
10	3.49×10 <sup>-6</sup>	(4.94×10 <sup>-6</sup> )	1569.879 (0.8029)	0.439 (0.5987)
15 <sup>e</sup>	6.01×10 <sup>-6</sup>	(5.12×10 <sup>-6</sup> )	1569.211 (0.5749)	1.107 (0.3310)
20	9.42×10 <sup>-6</sup>	(5.48×10 <sup>-6</sup> )	1568.171 (0.3418)	2.147 (0.1589)
25	1.22×10 <sup>-5</sup>	(6.73×10 <sup>-6</sup> )	1567.998 (0.3135)	2.320 (0.1418)
30	1.63×10 <sup>-5</sup>	(8.56×10 <sup>-6</sup> )	1567.791 (0.2826)	2.527 (0.1241) <sup>d</sup>

<sup>a</sup> Deviance is -2 × Logarithm of the Likelihood. -2 × Ln (Likelihood) = 1570.318 when beta = 0 (null model). The decrease in the deviance at a specific exposure lag (compared with the deviance at 0-years lag) has to be at least 3.84 for the improvement in the deviance to be statistically significant at the 5% significance level. The decrease in the deviance at a non-zero exposure lag (compared with the deviance for the null model) has to be at least 5.99 for the improvement in the deviance to be statistically significant at the 5% significance level.

<sup>b</sup> p-value vs null compares the maximum likelihood of the model fit to the maximum likelihood of the null model. A small p-value indicates that the model with the specified lag fits the data better than the null model.

<sup>c</sup> p-value vs lag compares the maximum likelihood of the model fit with the specified lag to the maximum likelihood of the model with zero lag. A small p-value indicates that the model with the specified lag fits the data better than the model with zero lag.

<sup>d</sup> Deviance for the model fit to breast cancer with exposures lagged 35 years is 1568.037 (not shown) so that the deviance does not continue to increase as the lag increases.

<sup>e</sup> Exposure lag ultimately used by USEPA (2016).

Regarding Table 10, the log-linear model did not fit the breast cancer *mortality* data statistically better than the null model (zero slope). However, it does fit the breast cancer *incidence* data better than the null model (see Table 4-14 in Appendix 5). Unfortunately, the NIOSH breast cancer incidence data were not publicly available for independent analysis. Therefore, the TCEQ

will not utilize Table 10 results, but rather consider log-linear (standard Cox regression) 15-year exposure-lagged model results for breast cancer incidence (subcohort with interviews) from USEPA (2016). Table 11 contains relevant results adapted from Table 4-12 of USEPA (2016).

**Table 11: Breast Cancer Incidence (with interviews) - NIOSH (females) - MLE and SE of the Estimate <sup>a</sup>**

Model	Lag (years)	MLE	(SE)
log-linear (standard Cox regression)	15	$9.5 \times 10^{-6}$	$4.1 \times 10^{-6}$

<sup>a</sup> Adapted from Table 4-12 of USEPA (2016).

### 3.4.1.5.2 Risk-Based Air Concentrations and URFs

#### 3.4.1.5.2.1 Lymphoid Cancer

Consistent with the discussions above, 15-year lagged results are highlighted and bolded in Tables 12, 13, and 14 below, which contain environmental EtO air concentrations corresponding to the cited excess risk levels and associated URFs for lymphoid cancer mortality in the NIOSH (male + female), NIOSH (male only), and UCC (male only) cohorts, respectively. The lymphoid cancer calculations include adjustments for ADAFs using the approach described in Sielken and Valdez-Flores (2009).

**Table 12: Lymphoid Cell Lineage Tumor Mortality - NIOSH (male + female) - MLE and 95% Lower Confidence Limit (95% LCL) of the Environmental EtO Concentration at 1 in 100,000 Excess Risk**

Lag (years)	MLE Environmental Concentration (1/100,000 excess risk) ppm <sup>a</sup>	95% LCL Environmental Concentration (1/100,000 excess risk) ppm <sup>a</sup>	MLE URF per ppm	95% UCL URF per ppm
0	$8.02 \times 10^{-3}$	$4.30 \times 10^{-3}$	$1.25 \times 10^{-3}$	$2.32 \times 10^{-3}$
5	$8.82 \times 10^{-3}$	$4.57 \times 10^{-3}$	$1.13 \times 10^{-3}$	$2.19 \times 10^{-3}$
10	$1.08 \times 10^{-2}$	$4.93 \times 10^{-3}$	$9.30 \times 10^{-4}$	$2.03 \times 10^{-3}$
15 <sup>b</sup>	<b><math>1.32 \times 10^{-2}</math></b>	<b><math>5.18 \times 10^{-3}</math></b>	<b><math>7.57 \times 10^{-4}</math></b>	<b><math>1.93 \times 10^{-3}</math></b>
20	$2.49 \times 10^{-2}$	$5.18 \times 10^{-3}$	$4.01 \times 10^{-4}$	$1.93 \times 10^{-3}$
25	$3.20 \times 10^{-2}$	$4.73 \times 10^{-3}$	$3.12 \times 10^{-4}$	$2.11 \times 10^{-3}$
30	$2.71 \times 10^{-2}$	$4.19 \times 10^{-3}$	$3.69 \times 10^{-4}$	$2.38 \times 10^{-3}$

<sup>a</sup> Environmental concentration = (240 days/365 days) × (10 m<sup>3</sup>/20 m<sup>3</sup>) × occupational concentration.

<sup>b</sup> Exposure lag ultimately used by USEPA (2016).

**Table 13: Lymphoid Cell Lineage Tumor Mortality - NIOSH (male only) - MLE and 95% LCL of the Environmental EtO Concentration at 1 in 100,000 Excess Risk**

Lag (years)	MLE Environmental Concentration (1/100,000 excess risk) ppm <sup>a</sup>	95% LCL Environmental Concentration (1/100,000 excess risk) ppm <sup>a</sup>	MLE URF per ppm	95% UCL URF per ppm
0	$5.83 \times 10^{-3}$	$3.34 \times 10^{-3}$	$1.71 \times 10^{-3}$	$3.00 \times 10^{-3}$
5	$6.43 \times 10^{-3}$	$3.56 \times 10^{-3}$	$1.56 \times 10^{-3}$	$2.81 \times 10^{-3}$
10	$7.84 \times 10^{-3}$	$3.86 \times 10^{-3}$	$1.28 \times 10^{-3}$	$2.59 \times 10^{-3}$
15 <sup>b</sup>	<b><math>9.67 \times 10^{-3}</math></b>	<b><math>4.07 \times 10^{-3}</math></b>	<b><math>1.03 \times 10^{-3}</math></b>	<b><math>2.46 \times 10^{-3}</math></b>
20	$2.08 \times 10^{-2}$	$4.06 \times 10^{-3}$	$4.81 \times 10^{-4}$	$2.46 \times 10^{-3}$
25	$5.94 \times 10^{-2}$	$3.64 \times 10^{-3}$	$1.68 \times 10^{-4}$	$2.75 \times 10^{-3}$
30	$2.64 \times 10^{-2}$	$2.81 \times 10^{-3}$	$3.79 \times 10^{-4}$	$3.56 \times 10^{-3}$

<sup>a</sup> Environmental concentration = (240 days/365 days)  $\times$  (10 m<sup>3</sup>/20 m<sup>3</sup>)  $\times$  occupational concentration.

<sup>b</sup> Exposure lag ultimately used by USEPA (2016).

**Table 14: Lymphoid Cell Lineage Tumor Mortality - UCC/DOW 2013 Update (males) - MLE and 95% LCL of the Environmental EtO Concentration at 1 in 100,000 Excess Risk**

Lag (years)	MLE Environmental Concentration (1/100,000 excess risk) ppm <sup>a</sup>	95% LCL Environmental Concentration (1/100,000 excess risk) ppm <sup>a</sup>	MLE URF per ppm	95% UCL URF per ppm
0	n/a <sup>c</sup>	$2.59 \times 10^{-2}$	0	$3.86 \times 10^{-4}$
5	n/a	$4.76 \times 10^{-2}$	0	$2.10 \times 10^{-4}$
10	n/a	$1.24 \times 10^{-1}$	0	$8.06 \times 10^{-5}$
15 <sup>b</sup>	<b>n/a</b>	<b><math>8.70 \times 10^{-2}</math></b>	<b>0</b>	<b><math>1.15 \times 10^{-4}</math></b>
20	n/a	$3.08 \times 10^{-2}$	0	$3.25 \times 10^{-4}$
25	n/a	$2.35 \times 10^{-2}$	0	$4.25 \times 10^{-4}$
30	n/a	$1.79 \times 10^{-2}$	0	$5.58 \times 10^{-4}$

<sup>a</sup> Environmental concentration = (240 days/365 days)  $\times$  (10 m<sup>3</sup>/20 m<sup>3</sup>)  $\times$  occupational concentration.

<sup>b</sup> Exposure lag ultimately used by USEPA (2016).

<sup>c</sup> n/a implies that the estimated dose-response relationship was non-increasing.

For lymphoid cancer in the NIOSH cohort (male + female), Table 12 provides an EtO air concentration of 13.2 ppb (1.32E-02 ppm) as corresponding to a no significant excess risk level of 1 in 100,000 based on the MLE for the cohort (15-year exposure lag). Based on the 95% LCL (i.e.,  $LEC_{01}$ ), 5.2 ppb (5.18E-03 ppm) is the EtO air concentration corresponding to a 1 in 100,000 excess risk. *These lymphoid cancer excess risk results are consistent with TCEQ conclusions regarding the range of EtO air concentrations most likely to be associated with excess risk considering normal endogenous levels* (see Sections 3.4.1.2.1 and 3.4.1.4.1). For example, a continuous EtO air concentration  $\geq \approx 4.6$ -7 ppb would itself produce an internal exposure above the normal endogenous range and is considered most likely to be associated with excess (i.e., above and distinguishable from background) risk. Thus, the range of 5.2-13.2 ppb for a 1 in 100,000 excess risk is considered biologically plausible considering normal background endogenous levels. Even at a 1 in 1,000,000 excess risk level, the upper end of the corresponding EtO air concentration range (1.32 ppb) would also correspond to a 1 SD increase in internal exposure over normal endogenous levels, which is predicted to be sufficient to move those at the 90<sup>th</sup> percentile of normal background endogenous levels to over the 95<sup>th</sup> percentile (Table 4 of Kirman and Hays 2017). This would be a statistically significant increase and could be potentially biologically meaningful/significant (see Section 3.4.1.2.1). Additionally, unlike the USEPA (2016) URF for lymphoid cancer incidence, use of the URFs corresponding to the MLE (7.57E-07 per ppb) and 95% UCL (1.93E-06 per ppb) along with the EtO air concentrations corresponding to the means of background levels in the unexposed population (1.9 ppb) and smokers (18.8 ppb) does not predict a nonsmoker/smoker population-weighted background rate of lymphoid cancer mortality above the actual applicable background rate (e.g., 0.53% for lymphoid cancer mortality, male + female, 70-year lifetime). *Accordingly, based on normal endogenous/background levels and this URF reality check, the TCEQ considers these 1 in 100,000 excess risk level EtO air concentrations as both biologically plausible and scientifically reasonable, and therefore has some confidence in them.* Results are similar for NIOSH males only. That is, Table 13 provides MLE and 95% LCL 1 in 100,000 excess risk EtO air concentrations of 9.7 ppb (9.67E-03 ppm) and 4.1 ppb (4.07E-03 ppm), respectively.

For lymphoid cancer in the UCC cohort (males), Table 14 provides an EtO air concentration of 87 ppb (8.70E-02 ppm) that corresponds to a no significant excess risk level of 1 in 100,000 based on the 95% LCL for the cohort (15-year exposure lag), which is 6.6 times higher than the corresponding value based on the NIOSH cohort (males + females). No MLE value is provided because of the negative value in Table 9, consistent with no increased risk with cumulative EtO exposure for the cohort as modeled and reported. The 87 ppb EtO concentration corresponding to a 1 in 100,000 excess risk level for lymphoid cancer (based on the 95% LCL) for the UCC cohort is well above the lower end of the range of continuous EtO air concentrations ( $\geq \approx 4.6$ -7 ppb) that would itself produce internal exposures above the normal endogenous range, and an EtO air concentration above this range is considered most likely to be associated with excess (i.e., above and distinguishable from background) risk. Even at a 1 in 1,000,000 excess risk level,



the corresponding EtO air concentration (8.7 ppb) would also correspond to an increase in internal exposure predicted to be greater than the upper end of the normal endogenous range (Table 4 of Kirman and Hays 2017). Thus, considering normal background endogenous levels, it is biologically plausible that such a change would be associated with excess risk. Additionally, unlike the USEPA (2016) URF for lymphoid cancer incidence, use of the URF corresponding to 95% UCL (1.15E-07 per ppb) along with the EtO air concentrations corresponding to the means of background levels in the unexposed population (1.9 ppb) and smokers (18.8 ppb) does not predict a nonsmoker/smoker population-weighted background rate of lymphoid cancer mortality above the actual applicable background rate (e.g., 0.65% for lymphoid cancer mortality, males only, 70-year lifetime). Accordingly, based on normal endogenous/background levels and this URF reality check, the TCEQ considers excess risk at this air concentration as both biologically plausible and scientifically reasonable.

*However, the fact that the associated MLE, which represents the best fit to the data (i.e., by definition, the MLE maximizes the likelihood of the observed data), is consistent with no excess lymphoid cancer mortality risk for the UCC cohort:*

- Suggests that the use of statistical bound results (95% LCL/UCL) for estimating excess risk for both the UCC cohort and other populations (e.g., the general population) may be conservative; and
- Similarly, as part of the weight of evidence, suggests that use of lymphoid cancer excess risk results based on the NIOSH cohort for extrapolation to other populations, even highly exposed occupational populations, may be conservative (especially use of the 95% upper statistical bound on excess risk).

This is further supported by the fact that *none of the slopes for lymphoid mortality in the NIOSH cohort (male + female, male only) or UCC cohort (males) are statistically significantly greater than zero (at the 5% significance level)*. Thus, *any excess risk estimates based on these lymphoid cancer analyses may be considered conservative and health-protective*, particularly if the 95% UCL URF is utilized for calculation of the EtO air concentration corresponding to 1 in 100,000 excess risk.

#### **3.4.1.5.2.2 Breast Cancer**

Table 15 contains environmental EtO air concentrations corresponding to the cited excess risk level and associated URFs for breast cancer incidence in the NIOSH (female only) cohort.

**Table 15: Breast Cancer Incidence (with interviews) - NIOSH (females) - MLE and 95% LCL of the Environmental EtO Concentration at 1 in 100 Excess Risk <sup>a</sup>**

Model	Lag (years)	EC <sub>01</sub> ppm	URF per ppm <sup>b</sup>	LEC <sub>01</sub> ppm <sup>c</sup>	URF per ppm <sup>b</sup>
log-linear (standard Cox regression)	15	0.126	$7.94 \times 10^{-2}$	0.0737	$1.36 \times 10^{-1}$

<sup>a</sup> Adapted from Table 4-15 of USEPA (2016).

<sup>b</sup> URF = 0.01/ EC<sub>01</sub> or LEC<sub>01</sub>.

<sup>c</sup> Confidence intervals used in deriving the LEC<sub>01</sub> was estimated employing the Wald approach for the log-linear RR models.

For breast cancer incidence, the MLE URF ( $7.94 \times 10^{-5}$  per ppb) in Table 15 corresponds to an EtO air concentration of 0.13 ppb for a no significant excess risk level of 1 in 100,000 based on females in the NIOSH cohort (15-year exposure lag). Based on the 95% UCL URF ( $1.36 \times 10^{-4}$  per ppb), 0.074 ppb is the EtO air concentration corresponding to a 1 in 100,000 excess risk. *These breast cancer incidence excess risk results are not consistent with TCEQ conclusions regarding the range of EtO air concentrations likely to be associated with excess risk considering normal endogenous EtO levels* (see Sections 3.4.1.2.1 and 3.4.1.4.1). For example, the EtO air concentration corresponding to the mean endogenous level in the unexposed population is 1.9 ppb, and continuous exposure to 0.074-0.13 ppb EtO is predicted to correspond to an increase of only ~6-10% of the SD for normal endogenous levels; a deviation well within the range of normal endogenous variation in the unexposed population (Table 4 of Kirman and Hays 2017). For additional perspective, the cumulative exposure associated with a lifetime of environmental exposure to 0.074-0.13 ppb ( $\approx 1.9$ -3.3 ppm  $\times$  days) is >4,430-7,695 times less than the lowest cumulative exposure levels associated with a statistical increase in breast cancer incidence in the NIOSH cohort (>14,620 ppm-days, 15-year lagged exposure; Table 5). *The TCEQ finds no basis to conclude that the resulting change in internal dose from continuous exposure to 0.074-0.13 ppb EtO would be biologically meaningful/significant, or from a biological plausibility perspective, would be expected to result in excess risk* (i.e., above and distinguishable from normal endogenous EtO contributions to background risk). The TCEQ is not confident in the scientific reasonableness of these excess risk results for breast cancer incidence.

### 3.4.1.6 Selection of Critical Cancer Endpoint and Final URF

#### 3.4.1.6.1 Critical Cancer Endpoint

As discussed above, lymphoid cancer mortality excess risk results are consistent with the range of EtO air concentrations expected to most likely be associated with excess risk. *The TCEQ considers the 1 in 100,000 excess risk level EtO air concentrations for lymphoid cancer based on Cox proportional hazards modeling (15-year exposure lag) to be both biologically plausible and scientifically reasonable, thereby increasing confidence in their use for regulatory purposes.* For

example, unlike the USEPA (2016) URF for lymphoid cancer incidence, use of the URFs corresponding to the MLE (7.57E-07 per ppb) and 95% UCL (1.93E-06 per ppb) for the full NIOSH cohort (male + female) along with the EtO air concentrations corresponding to the means of background levels in the unexposed population (1.9 ppb) and smokers (18.8 ppb) does not predict a nonsmoker/smoker population-weighted background rate of lymphoid cancer mortality above the actual applicable background rate (e.g., 0.53% for lymphoid cancer mortality, male + female, 70-year lifetime). *By contrast, the TCEQ lacks confidence in the scientific reasonableness of excess risk results for breast cancer incidence* (e.g., exposure to the calculated 1 in 100,000 excess risk EtO air concentrations would result in internal exposures well within the range of normal endogenous variation of nonsmokers). Consequently, after due consideration of both cancer endpoints, *the TCEQ ultimately selects lymphoid cancer as the critical cancer endpoint for derivation of the EtO URF.*

#### **3.4.1.6.2 Final URF and Air Concentrations at 1 in 100,000 Excess Risk**

For lymphoid tumors, Tables 12, 13, and 14 contain URFs and 1 in 100,000 excess risk EtO air concentrations based on the NIOSH (male + female), NIOSH (male only), and UCC (males) cohorts, respectively. *For protection against lymphoid tumors, a value based on males is considered most conservative as the lymphoid tumor slope for females in the NIOSH cohort was not positive* (denoted by “-ns” in Table 6). For example, the URF (MLE) for NIOSH (male + female) is 7.57E-07 per ppb (15-year lag; Table 12) whereas the URF (MLE) for NIOSH (males only) is 1.03E-06 per ppb (15-year lag; Table 13), which is 36% higher. *When determining the final EtO URF, the weighting of data from both cohorts (NIOSH and UCC) must be considered.* For example, in TCEQ’s (2011) assessment of the carcinogenicity for nickel a weighting factor of  $\text{person-years} \times 1/SE^2$  was used to combine URFs. Similarly, in the carcinogenic assessment of inorganic arsenic (TCEQ 2012), the inverse of the variance ( $1/SE^2$ ) for the  $\beta$  (MLE) was used to weight URFs for the final URF. Inverse-variance weighting (without a person-years weighting factor) is a more standard statistical procedure used in meta-analyses.

SE values for the slopes were obtained from Tables 8 and 9 (15-year lag) for the Cox proportional hazards model evaluation of lymphoid tumors in NIOSH males ( $SE=2.61E-06$ ) and UCC males ( $SE=9.94E-06$ ), respectively. For comparison, it is noted that the SE ( $2.65E-06$ ; Table 7) for the full NIOSH cohort (male + female) provides similar weighting results. Both types of weighting factors previously used by the TCEQ were calculated (i.e.,  $1/SE^2$  and  $\text{person-years} \times 1/SE^2$ ) and are provided in Table 16.

**Table 16: Weighting Factors for the Lymphoid Tumor Analyses for the NIOSH and UCC Cohorts**

Cohort	Gender	Slope SE	Weight 1/SE <sup>2</sup>	Weight Ratio NIOSH/ UCC	Person- Years	Total Weight Person-Years × 1/SE <sup>2</sup>	Relative Total Weight NIOSH/ UCC
NIOSH	M	2.61E-06	1.47E+11	14.5	189,868	2.79E+16	33.0
NIOSH	M/F	2.65E-06	1.42E+11	14.1	450,906	6.42E+16	76.0
UCC	M	9.94E-06	1.01E+10		83,524	8.45E+14	

As seen from Table 16, using person-years × 1/SE<sup>2</sup> as a weighting factor results in the NIOSH (males only) cohort receiving ≥33-fold greater weight than the UCC (males) cohort. Aside from consideration of cohort person-years or the number of cohort cancer mortalities observed, using 1/SE<sup>2</sup> as a weighting factor produces qualitatively similar results, with the NIOSH (males only) cohort receiving >10-times more weight than the UCC (males) cohort. *Thus, based on the considerations inherent to the weighting factors applied, results suggest that for all practical purposes the URF (and corresponding 1 in 100,000 excess risk air concentration) should be based on the NIOSH cohort.*

In accordance with the considerations discussed above, the final EtO URF for lymphoid cancer will be based on the NIOSH (males only) cohort (15-year lagged exposure). *Furthermore, as both a scientifically reasonable and conservative selection, the URF (95% UCL) of 2.5E-06 per ppb will serve as the final URF for lymphoid tumors (Table 13).*

**EtO Lymphoid Cancer URF = 2.5E-06 per ppb or 1.4E-06 per µg/m<sup>3</sup>**

*The corresponding 1 in 100,000 excess risk EtO air concentration for lymphoid tumors is 4 ppb or 7 µg/m<sup>3</sup> (i.e., 1E-05/2.5E-06 per ppb = 4.0 ppb × 1.83 µg/m<sup>3</sup>/ppb = 7.3 µg/m<sup>3</sup>). As indicated previously (Section 3.4.1.5.2.1), these results incorporate USEPA (2005b) ADAFs in consideration of the MOA analysis and the potential for increased early-life susceptibility. A lymphoid cancer 1 in 100,000 excess risk EtO air concentration value based on the full NIOSH (male + female) cohort would be somewhat higher at 5.2 ppb, but within a factor of 1.3. Similarly, based on the URF (MLE) values, EtO air concentrations corresponding to 1 in 100,000 excess risk for both the NIOSH (male + female) full cohort and NIOSH (males only) cohort would be somewhat higher at 13.2 ppb and 9.7 ppb, respectively (Tables 12 and 13). As stated previously, EtO air concentrations that themselves produce internal exposures above the normal endogenous range (e.g., continuous air exposure concentrations ≥ ≈4.6-7 ppb) are considered most likely to be associated with excess (i.e., above background) risk, and the TCEQ notes that these calculated risk-based air concentrations for lymphoid tumors are remarkably consistent with this expectation.*

For additional context, continuous exposure to 4 ppb EtO would be predicted to result in an HEV burden (as a biomarker of internal exposure) of approximately 43.6 pmol/g Hb. This HEV level roughly approximates the mean +1 SD ( $21.1 + 14.6$  pmol/g Hb = 35.7 pmol/g Hb) of the normal distribution in the non-smoking population that results from endogenous EtO exposure (Table 4 of Kirman and Hays 2017). An additional  $\approx 43.6$  pmol/g Hb due to continuous exogenous exposure to 4 ppb would be predicted to:

- Increase the HEV level for the median non-smoker to between the 95<sup>th</sup> and 99<sup>th</sup> percentiles of normal endogenous background levels; and
- Increase the HEV level in 90<sup>th</sup> percentile non-smokers to over the 99<sup>th</sup> percentile.

An exogenous EtO exposure concentration that results in endogenous levels rising above the normal background range in some appreciable portion of the population (e.g., the 90<sup>th</sup> percentile to > 99<sup>th</sup> percentile) is considered consistent with the assessment of “excess” (i.e., above background) risk. By contrast, continuous exposure to 0.001 ppb EtO (i.e., the 1 in 100,000 excess risk air concentration using USEPA’s URF) would result in  $\approx 0.0109$  pmol/g Hb added HEV, a mere 0.075% of the SD for normal background endogenous levels and over 360 times less than even the 1<sup>st</sup> percentile of normal background endogenous levels - this magnitude of change in HEV may be reasonably characterized as biologically insignificant. Extremely low air concentrations corresponding to internal exposure increases that represent such minuscule, *de minimus* fractions of normal endogenous background levels do not provide a scientific basis, much less a robust one, for the biological or mechanistic plausibility of any appreciable excess (i.e., above background) risk. In fact, it suggests the opposite due to the body's inherent ability to deal with typical endogenous levels through normal detoxification and repair processes.

Thus, based on the data evaluated and considerations discussed, an EtO <sup>chronic</sup>ESL<sub>nonthreshold(c)</sub> of **4 ppb** is considered health-protective, scientifically reasonable, and relatively consistent with the assessment of excess risk as being above and distinguishable from normal endogenous EtO contributions to background risk. Continuous exposure to 4 ppb EtO would be predicted to correspond to internal exposure level increases to or above the upper end of the range (e.g., 95<sup>th</sup>-99<sup>th</sup> percentile) of normal endogenous levels at least for some percentage of the population (e.g., those at  $\approx 90^{\text{th}}$  percentile). Additionally, as shown in Appendix 3, the Cox proportional hazards model assessment used by the TCEQ (log-linear, 15-year exposure lag, 95% UCL) neither statistically over- or under-predicts the lymphoid cancer numbers observed in the NIOSH cohort. The calculated EtO <sup>chronic</sup>ESL<sub>nonthreshold(c)</sub> (4 ppb) falls within the range (0.13-6.9 ppb) supported by the approach in Kirman and Hays (2017) as protective of human health, and is conservative (60-87% lower) compared to that proposed by Valdez-Flores et al. (2010) at the 1 in 100,000 excess risk level (i.e., 1-3 ppb at  $1\text{E-}06 \approx 10\text{-}30$  ppb at  $1\text{E-}05$  compared to 4 ppb). Lastly, it is simply noted that the European Commission’s Scientific Committee on Occupational

Exposure Limits has adopted the same modeling approaches of Valdez-Flores et al. for EtO cancer assessment (SCOEL 2012, Valdez-Flores et al. 2011).

### 3.4.2 Evaluating Susceptibility from Early-Life Exposures

Per Section 3.3.1, the weight of evidence supports a mutagenic MOA for EtO carcinogenicity. The mutagenic MOA is considered relevant to all populations and life stages. See Section 3.5.2 of USEPA (2016) for available information on potentially susceptible life stages and populations (e.g., those with higher HEV adduct levels due to a null GSTT1 genotype or with DNA repair deficiencies). USEPA (2016) indicates that there are no data on the relative susceptibility of children to EtO (e.g., the potential for decreased detoxification/clearance by hydrolysis as a primary metabolic pathway and/or glutathione conjugation). In the absence of chemical-specific data to evaluate potential child/adult differences in susceptibility, USEPA (2005b) provides default ADAFs to account for potentially increased susceptibility in children due to early-life exposure when a chemical has been identified as acting through a mutagenic MOA. Therefore, because of the weight of evidence supporting a mutagenic MOA and the lack of chemical-specific data on potential differences in susceptibility, increased early-life susceptibility should be assumed and ADAFs applied (TCEQ 2015). As previously mentioned, the results utilized by the TCEQ (e.g., Table 13) already inherently incorporate USEPA (2005b) ADAFs. As such, no further adjustments are necessary.

### 3.4.3 Final EtO URF and $\text{chronicESL}_{\text{nonthreshold}(c)}$

### 3.5 Long-Term ESL and Value for Air Monitoring Evaluation

The chronic evaluation resulted in the derivation of the following values for EtO:

- $\text{chronicESL}_{\text{nonthreshold}(c)} = 7 \mu\text{g}/\text{m}^3$  (4 ppb) (rounded to one significant figure)
- URF =  $1.4\text{E-}06$  per  $\mu\text{g}/\text{m}^3$  ( $2.5\text{E-}06$  per ppb) for lymphoid cancer

The long-term ESL for air permit reviews and the evaluation of long-term ambient air monitoring data, set at an excess risk of 1 in 100,000, is the  $\text{chronicESL}_{\text{nonthreshold}(c)}$  of  $7 \mu\text{g}/\text{m}^3$  (4 ppb). The URF is  $2.5\text{E-}06$  per ppb for lymphoid cancer or  $1.4\text{E-}06$  per  $\mu\text{g}/\text{m}^3$  (see Section 3.4.1.6.2).

## Chapter 4 References

- Agency for Toxic Substances and Disease Registry (ATSDR). 1990. Toxicological profile for ethylene oxide.
- Ambroise, D, Moulin, JJ, Squinazi, F, Protois, JC, Fontana, JM, Wild, P. 2005. Cancer mortality among municipal pest-control workers. *Int Arch Occup Environ Health*. 78:387-393.
- Austin, S, Sielken, R. 1988. Issues in assessing the carcinogenic hazards of ethylene oxide. *Journal of Occupational Medicine*. 30(3):236-245.
- Bisanti, L, Maggini, M, Raschetti, R, Spila Alegiani, S, Menniti Ippolito, F, Caffari, B, Segnan, N, Ponti, A. 1993. Cancer mortality in ethylene oxide workers. *British Journal of Industrial Medicine*. 50:317-324.
- Bogen, K, Sheehan, P, Valdez-Flores, C, Li, A. 2019. Reevaluation of historical exposures to ethylene oxide among U.S. sterilization workers in the National Institute of Occupational Safety and Health (NIOSH) study cohort. *Int. J. Environ. Res. Public Health* 16:1738.
- Bratu, AM. 2019. Spectroscopic study of breath ethylene via the mouth and nose. *Lasers in Medical Science* 34:773-778.
- ChemSpider. 2019. <http://www.chemspider.com>
- Coggon, H, Harris, E, Poole, J, Palmer, K. 2004. Mortality of workers exposed to ethylene oxide extended follow up of a British cohort. *Occup Environ Med*. 61:358-362.
- Crump, KS. 2005. The effect of random error in exposure measurement upon the shape of the exposure response. *Dose Response* 3(4):456-464.
- Crump, KS, & Allen, BC. 1985. Methods for Quantitative Risk Assessment Using Occupational Studies. *The American Statistician* 39(4):442-450.
- Donner, EM, Wong, BA, James, RA, Preston, RJ. 2010. Reciprocal translocations in somatic and germ cells of mice chronically exposed by inhalation to ethylene oxide: Implications for risk assessment. *Mutagenesis* 25:49-55.
- "Ethylene Oxide Frequently Asked Questions." American Chemistry Council (ACC). 2018. Retrieved from <https://www.americanchemistry.com/EO/Ethylene-Oxide-Frequently-Asked-Questions.pdf>

"Ethylene Oxide Sterilization for Medical Devices." United States Food and Drug Administration (USFDA) (April 2019). Retrieved from <https://www.fda.gov/medical-devices/general-hospital-devices-and-supplies/ethylene-oxide-sterilization-medical-devices>

"Ethylene Oxide. 75-21-8." United States Environmental Protection Agency (USEPA). Retrieved from <https://www.epa.gov/sites/production/files/2016-09/documents/ethylene-oxide.pdf>

Fenske, J, and Paulson S, 1999. Human breath emissions of VOCs. Journal of the Air & Waste Management Association 49:594-598.

Fondelli, C, Costantini, A, Ercolanelli, M, Pizzo, A, Maltoni, S, Quinn, M. 2007 Exposure to carcinogens and mortality in a cohort of restoration workers of water-damaged library materials following the River Arno flooding in Florence, 4 November 1966. Med Lav. 98, 5:422-431.

Gardner, M, Coggon, D, Pannett, B, Harris, E. 1989. Workers exposed to ethylene oxide: a follow up study. British Journal of Industrial Medicine. 46:860-865.

Ginevan, ME, & Watkins, DK. 2010. Logarithmic dose transformation in epidemiologic dose-response analysis: use with caution. Regul Toxicol Pharmacol 58(2):336-340.

Greenberg, H, Ott, M, Shore, R. 1990. Men assigned to ethylene oxide production or other ethylene oxide related chemical manufacturing: a mortality study. British Journal of Industrial Medicine. 47:221-230.

Greife, A, Hornung, R, Stayner, G, Steenland, K. 1988. Development of a model for use in estimating exposure to ethylene oxide in a retrospective cohort mortality study. Scand J Work Environ Health. 14(1):29-30.

Hagmar, L, Welinder, H, Lindinl, K, Attewelll, R, Osterman-Golkar, S., Tornqvist, M. 1991. An epidemiological study of cancer risk among workers exposed to ethylene oxide using hemoglobin adducts to validate environmental exposure assessments. Int Arch Occup Environ Health. 63:271-277.

Hagmar, L, Mikoczy, Z, Welinder, H. 1995. Cancer incidence in Swedish sterilant workers exposed to ethylene oxide. Occupational and Environmental Medicine. 52:154-156.

Health Canada, 2016. Screening Assessment of Ethene (Ethylene), Chemical Abstracts Service Registry Number (CAS RN) 74-85-1, Environment and Climate Change Canada, Health Canada, May 2016.



- Hill, AB. 1965. The Environment and Disease: Association or Causation? *Proc R Soc Med* 58:295-300.
- Hogstedt, C, Rohlen, O, Berndtsson, B, Axelson, O, Ehrenberg, L. 1979a. A cohort study of mortality and cancer incidence in ethylene oxide production workers. *British Journal of Industrial Medicine*. 36:276-280.
- Hogstedt, C, Malmqvist, N, Wadman, B. 1979b. Leukemia in workers exposed to ethylene oxide. *JAMA*. 241(11):1132-1133.
- Hogstedt, C., Aringer, L, Gustavsson, A. 1986. Epidemiologic support for ethylene oxide as a cancer-causing agent. *JAMA*. 255(12):1575-1578.
- Hogstedt, C. 1988. Epidemiological studies on ethylene oxide and cancer: an updating. *IARC Sci Publ*. 89:265-70.
- Hornung, R, Greife, A, Stayner, L, Steenland, K, Herrick, R, Elliott, L, Ringenburt, V, Morawetz. 1994. Statistical model for prediction of retrospective exposure to ethylene oxide in an occupational mortality study. *American Journal of Industrial Medicine*. 25:825-836.
- International Agency for Research on Cancer (IARC). 2008. IARC monographs on the evaluation of carcinogenic risks to humans: 1,3-butadiene, ethylene oxide and vinyl halides (vinyl fluoride, vinyl chloride and vinyl bromide). Lyon, France: International Agency for Research on Cancer.
- International Agency for Research on Cancer (IARC). 2012. IARC monographs on the evaluation of carcinogenic risks to humans, No. 100F. Lyon, France: International Agency for Research on Cancer.
- Kardos, L, Szeles, G, Gombkoto, G, Szeremi, M, Tompa, A, Adany, R. 2003. Cancer deaths among hospital staff potentially exposed to ethylene oxide an epidemiological analysis. *Environmental and Molecular Mutagenesis*. 42:59-60.
- Kiesselbach, N, Ulm, K, Lange, H-J, Korallus, U. 1990. A multicentre mortality study of workers exposed to ethylene oxide. *British Journal of Industrial Medicine*. 47:182-188.
- Kiran, S, Cocco, P, Mannetje, A, Satta, G, D'Andrea, I, Becker, N, de Sanjose, S, Foretova, L, Staines, A, Kleefeld, S, Maynadie', M, Nieters, A, Brennan, P, Boffetta, P. 2010. Occupational exposure to ethylene oxide and risk of lymphoma. *Epidemiology*. 21:905-910.

- Kirman, C, Sweeney, L, Teta, M, Sielken, R, Valdez-Flores, C, Albertini, R, Gargas, M. 2004. Addressing nonlinearity in the exposure–response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide. *Risk Anal.* 24 (5): 1165-1183.
- Kirman, C, Hays, S. 2017. Derivation of endogenous equivalent values to support risk assessment and risk management decisions for an endogenous carcinogen. *Regulatory Toxicology and Pharmacology.* 91:165-172.
- Kita, M. 1991. Mortality among workers exposed to ethylene oxide 16-year average follow-up of over 18,000 workers. *Journal of Insurance Medicine.* 23(3):176-179.
- Li, A, Sheehan, P, Valdez-Flores, C, et al. 2019. Updated modeling indicates historical sterilization worker ethylene oxide exposures were higher than assumed in the US EPA IRIS assessment. *The Toxicologist* 168:1855.
- Mikoczy, Z, Tinnerberg, H, Björk, J, Albin, M. 2011. Cancer incidence and mortality in Swedish sterilant workers exposed to ethylene oxide updated cohort study findings 1972-2006. *Int. J. Environ. Res. Public Health.* 8:2009-2019.
- Morgan, R, Claxton, K, Divine, B, Kaplan, S, Harris, V. 1981. Mortality among ethylene oxide workers. *Journal of Occupational Medicine.* 23(11):767-77.
- Mosavi-Jarrahi, A, Mohagheghi, M, Kalaghchi, B, Mousavi-Jarrahi, Y, Kolahi, A, Noori, M. 2009. Estimating the incidence of leukemia attributable to occupational exposure in Iran. *Asian Pacific Journal of Cancer Prevention.* 10:67-70.
- “NATA Frequent Questions. National Air Toxics Assessment.” USEPA. Retrieved from <https://www.epa.gov/national-air-toxics-assessment/nata-frequent-questions#results>
- Norman, S, Berlin, J, Soper, K, Middendorf, B, Stolley, P. 1995. Cancer incidence in a group of workers potentially exposed. *International Journal of Epidemiology.* 24(2):276-284.
- Olsen, G, Lacy, S, Bodner, K, Chau, M, Arceneaux, T, Cartmill, J, Ramlow, J, Boswell, J. 1997. Mortality from pancreatic and lymphopietic cancer among workers in ethylene and propylene chlorohydrin production. *Occup Environ Med.* 54:592-598.
- Schulte, PA, Boeniger, M, Walker, JT, Schober, SE, Pereira, MA, Gulati, DK, Wojciechowski, JP, Garza, A, Froelich, R, Strauss, G. 1992. Biologic markers in hospital workers exposed to low levels of ethylene oxide. *Mutat Res* 278:237-251.

- Scientific Committee on Occupational Exposure Limits (SCOEL). 2012. Recommendation from the Scientific Committee on Occupational Exposure Limits for Ethylene Oxide, SCOEL/SUM/160.
- Shore, R, Gardner, M, Pannett, B. 1993. Ethylene oxide an assessment of the epidemiological evidence on carcinogenicity. *British Journal of Industrial Medicine*. 50:971-997.
- Sielken Jr, R, Valdes-Flores, C. 2009a. Calculating excess risk with age-dependent adjustment factors and cumulative doses ethylene oxide case study. *Regulatory Toxicology and Pharmacology*. 55:76-81.
- Sielken Jr, R, Valdes-Flores, C. 2009b. Life-table calculations of excess risk for incidence versus mortality. *Regulatory Toxicology and Pharmacology*. 55:82-89.
- Stayner, L, Steenland, K, Greife, A, Hornung, R, Hayes, R, Nowlin, S, Morawetz, J, Ringenburg, V, Elliot, L, Halperin, W. 1993. Exposure response analysis of cancer mortality in a cohort of workers exposed to ethylene oxide. *American Journal of Epidemiology*. 138:787-798.
- Steenland, K, Stayner, L, Greife, A, Halperin, W, Hayes, R, Hornung, R, Nowlin, S. 1991 Mortality among workers exposed to ethylene oxide. *The New England Journal of Medicine*. 324(20):1402-1407.
- Steenland, K, Whelan, E, Deddens, J, Stayner, L, Ward, E. 2003. Ethylene oxide and breast cancer incidence in a cohort study of 7576 women (United States). *Cancer Causes and Control*. 14:531-539.
- Steenland, K, Stayner, L, Deddens, J. 2004. Mortality analyses in a cohort of 18 235 ethylene oxide exposed workers: follow up extended from 1987 to 1998. *Occup Environ Med*. 61:2-7.
- Steenland, K, Seals, R, Klein, M, Jinot, J, Kahn, H. 2011. Risk Estimation with Epidemiologic Data When Response Attenuates at High-Exposure Levels. *Environmental Health Perspectives*. 119(6):831-837.
- Swaen, G, Slangen, J, Ott, M, Kusters, E, Van Den Langenbergh, G, Arends, J, Zober, A. 1996. Investigation of a cluster of ten cases of Hodgkin's disease in an occupational setting. *Int Arch Occup Environ Health*. 68:224-228.
- Swaen, G, Burns, C, Teta, J, Bodnar, K, Keenan, D, Bodnar, C. 2009. Mortality study update of ethylene oxide workers in chemical manufacturing: a 15 year update. *JOEM*. 51(6):714-723.

- Swenberg, JA, Fryar-Tita, E, Jeong, YC, Boysen, G, Starr, T, Walker, VE, & Albertini, RJ. 2008. Biomarkers in toxicology and risk assessment: informing critical dose-response relationships. *Chem Res Toxicol* 21(1):253-265.
- Teta, M, Benson, L, Vitale, J. 1993. Mortality study of ethylene oxide workers in chemical manufacturing a 10 year update. *British Journal of Industrial Medicine*. 50:704-709.
- Teta, J, Sielken Jr, R, Valdez-Flores, C. 1999. Ethylene oxide cancer risk assessment based on epidemiological data application of revised regulatory guidelines. *Risk Analysis*. 19(6):1135-1155.
- TCEQ. 2015. Guidelines to develop toxicity factors. RG-442: Texas Commission on Environmental Quality (TCEQ).
- United States Environmental Protection Agency (USEPA). 2005a. Guidelines for Carcinogen Risk Assessment. (EPA/630/P-03/001B). Washington, D.C.
- United States Environmental Protection Agency (USEPA). 2005b. Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens. (EPA/630/R-03/003F). Washington, D.C.
- United States Environmental Protection Agency (USEPA). 2016. Evaluation of the inhalation carcinogenicity of ethylene oxide (CASRN 75-21-8): In support of summary information on the Integrated Risk Information System (IRIS). EPA/635/R-16/350Fa. Washington, DC, U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment.
- Valdes-Flores, C, Sielken Jr, R, Teta, J. 2010 Quantitative cancer risk assessment based on NIOSH and UCC epidemiological data. *Regulatory Toxicology and Pharmacology*. 56:312-320.
- Valdez-Flores, C, Sielken Jr, R, Teta, J. 2011 Quantitative cancer risk assessment for ethylene oxide inhalation. *Arch Toxicol*. 85:1189-1193.
- Valdez-Flores, C, Sielken Jr, R. 2013. Misinterpretation of categorical rate ratios and inappropriate exposure-response model. *Regulatory Toxicology and Pharmacology*. 67:206-214.
- van Sittert, NJ, Beulink, GD, van Vliet, E, van der Waal, H, 1993. Monitoring occupational exposure to ethylene oxide by the determination of hemoglobin adducts. *Environ Health Perspect* 99:217-220.

World Health Organization (WHO). 2003. Concise international chemical assessment document: Ethylene oxide. In Concise International Chemical Assessment: Ethylene Oxide. Geneva, Switzerland: World Health Organization, International Programme on Chemical Safety.

Wong, O, Trent, L. 1993. An epidemiological study of workers potentially exposed to ethylene oxide. British Journal of Industrial Medicine. 50:308-316.

## Appendix 1 Systematic Review and Evidence Integration

### A1.1 Problem Formulation and Protocol

Problem formulation identifies and defines the causal questions and describes the extent of the evaluation. These questions structured the systematic review for EtO:

- What are the physical and chemical properties of EtO?
- What is the critical effect following exposure to EtO?
- Are there sensitive subpopulations?
- What is the mode of action (MOA)?
- Does route of exposure play a role?
- Is EtO carcinogenic, and if so, is it carcinogenic by a specific route of exposure?

Protocol development is another important aspect in the initial process. A protocol is typically developed around a PECO statement: Populations, Exposure, Comparator/Control, and Outcomes. These identifiers are used to lay out the framework for the literature search and inclusion/exclusion criteria. The PECO statement for EtO followed these criteria:

**Table 17: PECO Statement used by the TCEQ to Develop Toxicity Factors for EtO**

<u>P</u> opulation	General human population and any relevant sensitive subpopulations, animals, and vegetation
<u>E</u> xposure	Exposure to EtO, surrogates with demonstrated similar MOAs, and any identified metabolites
<u>C</u> omparator/ <u>C</u> ontrol	Populations exposed to concentrations below the concentration that causes the most sensitive critical effect
<u>O</u> utcome(s)	The most sensitive critical effect directly related to EtO exposure

The protocol used for the systematic review and the development of toxicity factors for EtO is as follows:

1. Identify the chemical of interest and define the causal questions
2. Conduct a systematic review
  - a. Conduct a systematic literature search
  - b. Identify the inclusion/exclusion criteria
  - c. Extract the relevant data from each data stream (human, animal, mechanistic)
  - d. Assess the study quality and conduct a risk of bias analysis
  - e. Weigh the evidence in each data stream and then integrate the evidence across the data streams

- f. Rate the confidence in the evidence
3. Derive toxicity factors (TCEQ 2015)
  - a. Review the essential data, including chemical/physical properties and selected key studies from the systematic review
  - b. Conduct MOA analysis
  - c. Choose the appropriate dose metric considering toxicokinetics and MOA
  - d. Select critical effect, based on human equivalent exposure considering each key study
  - e. Extrapolate from the adjusted POD to lower exposures based on MOA analysis

### **A1.2 Systematic Literature Review and Study Selection**

As a first step, publically available databases were searched using explicitly stated search criteria. Please see TCEQ (2015) for a list of available databases that were searched. The search terms used in literature review for EtO, along with the number of results from PubMed, are found in Table 18. Additional references were also identified using the reference sections from some of the selected studies. This literature review was conducted in December 2018, and therefore studies published after this date were not available at the time of the review.

**Table 18: Search Strings used in the Literature Review of EtO**

Search Term/String	PubMed Results
ethylene oxide	9,626
"ethylene oxide"	7,478
"ethylene oxide" OR oxirane	10,374
"ethylene oxide" OR oxirane OR 75-21-8	10,374

These 10,374 studies were imported into the desktop application SWIFT-Review by Sciome and briefly searched to ensure that the key studies used in several other reviews were present in the data set. The data set was further narrowed down using the tag levels created by the SWIFT-Review software. The tags used and the number of studies that each tag removed can be found in Table 19.

**Table 19: SWIFT-Review Tags and Results**

Data Set/Tag	Number of Studies
Initial PubMed Search	10,374
Tag – Health Outcomes, any (excluded studies with no tag)	7,468
Tag – Evidence Stream, any (excluded studies with no tag)	4,914
Tag – MeSH Chemicals, only Ethylene Oxide (excluded everything else)	1,520

Additionally, several governmental and private sector organizations were searched for published literature and toxicity values for EtO (Table 20), and the available documents along with their relevant references were added to the pool of selected material as needed.

**Table 20: Available Reviews and Inhalation Toxicity Values for EtO**

Organization	Year	Toxicity Value
Agency for Toxic Substances and Disease Registry (ATSDR) Toxicological Profiles	1990	Intermediate MRL*
Integrated Risk Information System (IRIS) USEPA	2016	Inhalation Unit Risk
Office of Environmental Health Hazard Assessment (OEHHHA) CalEPA	2000	Chronic REL* Inhalation Slope Factor

MRL – minimal risk level, REL – reference exposure level

Following this initial review, specific inclusion and exclusion criteria were used to narrow down the pool of available data. The criteria along with examples of the kinds of studies that were excluded can be found in Table 21.



**Table 21: Inclusion/Exclusion Criteria used in the Review of EtO**

Study Type	Inclusion Criteria	Exclusion Criteria
General	Complete study available for review	<ul style="list-style-type: none"> <li>- Only abstract is available</li> <li>- Study in a language other than English</li> <li>- Unpublished report/unable to retrieve</li> </ul>
	Study contains original data or utilizes existing data in a novel way	<ul style="list-style-type: none"> <li>- Study is a review article or meta-analysis</li> <li>- Study comments on a previous method without providing a sufficient alternative</li> </ul>
	Exposure concentration is known or can be reasonably estimated	<ul style="list-style-type: none"> <li>- Exposure concentration unknown</li> <li>- Exposure environment/conditions unsuitable to concentration estimation</li> </ul>
	Study examines effects related to chemical exposure	<ul style="list-style-type: none"> <li>- Study measures concentration in air, factories, etc.</li> <li>- Study does not examine health effects</li> </ul>
	Study focused on the chemical of concern	<ul style="list-style-type: none"> <li>- Study examined mixture effects</li> <li>- Study on treatment following EtO exposure</li> </ul>
	Route of exposure is relevant to exposure and toxicity factor development	<ul style="list-style-type: none"> <li>- Exposure through i.v., i.p., or subcutaneous injection</li> <li>- Study examining oral or dermal exposure</li> </ul>
Animal	Relevant animal model and endpoints examined	<ul style="list-style-type: none"> <li>- Study used non-mammalian animal models</li> <li>- Endpoint studied not relevant to human health</li> <li>- Endpoint not applicable to toxicity factor development</li> </ul>
	Appropriate study populations and methods were used	<ul style="list-style-type: none"> <li>- Study lacked appropriate numbers or doses</li> <li>- Exposure method unsuitable for dose-response</li> </ul>
Human/Epi	Relevant endpoints examined	<ul style="list-style-type: none"> <li>- Study focused solely on cytotoxicity</li> <li>- Study only measured sister chromatid exchanges (SECs), protein adducts, or chromosomal changes</li> </ul>
	Study populations allowed for significant findings and follow ups	<ul style="list-style-type: none"> <li>- Case studies examining single high-dose exposures</li> <li>- Studies without appropriate follow-up studies</li> <li>- Historical studies that have been updated</li> </ul>

i.v. – intravenous, i.p. – intraperitoneal

Studies were then divided into groups by evidence stream (i.e. human, animal) and effect group (i.e., acute, chronic non-carcinogenic, carcinogenic). For the purposes of this DSD, only the human carcinogenic/epidemiologic data were considered for several reasons:

1. In order to expedite the process, it was decided that only a health-based chronic carcinogenic toxicity factor would be derived for EtO in this DSD. Other toxicity factors (i.e. health- and welfare-based acute and chronic non-carcinogenic) may be evaluated at a later date with an additional systematic review picking up where this systematic review left off.
2. Sufficient human data exist for EtO such that animal data, although used to strengthen the carcinogenicity class, would not be used to derive a chronic carcinogenic toxicity factor. TCEQ (2015) states that in general, human data are preferred over animal data when developing toxicity factors.
3. Similarly, mechanistic data remain supportive (e.g., MOA), but not useful as a basis in the derivation of a chronic carcinogenic toxicity factor.
4. And finally, human data looking solely at cytotoxicity, sister chromatid exchanges, or chromosomal abnormalities were considered useful in developing the MOA of EtO, but not useful as a basis for derivation of a health-based toxicity factor.

After full text review and screening with the inclusion/exclusion criteria listed above, eight human carcinogenic studies were identified for further use in this systematic review. Several human studies (directly or indirectly related to carcinogenicity) were reviewed and later excluded due to various reasons (Table 22).

**Table 22: Excluded Human Studies Related to Carcinogenicity**

Reason for Exclusion	Study	
No exposure or dose-response information available to directly derive a toxicity factor (Not useful in the development of a carcinogenic-based toxicity factor)	Ambroise et al., 2005 Austin and Sielken, 1988 Bisanti et al., 1993 Coggon et al., 2004 Fondelli et al., 2007 Gardner et al., 1989 Greenburg et al., 1990 Greife et al., 1988 Hagmar et al., 1991 Kardos et al., 2003	Kiesselbach et al., 1990 Kiran et al., 2010 Kirman and Hays, 2017 Morgan et al., 1981 Mosavi-Jarrahi et al., 2009 Norman et al., 1995 Olsen et al., 1997 Swaen et al., 1996 Wong and Trent, 1993
Follow up study available	Greenberg et al., 1990 Hagmar et al., 1995 Hogstedt et al., 1979a Hogstedt et al., 1986	Stayner et al., 1993 Steenland et al., 1991 Teta et al., 1993
Review, methods, or case study	Hogstedt et al., 1979b Hornung et al., 1994 Kita, 1991 Shore et al., 1993 Sielken and Valdez-Flores, 2009a	Sielken and Valdez-Flores, 2009b Steenland et al., 2011 Valdez-Flores et al., 2011 Valdez-Flores and Sielken, 2013

### **A1.3 Data Extraction**

Each of the identified studies was reviewed in detail and the primary data were extracted for potential use in the development of the chronic carcinogenic toxicity factor in this DSD (Table 23).

**Table 23: Data Extraction from Epidemiological Studies**

Study (cohort)	Size	Exposure Measurement	Tumor Type(s)	Notable Results <sup>1</sup>	Notes
Hogstedt 1988 (Swedish, chemical)	539 m 170 f	Years of employment, 1-9 years, ≥ 10 years	Stomach	SMRs – 597, 608	Exposure estimates conducted in original study but not presented here.
			Blood/Lymphatic	SMRs – 380, 330	
			Leukemia	SMRs – 322, 880	
Kirman 2004 (NIOSH + UCC)	18,254 (NIOSH) (55% m, 45% f) 1,896 m (UCC)	ppm-years, 7.4, 64.8, 187.4, 477.7	Leukemia	POD-ED <sub>001</sub> estimated at 265 ppm-years, URFs: linear $4.5 \times 10^{-7}$ / $\mu\text{g}/\text{m}^3$ Quadratic $4.5 \times 10^{-8}$ / $\mu\text{g}/\text{m}^3$ (no lag or latency periods)	Concentration at $1 \times 10^{-5}$ cancer risk: Linear – 22 $\mu\text{g}/\text{m}^3$ (12 ppb) Quadratic – 222 $\mu\text{g}/\text{m}^3$ (120 ppb) Nonlinear – 37 $\mu\text{g}/\text{m}^3$ (21 ppb)
Mikoczy 2011 (Swedish, sterilant)	862 m 1,309 f	ppm-years, 0-0.13, 0.14-0.21, ≥ 0.22	Breast	SIRs – 0.52, 1.06, 1.12	Compared with/out 15-year latency and between follow-ups, healthy worker effect likely influenced results
			LHN	SIRs – 1.35, 1.32, 1.08	
Steenland 2003 (NIOSH)	7,576 f (5,139 f interviewed)	ppm-days, 0, >0-647, 647-2026, 2026-4919, 4919-14620, 14620+	Breast (Compared to US population)	SIRs – 0.88, 0.77, 0.77, 0.94, 0.83, 1.27 (15-year lag, cumulative)	Subset of the NIOSH cohort, multiple other comparisons presented, including cumulative, categorical, and log cumulative exposure, positive trends for continuous exposure, duration of exposure, and log of cumulative exposure. Overall SMR for NIOSH cohort for breast cancer is 0.99. Exposure-response analysis showed highest group SMR of 1.27, with 20-year lag increased to 2.07 (95% CI: 1.0-3.54)
			Breast (Compared to study population, whole cohort)	Odds Ratios – 1.00, 1.07, 1.00, 1.24, 1.17, 1.74* (15-year lag, categorical, cumulative)	
			Breast (Compared to study population, only interviewed cohort)	Odds Ratios – 1.00, 1.06, 0.99, 1.24, 1.42, 1.87* (15-year lag, categorical, cumulative)	

Study (cohort)	Size	Exposure Measurement	Tumor Type(s)	Notable Results <sup>1</sup>	Notes
Steenland 2004 (NIOSH)	7,645 m 9,885 f	ppm-days, 0, >0-1199, 1200-3679, 3680-13499, 13500+	NHL	SMRs – 2.09, 0.61, 0.88, 0.79, 2.37* m, 10-year lag, cumulative	Multiple other comparisons presented, including cumulative, categorical, and log cumulative exposure, 10, 15, and 20-year lag, positive trend for lymphoid tumors
		ppm-days, 0, >0-646, 647-2779, 2780-12321, 12322+	Breast	SMRs –0.80, 1.05, 1.01, 1.15, 2.07* f, 20-year lag, cumulative	
Swaen 2009 (UCC)	2,063 m	ppm-years, 0-15, 15-65, 65+	None	Authors state no long-term carcinogenic effects associated with EtO exposure	Healthy worker effect likely influenced results, cohort experienced more than twice the average estimated cumulative exposure compared to NIOSH cohort
Teta 1999 (multiple reviewed, dose-response done for NIOSH and UCC)	Multiple, meta-analysis 8,214 m & 10,040 f (NIOSH) 1,896 m (UCC)	ppm-years, 0, 0-33, 33-125, 125-285, >285	Lymphoid (lymphocytic leukemia and NHL)	Added Risk (environmental) UCC – none NIOSH – $10^{-8}$ – $10^{-5}$ /ppb	Compared 0 and 10-year latency, and 0 and 5y lag periods, POD-ED <sub>001</sub> values ranged from 0.81-1.58 ppm assuming a 10-year latency and a 5-year lag period. POD-ED <sub>001</sub> of 0.81 ppm gives a URF of 0.12/ppm, and a concentration at $1 \times 10^{-5}$ cancer risk of 0.083 ppb (0.15 $\mu\text{g}/\text{m}^3$ )
			Leukemia	Added Risk (environmental) UCC – $10^{-12}$ – $10^{-6}$ /ppb NIOSH – $10^{-15}$ – $10^{-6}$ /ppb	
Valdez-Flores 2010 (NIOSH + UCC)	7,634 m & 9,859 f (NIOSH) 2,063 m (UCC)	ppm-days, dose ranges varied by endpoint	Examined 12 cancer endpoints in 6 subcohorts	No statistically significant increases in SMRs, trends, cumulative continuous, or categorical exposure.	No heterogeneity between dose-response models of the two major cohorts and the pooled study, combining increases the power.

<sup>1</sup> Due to space constraints, only notable results are presented here. See individual studies for a more in-depth review.

\* Denotes significance, confidence interval does not include 1

SMR – Standardized mortality ratio, SIR – Standardized Incidence Ratio, NHL – Non-Hodgkin's Lymphoma, LHN – Lymphohematopoietic Neoplasms, m – males, f – females

#### A1.4 Study Quality and Risk of Bias (ROB)

Each of the selected studies was evaluated for study quality and ROB based on a number of attributes determined prior to this review. For this review, study quality methods were adapted from the USEPA version of the Health Assessment Workspace Collaboration (HAWC) online software. For epidemiology studies, seven evaluation domains are used to critically assess different aspects of study design and conduct relating to reporting, risk of bias and study sensitivity. Each domain receives a score of Good, Adequate, Deficient, Critically Deficient, or Not Reported, and once all domains are evaluated, a confidence rating of High, Medium, or Low confidence or Uninformative is assigned to each study. The evaluated domains and explanations can be found in Table 24, while the general guidance for scoring each of the studies can be found in Tables 25 and 26.

**Table 24: Study Quality Domains for Epidemiology Studies (taken from HAWC)**

Domain	Study Design Questions and Aspects
Selection and Performance/ Participant Selection	<p><b>Is there evidence that selection into or out of the study (or analysis sample) was jointly related to exposure and to outcome?</b></p> <p>Study design, where and when was the study conducted, and who was included? Recruitment process, exclusion and inclusion criteria, type of controls, total eligible, comparison between participants and nonparticipants (or followed and not followed), final analysis group. Does the study include potential vulnerable/susceptible groups or life stages?</p>
Exposure Methods/ Measures	<p><b>Does the exposure measure reliably distinguish between levels of exposure in a time window considered most relevant for a causal effect with respect to the development of the outcome?</b></p> <p>Source(s) of exposure (consumer products, occupational, an industrial accident) and source(s) of exposure data, blinding to outcome, level of detail for job history data, when measurements were taken, type of biomarker(s), assay information, reliability data from repeat measures studies, validation studies.</p>
Outcome Methods/Results Presentation	<p><b>Does the outcome measure reliably distinguish the presence or absence (or degree of severity) of the outcome?</b></p> <p>Source of outcome (effect) measure, blinding to exposure status or level, how measured/classified, incident versus prevalent disease, evidence from validation studies, prevalence (or distribution summary statistics for continuous measures).</p>
Confounding	<p><b>Is confounding of the effect of the exposure unlikely?</b></p> <p>Background research on key confounders for specific populations or settings; participant characteristic data, by group; strategy/approach for consideration of potential confounding; strength of associations between exposure and potential confounders and between potential confounders and outcome; degree of exposure to the confounder in the population.</p>

Domain	Study Design Questions and Aspects
Analysis	<p><b>Does the analysis strategy and presentation convey the necessary familiarity with the data and assumptions?</b></p> <p>Extent (and if applicable, treatment) of missing data for exposure, outcome, and confounders, approach to modeling, classification of exposure and outcome variables (continuous versus categorical), testing of assumptions, sample size for specific analyses, relevant sensitivity analyses.</p>
Selective Reporting	<p><b>Is there concern for selective reporting?</b></p> <p>Are results presented with adequate detail for all the endpoints of interest? Are results presented for the full sample as well as for specified subgroups? Were stratified analyses (effect modification) motivated by a specific hypothesis?</p>
Sensitivity	<p><b>Are there concerns for study sensitivity?</b></p> <p>What exposure range is spanned in this study? What are the ages of participants (e.g., not too young in studies of pubertal development)? What is the length of follow-up (for outcomes with long latency periods)? Choice of referent group and the level of exposure contrast between groups (i.e., the extent to which the 'unexposed group' is truly unexposed, and the prevalence of exposure in the group designated as 'exposed'). Is the study relevant to the exposure and outcome of interest?</p>
Overall Study Confidence	<p><b>Once the evaluation domains have been classified, these ratings will be combined to reach an overall study confidence classification of High, Medium, Low, or Uninformative.</b></p> <p>This classification will be based on the classifications in the evaluation domains and will include consideration of the likely impact of the noted deficiencies in bias and sensitivity on the results.</p>

**Table 25: Study Quality Domain Scoring**

Score	Reasoning
++	<b>Good</b> – Study meets or exceeds domain properties, may have minor deficiencies but none that would affect the outcome of the study or the development of toxicity factors.
+	<b>Adequate</b> – Study meets most of the domain properties, may have some deficiencies but none are severe nor are expected to have a serious effect on the development of toxicity factors.
-	<b>Deficient</b> – Study has one or more deficiencies that are likely to affect the outcome of the study or the development of toxicity factors, but development may still occur with some added uncertainty.
--	<b>Critically Deficient</b> – Study has serious deficiencies that would severely inhibit the development of toxicity factors. These studies are typically classified as “uninformative” unless a detailed explanation otherwise is provided.
NR	<b>Not Reported</b> – Domain properties are not provided in the study or referred to in previous author’s studies. Depending on the domain and type of study, these studies should be carefully considered prior to use.

**Table 26: Study Quality Confidence Rating Scoring**

Score	Reasoning
++	<b>High</b> – Overall a well conducted study, no serious deficiencies identified, no concern for issues with sensitivity or ROB, most domains should be scored good or adequate.
+	<b>Medium</b> – Some deficiencies may be noted, but nothing that would cause significant concern for issues with sensitivity or ROB, most domains should be scored adequate.
-	<b>Low</b> – Deficiencies noted, some severe, and some concern over bias or sensitivity that may impact the assessment, study has domains that scored deficient.
--	<b>Uninformative</b> – Severe deficiencies that would seriously impact the assessment, study is typically unusable for toxicity factor development without a detailed explanation. Any study with a domain listed as “Critically Deficient” should be considered for this category.

Scoring for each of the included studies can be found in Table 27. Each reviewer scored the included studies independently, then came together to agree on a single score for each domain/study (individual scoring not shown).



**Table 27: Study Quality and ROB Scoring Visual**

Domain/Study	Hogstedt 1988	Kirman 2004	Mikoczy 2011	Steenland 2003	Steenland 2004	Swaen 2009	Teta 1999	Valdez-Flores 2010
Selection and Performance/Participant Selection	+	++	+	+	++	+	++	++
Exposure Methods/Measures	-	+	-	+	+	-	+	+
Outcome Methods/Results Presentation	+	+	++	+	+	+	+	++
Confounding	-	+	-	++	+	+	+	+
Analysis	+	+	+	+	++	+	+	++
Selective Reporting	+	+	+	+	+	+	+	+
Sensitivity	-	+	-	+	+	+	+	+
Overall Study Confidence	-	+	+	+	+	+	+	+

### A1.5 Evidence Integration

After addressing the study quality and ROB for each of the selected studies, the primary information from each of the studies was compiled together and each study was assessed for use as a key, supporting, or informative study (Table 28).

**Table 28: Evidence Integration Table for Human Studies**

Study	Cohort	Type	Reasoning
Hogstedt 1988	Swedish chemical workers	Informative	<ul style="list-style-type: none"> <li>- Relatively small cohort with little information on co-exposures</li> <li>- Exposure concentrations or estimations not provided</li> <li>- Primary cohort to show increased leukemia mortality rates</li> <li>- Also presented increased stomach and blood/lymphatic cancer</li> </ul>
Kirman 2004	NIOSH + UCC	Supporting	<ul style="list-style-type: none"> <li>- Combined data from two largest cohorts and examined leukemia and lymphoid tumor mortality data</li> <li>- Provided results for several different extrapolation methods</li> <li>- Selected a single outcome and POD to carry through</li> </ul>
Mikoczy 2011	Swedish sterilant workers	Informative	<ul style="list-style-type: none"> <li>- Relatively small cohort with little exposure information presented</li> <li>- Healthy worker effect likely influenced the results</li> <li>- Non-significant increases in leukemia, NHL, and lymphohematopoietic cancer mortality</li> <li>- Significant increases in the rate ratios of breast cancer in the two highest exposure groups</li> </ul>
Steenland 2003	NIOSH (females only)	Informative	<ul style="list-style-type: none"> <li>- Subset of the largest cohort study available, additional nested case-control using subjects who answered personal interviews</li> <li>- Examined breast cancer mortality and incidence data</li> <li>- Positive trend for increased incidence, but not significantly increased</li> </ul>
Steenland 2004	NIOSH	Supporting	<ul style="list-style-type: none"> <li>- Update to the largest EtO-exposed cohort data available</li> <li>- Focused mainly on hematopoietic and breast cancers, and examined various exposure variables and lag periods</li> <li>- No significantly increased cancer incidences, but a positive trend observed for lymphoid tumors (males, 15-year lag)</li> </ul>

Study	Cohort	Type	Reasoning
Swaen 2009	UCC	Supporting	<ul style="list-style-type: none"> <li>- Although a relatively smaller cohort, the strength of the update was made up for in the length of follow-up and number of deaths</li> <li>- Little to no exposure monitoring data available, estimates made from work history</li> <li>- Examined a wide array of cancer types but no lag/latency periods</li> <li>- No cancer associations observed, likely influenced by the healthy worker effect</li> </ul>
Teta 1999	Meta-analysis, NIOSH, UCC	Supporting	<ul style="list-style-type: none"> <li>- Very basic meta-analysis of 10 EtO cohorts but lacked dose-response data, detailed analysis on individual NIOSH and UCC cohorts only</li> <li>- Examined lymphoid and leukemia rates with various lags and latency periods and control groups using Poisson regression</li> <li>- UCC cohort showed no added risk, while NIOSH cohort predictions were in the range of <math>10^{-7}</math> to <math>10^{-5}</math> at 1 ppb environmental exposures</li> </ul>
Valdez-Flores 2010	NIOSH + UCC	Key	<ul style="list-style-type: none"> <li>- Combined most recent data from the UCC and NIOSH cohorts</li> <li>- Examined 12 cancer endpoints (breast, leukemia, lymphoid, etc.) and 6 sub-cohorts (NIOSH males, females, UCC males, etc.) using Cox proportional analyses without latency/lag periods</li> <li>- No statistically significantly increasing SMRs or trends in any of the cancer endpoints examined</li> </ul>

After final review of the included studies, the Valdez-Flores et al. (2010) study had the most thorough and complete analysis (e.g., data from both the NIOSH and UCC cohorts, multiple cancer endpoints examined) and was therefore selected as the key study. While the Valdez-Flores et al. (2010) study also utilized a default lifetime duration (70 years) consistent with TCEQ guidance (TCEQ 2015), there were aspects that were not ideal, such as the lack of exposure lags. So rather than select a POD from the key study, the Toxicology, Risk Assessment, and Research Division (TRARD) selected data from both cohorts evaluated in the study (i.e., the NIOSH and UCC cohorts) as the key epidemiological data and conducted an independent assessment using the same approach but with supplemental analyses (e.g., the evaluation of various exposure lags). Selection of data from the NIOSH and UCC cohorts as the key epidemiological data and use of specific, TCEQ-directed dose-response assessment analyses

(rather than selection of a study POD) provide the best basis for a carcinogenic assessment of EtO for several reasons:

1. Both the NIOSH and UCC cohorts have adequate size, exposure information, and follow-up, making consideration of all the data ideal for toxicity factor development (e.g., weight of evidence, more analyses to consider).
2. The Valdez-Flores et al. (2010) study makes use of the Cox Proportional Hazard model, a standard model that the TRARD has used previously in dose-response assessments (also considered by USEPA 2016).
3. Although Valdez-Flores et al. (2010) did not include exposure lag results in their publication, supplemental analyses involving a reassessment of the data using various exposure lags allow for the consideration of even more assessment results in the DSD.
4. Additionally, since published in 2010, an update to the UCC data through 2013 has become available to the first author of the Valdez-Flores et al. (2010) study (submitted for publication), who the TCEQ contracted with to perform supplemental analyses; consequently, results from the new study update with a longer follow-up period can also be included in the DSD.
5. Unlike USEPA (2016) that uses a lifetime exposure duration value of 85 years, the TCEQ-directed dose-response analyses use a standard default of 70 years consistent with TCEQ guidance (TCEQ 2015).
6. And finally, conducting these new analyses will allow for the appropriate consideration of model fit to the individual data (rather than the categorical data) for the model assessment ultimately selected by the TRARD.

#### **A1.6 Confidence Rating**

Table 29 provides scoring criteria to rate the confidence and uncertainty for each aspect or element of the toxicity assessment. The table provides the name of the element and the magnitude of the confidence in each element using a qualitative ranking system of low, medium, or high confidence. Table 30 displays the overall confidence in the EtO carcinogenic assessment. Once the noncarcinogenic assessments are completed for EtO, the confidence rating will be updated to cover the entire assessment.

**Table 29: Confidence Scoring Criteria for EtO Carcinogenic Assessment**

Element	Low	Medium	High
Database Completeness	Only a single study or a few low-quality studies were available.	Several studies were available, but some important studies were missing.	Several high-quality studies were available to select from.
Systematic Review	A systematic approach was not used.	A systematic approach was considered and some methods were applied, but a full review was not conducted	A systematic approach was used in study evaluation and clear criteria were established for judgment
Key Study Quality	Selected study has deficiencies, but was still considered useful	Selected study was reasonably well done but some restrictions must be considered	Selected study was well done and can be used without restriction
Critical effect	Critical effect or dose-response curve was moderate to severe. MOA information was not available.	Critical effect was moderate; other studies were deemed necessary to determine the critical effect.	Critical effect was minimal, or the confidence in the critical effect was high. MOA information was available.
Relevance of Critical Effect	Critical effect was only presumed to be relevant for the general population; MOA was not known for the critical effect.	Critical effect appeared to be relevant for the general population. MOA was known for the critical effect and possibly relevant to humans.	Critical effect based on a human study or matches observed human experience; MOA was well understood so critical effect was assumed relevant.
Point of Departure (POD)	Many uncertainties exist in POD; only a few dose groups; no dose-response modeling was used.	Some uncertainty exists in POD; few dose groups; difference between confidence limits was large.	Basis for POD well understood; multiple dose groups, dose-response modeling was conducted.
Sensitive Populations	Many uncertainties on sensitive population(s) existed and were not addressed.	Information on sensitive population(s) was not known but default procedures are presumed to be conservative.	Human data on sensitive populations were available and uncertainties were addressed.
Peer Review	Limited or no peer review; disregarded comments would significantly change risk value; no independent check	Adequate peer review. Most substantive comments addressed; disregarded comments would not significantly change value	High quality panel peer review with appropriate experts; all substantive comments addressed as per independent check
Toxicity Value Comparison	Relevant risk values show a greater than 10-fold difference without justification.	Some relevant risk values agreed within 3-fold of each other, others disagreed within 10-fold without justification.	All relevant risk values agreed within 3-fold of each other or there was sufficient justification for differences.

**Table 30: Confidence in the Toxicity Assessment**

Element	Score	Basis
Database Completeness	Medium	<ul style="list-style-type: none"> <li>- Several occupational cohorts (i.e., preferred human data) and animal studies available</li> <li>- Evidence of carcinogenic effects found in both human epidemiological and animal studies</li> <li>- However, estimated exposures are based on incomplete information, are remarkably high, and are not in/near lower range of interest (i.e., not environmentally relevant)</li> </ul>
Systematic Review	High	<ul style="list-style-type: none"> <li>- Systematic review conducted</li> </ul>
Key Study Quality	High	<ul style="list-style-type: none"> <li>- Well-conducted study of two cohorts and multiple cancer endpoints with standard Cox proportional hazards modeling but lacked the use of a lag period</li> <li>- Reassessment of these key epidemiological data utilizing multiple exposure lags and new UCC cohort data allowed for informative supplemental and updated analyses</li> </ul>
Critical effect	Low	<ul style="list-style-type: none"> <li>- Human data not conclusive despite remarkably high exposure (e.g., results vary between studies)</li> <li>- Model (slope &gt; 0) not statistically significantly different than the null model (slope = 0) at the 5% significance level</li> </ul>
Relevance of Critical Effect	Medium	<ul style="list-style-type: none"> <li>- Assumed relevant although general population exposed to levels orders of magnitude lower than the occupational study wherein lymphoid cancer was statistically increased only in the highest cumulative exposure group</li> </ul>
Point of Departure (POD)	High	<ul style="list-style-type: none"> <li>- Cox Proportional Hazard model used</li> <li>- Modeling results demonstrated to be predictive</li> </ul>
Sensitive Populations	Medium	<ul style="list-style-type: none"> <li>- No specific data on sensitive subpopulations</li> <li>- Default ADAFs were applied to account for potentially increased susceptibility in children due to early-life exposure</li> </ul>
Peer Review	Medium	<ul style="list-style-type: none"> <li>- DSD proposed for public comment and reviewed by a consulting academic statistician and subject matter expert in regard to potential statistical issues at TCEQ's direction</li> </ul>
Toxicity Value Comparison	High	<ul style="list-style-type: none"> <li>- TCEQ Chronic ESL based on lymphoid cancer mortality is 4,000 times higher than the USEPA value based on lymphoid/breast cancer incidence at the same excess risk level (1E-05)</li> </ul>

Element	Score	Basis
		<ul style="list-style-type: none"> <li>- TCEQ's approach is supported by multiple lines of evidence as discussed in the DSD, whereas USEPA's non-standard approach is not</li> <li>- Extensive comparisons, calculations, and explanations as to the differences and errors in USEPA's methods are included in the DSD (e.g., USEPA's model assessment is demonstrated to be statistically significantly over-predictive)</li> </ul>
Confidence Scoring Summary		
Not Evaluated	Low Confidence Critical Effect	<b>Medium Confidence</b> <ul style="list-style-type: none"> <li>Database Completeness</li> <li>Relevance of Critical Effect</li> <li>Sensitive Populations</li> <li>Peer Review</li> </ul>
		<b>High Confidence</b> <ul style="list-style-type: none"> <li>Systematic Review</li> <li>Key Study Quality</li> <li>Point of Departure</li> <li>Toxicity Value Comparison</li> </ul>

## Appendix 2 Additional Analysis of Kirman and Hays (2017) Data

Ciriaco Valdez-Flores, Ph.D., P.E.  
Professor of Practice  
Industrial and Systems Engineering  
Texas A&M University  
College Station, TX 77843

A statistically significant change in the true HEV mean based on the meta-analysis by Kirman and Hays (2017) for the nonsmoker/passive smoke-exposed (“unexposed”) population (n=661) was determined at the 0.05 significance level ( $\alpha$ ). The mean ( $\mu_L$ ) HEV from the study was 21.1 pmol/g Hb with a standard deviation ( $\sigma_L$ ) of 14.6 pmol/g Hb. This mean and standard deviation correspond to a lognormal distribution. That is, the natural logarithm of HEV ( $\ln(\text{HEV})$ ) follows a normal distribution with mean ( $\mu_N$ ) and standard deviation ( $\sigma_N$ ). The values corresponding to  $\mu_N$  and  $\sigma_N$  are determined from  $\mu_L$  and  $\sigma_L$  using the following relationship:

$$\mu_N = \ln \left( \frac{\mu_L^2}{\sqrt{\mu_L^2 + \sigma_L^2}} \right)$$

and

$$\sigma_N = \sqrt{\ln \left( \frac{\mu_L^2 + \sigma_L^2}{\mu_L^2} \right)}$$

Once the parameters of the distribution of the  $\ln(\text{HEV})$  are calculated, then the null hypothesis to test is:

$$H_0: \mu_N^* = \mu_N$$

where  $\mu_N^*$  is the true mean of the  $\ln(\text{HEV})$  of the distribution of the sample.



The significance level ( $\alpha=0.05$ ) and the sample size ( $n=661$ ) have to be specified to determine the maximum ( $\mu_N^{*+}$ ) and minimum ( $\mu_N^{*-}$ ) values of the sample average of  $\ln(\text{HEV})$  that result in statistically significant changes from the mean of the  $\ln(\text{HEV})$  ( $\mu_N$ ). These maximum and minimum values are calculated as follows:

$$\mu_N^{*+} = \mu_N + Z_{(1-\alpha)} \frac{\sigma_N}{\sqrt{n}} \text{ and } \mu_N^{*-} = \mu_N - Z_{(1-\alpha)} \frac{\sigma_N}{\sqrt{n}}$$

Note that the significance level ( $\alpha$ ) is a one-sided significance level. That is, if it is only interesting to detect an increase in the  $\ln(\text{HEV})$  then only the maximum is relevant.

Given  $\mu_N^{*+}$  and  $\mu_N^{*-}$ , the corresponding maximum and minimum sample geometric means that result in statistically significant changes from the mean  $\ln(\text{HEV})$  are  $\mu_G^{*+} = \exp\{\mu_N^{*+}\}$  and  $\mu_G^{*-} = \exp\{\mu_N^{*-}\}$ , respectively.

The maximum ( $\mu_L^{*+}$ ) and minimum ( $\mu_L^{*-}$ ) mean of the log-normal distribution corresponding to the HEV samples can be calculated as follows:

$$\mu_L^{*+} = \exp\left\{\mu_N^{*+} + \frac{\sigma_N^2}{2}\right\} \text{ and } \mu_L^{*-} = \exp\left\{\mu_N^{*-} + \frac{\sigma_N^2}{2}\right\}$$

Thus, the equivalent multiple of the mean that results in a statistically significant increase or decrease in HEV are given by  $\mu_L^{*+}/\mu_L$  and  $\mu_L^{*-}/\mu_L$  respectively. Similarly, the increase or decrease in the average HEV that result in a statistically significant change in the mean HEV are given by  $\mu_L^{*+} - \mu_L$  and  $\mu_L^{*-} - \mu_L$ , respectively.

Accordingly, the equation  $\mu_L^{*+} - \mu_L$  ultimately provides the statistically significant increase in the mean HEV for the population ( $n=661$ ) at the specified significance level ( $\alpha=0.05$ ).

The endogenous equivalent concentration in air that results in a statistically significant increase or decrease in the mean of  $\ln(\text{HEV})$  then is equal to  $\mu_L^{*+}/10.9$  or  $\mu_L^{*-}/10.9$ , respectively. The increase or decrease in the endogenous equivalent concentration that results in an increase or decrease in the mean of the  $\ln(\text{HEV})$  are then equal to  $(\mu_L^{*+} - \mu_L)/10.9$  or  $(\mu_L - \mu_L^{*-})/10.9$ , respectively.

Accordingly, the equation  $(\mu_L^{*+} - \mu_L)/10.9$  ultimately provides the continuous air exposure concentration corresponding to the calculated statistically significant increase in mean HEV for the population ( $n=661$ ) at the specified significance level ( $\alpha=0.05$ ).

Per the above approach, at a significance level ( $\alpha$ ) of 0.05 for the nonsmoker/passive smoke-exposed population (n=661) in the Kirman and Hays (2017) meta-analysis, an increase of 0.861 pmol/g in the HEV mean (from 21.1 to 21.961 pmol/g Hb) would be statistically significant ( $p=0.05$ ). A continuous ethylene oxide air exposure concentration  $\geq 0.079$  ppb is calculated to be sufficient to induce this increase in the HEV.

### **Appendix 3 Reality Check of Epidemiological Exposure-Response Model Results for EtO and Lymphoid Cancer Mortality**

USEPA fit several alternative parametric models for lymphoid cancer mortality in the NIOSH cohort and compared the predicted rate ratios by each model with non-parametric estimates of rate ratios. USEPA used the visual comparison of the parametric and non-parametric rate ratios as one of their criteria to select their parametric model. A more robust comparison is to see how reasonable the parametric models are when comparing what the models predict in terms of lymphoid cancer deaths versus the actual number of deaths in the NIOSH cohort. A good parametric model should predict the observed number of lymphoid cancer deaths with some confidence (e.g., the observed number of lymphoid cancer deaths in the NIOSH cohort should be inside a 95% confidence interval of the estimated number of lymphoid cancer deaths).

Here, some of the USEPA models and one model developed by Sielken & Associates (S&A) were used to check whether the models were reasonable; that is, whether the models predicted within a margin of error, the number of lymphoid cancer deaths in the NIOSH cohort. The estimated number of lymphoid cancer deaths for a specific model for the rate ratios were calculated using age-, sex-, race-, and calendar-year specific background hazard rates. Sections C and D of this appendix illustrates how the calculations to determine the number of expected deaths for each model were performed with methodology used in the calculation of standard mortality ratios (SMRs). The SMR is a measure that shows the ratio of observed to expected number of deaths in the cohort. Similarly, the  $100(1-\alpha)\%$  confidence interval on the SMR is a confidence interval on the ratio of observed to expected number of deaths in the cohort.

Herein, the inverse of the SMR is used as a measure of over-prediction or under-prediction of the actual number of observed deaths. That is, the inverse of the SMR ( $SMR^{-1}$ ) is the ratio of expected to observed number of deaths. Similarly, the inverse of the confidence limits of the  $100(1-\alpha)\%$  confidence interval on the SMR result in a  $100(1-\alpha)\%$  confidence interval on the inverse of the SMR. In turn, using the  $SMR^{-1}$  and its  $100(1-\alpha)\%$  confidence interval, a  $100(1-\alpha)\%$  confidence interval on the expected or predicted number of deaths can be easily calculated. Using this confidence interval on the predicted number of deaths can then be compared with the observed number of deaths. If the observed number of deaths is inside the  $100(1-\alpha)\%$  confidence interval, then the expected number and observed number of deaths are not statistically significantly different at the  $\alpha\%$  significance level. If the observed number of deaths is below the lower end or above the upper end of the  $100(1-\alpha)\%$  confidence interval, then the expected number is statistically significantly different than the observed number of deaths at the  $\alpha\%$  significance level.

At issue is the predictiveness (or lack thereof) of the model assessments ultimately used by USEPA and the TCEQ. *There is no fairer evaluation of the predictiveness of a given model assessment than direct numerical comparisons of the specific model's predictions to the reality of the dose-response data.* **Upon performing this evaluation, the sections below show that only the log-linear model (standard Cox proportional hazards model) and the best estimates of the linear model predict the number of observed lymphoid deaths in the NIOSH cohort with 95% confidence.** *By contrast, the specific model assessment chosen by USEPA (i.e., the upper bound of the linear two-piece spline model with the "knot" at 1,600 ppm-days; 15-year exposure lag) statistically significantly over-estimates (statistically significant at the 5% significance level) the number of observed lymphoid cancer deaths (even after restricting those models to assume zero increase in the rate ratio for cumulative exposures above the knot).*

### **A3.1 Predicted Versus Observed Number of Lymphoid Cancer Deaths in the NIOSH Cohort**

Table 31 and Figure 13 below shows the predicted number of lymphoid cancer deaths in the NIOSH cohort for male and female NIOSH workers using several different EtO exposure-response models. There are 53 lymphoid cancer deaths in the NIOSH cohort (brown horizontal line in Figure 13). Several exposure-response models fit to the NIOSH data were used to estimate the number of lymphoid cancer deaths that the model would predict in the NIOSH cohort, if the fitted model were true. The maximum likelihood estimates of the model as well as the upper 95% confidence limit on the model parameters were used to obtain the predicted number of deaths. In addition to calculating the expected number of deaths predicted by each model and its upper bound on the slope, a 95% confidence interval in the predicted number of deaths was derived using a confidence interval for the ratio of the predicted to the observed number of lymphoid cancer deaths in the NIOSH cohort.

**The 95% confidence intervals for the number of lymphoid cancer deaths predicted by the log-linear models and its upper bounds (Cox proportional hazards model, models 1, 2, 3, and 4) include the number of lymphoid cancer deaths actually observed (53) in the NIOSH cohort.** The 95% confidence interval for the number of lymphoid cancer deaths predicted by the best estimate of the linear model (model 5) also includes the number of lymphoid cancer deaths actually observed in the NIOSH cohort, but the upper bound of the linear model (model 6) statistically significantly over-predicts the observed number of lymphoid cancer deaths.

**Models 7, 8, 9 and 10 are USEPA's two-piece spline models. Every two-piece spline model estimate of the lymphoid cancer deaths in the NIOSH cohort statistically significantly over-predicts the actual number of lymphoid cancer deaths in the NIOSH cohort. For comparison purposes, Models 11, 12, 13 and 14 are USEPA two-piece spline models restrained by setting the slope after the knot equal to zero (i.e., the rate ratio increases with cumulative exposure up to the knot and stays flat after the knot). Even for these restrained two-piece spline**

models, for both the MLE and 95% UCL, every model estimate of the lymphoid deaths in the NIOSH cohort statistically significantly over-predicts the actual number of lymphoid deaths in the NIOSH cohort.

**Table 31: USEPA's Selected Model Assessment Statistically Significantly Over-Predicts Lymphoid Cancer Mortalities**

Model	Slope Parameter (per ppm-day)	Predicted if the Model were True	100% x Ratio: Predicted / Observed	95% CI on Predicted if the Model were True
Background (No Model)	n/a	50.39	95.1%	(38.5, 67.3)
1. S&A – Loglinear – 15-yr lag (MLE) <sup>1</sup>	2.81E-06	52.42	98.9%	(40.1, 70.0)
2. S&A – Loglinear – 15-yr lag (95% UCL) <sup>1</sup> - <b>TCEQ Adopted</b>	7.17E-06	58.75	110.8%	(44.9, 78.4)
3. USEPA - Loglinear - 15-yr Lag (MLE) <sup>1</sup> USEPA Table 4-2	4.74E-06 <sup>2</sup>	54.52	102.9%	(41.7, 72.8)
4. USEPA - Loglinear - 15-yr Lag (95% UCL) <sup>1</sup> USEPA Table 4-2	1.03E-05 <sup>3</sup>	66.41	125.3%	(50.8, 88.7)
5. USEPA - Linear - 15-yr Lag (MLE) USEPA Table D-36	1.23E-05 <sup>4</sup>	57.58	108.6%	(44.0, 76.9)
6. USEPA - Linear - 15-yr Lag (95% UCL) USEPA Table D-36	4.71E-05 <sup>5</sup>	77.3	145.8%	(59.1, 103.2)
<b>USEPA Spline Model with Knot at 1,600 ppm-days</b>				
7. USEPA – Loglinear Spline – 15-yr lag (MLE) – USEPA Table 4-4 Knot @ 1,600 ppm-days	4.89E-04 <sup>6</sup>	88.24	166.5%	(67.5, 117.8)
8. USEPA – Loglinear Spline – 15-yr lag (95% UCL) – USEPA Table 4-4 Knot @ 1,600 ppm-days	9.08E-04 <sup>7</sup>	144.15	272.0%	(110.2, 192.5)
9. USEPA – Linear Spline – 15-yr lag (MLE) – USEPA Table 4-4 Knot @ 1,600 ppm-days	7.58E-04 <sup>8</sup>	91.69	173.0%	(70.1, 122.4)
10. USEPA – Linear Spline – 15-yr lag (95% UCL) – USEPA Table 4-4 Knot @ 1,600 ppm-days - USEPA Selected	1.80E-03 <sup>9</sup>	141.09	266.2%	(107.9, 188.4)
<b>Results using above USEPA models</b>				
but assuming that slope for RR is zero after the “knot”				

Model	Slope Parameter (per ppm-day)	Predicted if the Model were True	100% x Ratio: Predicted / Observed	95% CI on Predicted if the Model were True
11. USEPA – Loglinear Spline – 15-yr lag (MLE) – USEPA Table 4-4 Knot @ 1,600 ppm-days	4.89E-04	84.59	159.6%	(64.7, 112.9)
12. USEPA – Loglinear Spline – 15-yr lag (95% UCL) – USEPA Table 4-4 Knot @ 1,600 ppm- days	9.08E-04	141.97	267.9%	(108.5, 189.5)
13. USEPA – Linear Spline – 15-yr lag (MLE) – USEPA Table 4-4 Knot @ 1,600 ppm-days	7.58E-04	86.39	163.0%	(66.0, 115.3)
14. USEPA – Linear Spline – 15-yr lag (95% UCL) – USEPA Table 4-4 Knot @ 1,600 ppm-days	1.80E-03	135.19	255.1%	(103.4, 180.5)

[**Boldface** values indicate that the model over-prediction of lymphoid cancer deaths is statistically significant.]

<sup>1</sup>The models used by Sielken & Associates and EPA [appearing as an appendix in USEPA (2016)] are the same models; however, USEPA did not use all of the individual data – Steenland et al. and USEPA only used a subsample of the individual data.

<sup>2</sup>The best estimate and standard error of the slope are 4.74E-06 and 3.35E-06, respectively.

<sup>3</sup>The 95% upper confidence limit on the slope is 1.03E-05 (4.74E-06 + 1.645×3.35E-06).

<sup>4</sup>The best estimate and standard error of the slope are 1.23E-05 and 2.12E-05, respectively. The standard error (2.12E-05) of the slopes was inferred from the upper bound on the slope (4.75E-05) given in Table D-36; that is 1.23E-05 = (4.71E-05 – 1.23E-05)/1.645.


<sup>5</sup>The 95% upper confidence limit on the slope is 4.71E-05 from Table D-36.

<sup>6</sup>The best estimate and standard error of the slope below the knot are 4.89E-04 and 2.55E-04, respectively. The slope and corresponding standard error after the knot are -4.86E-04 and 2.56E-04, respectively, from Tables 4-4 and D-33 log-linear with knot @ 1600 ppm-days.

<sup>7</sup>The slope after the knot is for the 95% upper confidence limit for the model is -9.07E-04 (-4.86E-04 - 1.645×2.56E-04, which a 95% LCL on the slope above the knot). This conservatively assumes perfect negative correlation of the slope below and after the knot. **Thus, the over-prediction may be larger than what is shown in the table.** The assumption of perfect negative correlation is consistent with the covariance values obtained by EPA for two-piece linear spline model; e.g., see footnote to Table D-36 in the appendices of EPA's report.

<sup>8</sup>The best estimate and standard error of the slope below the knot are 7.58E-04 and 6.32E-04, respectively. The slope and corresponding standard error after the knot are -7.48E-04 and 6.31E-04, respectively, from footnote to Table D-36.

<sup>9</sup>The slope after the knot is for the 95% upper confidence limit for the model is -1.79E-03 (-7.48E-04 - 1.645×6.32E-04, which a 95% LCL on the slope above the knot). This conservatively assumes perfect negative correlation of the slope below and after the knot. **Thus, the over-prediction may be larger than what is shown in the table.** The assumption of perfect negative correlation is consistent with the covariance values obtained by EPA (see footnote to Table D-36 in the appendices of EPA's report where the covariance is approximately equal to the negative of the variances for the slopes above and below the knot; i.e., covariance=-3.99E-07, Var1=3.99E-07, and Var2=3.98E-07).



**Figure 13: USEPA's Selected Model Statistically Significantly Over-Predicts Lymphoid Cancer Mortalities**

### A3.2 Predicted Versus Observed Number of Lymphoid Cancer Deaths in the NIOSH Cohort by Quintiles

Table 32 expands the results in Table 31 to calculate the observed and expected number of lymphoid cancer deaths in each of five quintiles. The NIOSH cohort was divided into five quintiles. A total of 53 lymphoid cancer deaths were observed in the NIOSH cohort. The first quintile included the nine NIOSH workers who died with lymphoid cancer and whose cumulative exposure to EtO (lagged 15 years) was equal to zero. Cumulative exposures to EtO lagged 15 years were defined so that quintiles 2 to 5 included the same number of lymphoid cancer deaths (11) in each quintile.

**Only the best estimates of the log-linear (Cox proportional hazards) model (models 1 and 3), the linear model (model 5), and the 95% upper confidence limit of the Sielken & Associates log-linear model (model 2) predict a number of lymphoid cancer mortalities that are consistent with the number of observed deaths in each of five quintiles.** USEPA's 95% UCL of the log-linear (model 4) and linear model (model 6) statistically significantly over-predict the number of the lymphoid cancer deaths in the highest exposure group.

USEPA's two-piece spline models (both the fitted models 7-10 and the restrained models 11-14) significantly over-predict the number of observed lymphoid cancer deaths at the lowest exposure quintile. *The 95% UCL of the two-piece spline models (for both the fitted models and the restrained models - models 8, 10, 12, and 14) significantly over-predict the number of observed lymphoid cancer deaths at every exposure quintile. More specifically, the model assessment selected by USEPA (i.e., the upper bound of the linear two-piece spline model with the "knot" at 1,600 ppm-days; 15-year exposure lag) statistically significantly over-predicts lymphoid cancer deaths for every quintile, even if the slope of the upper spline is set to zero (see Table 32 results for models 10 and 14).* The best estimates of the two-piece spline models (for both the fitted models and the restrained models - models 7, 9, 11, and 13) significantly over-predict the number of observed lymphoid cancer deaths in exposure quintiles 2 and 4 (model 9 also significantly over-predicts quintile 5).

Thus, in addition to USEPA's selected model assessment (i.e., upper bound of the linear two-piece spline model with the "knot" at 1,600 ppm-days; 15-year exposure lag) statistically significantly over-estimating the total number of observed lymphoid cancer deaths for the NIOSH cohort (141 predicted versus 53 actually observed; Table 31), their selected model also statistically significantly over-predicts lymphoid cancer deaths for every cumulative exposure group, even if the slope of the upper spline is set to zero (Table 32). By contrast, the model assessment selected by the TCEQ (i.e., upper bound of the log-linear/Cox proportional hazards model; 15-year exposure lag) is reasonably accurate, neither significantly over- or under-estimating lymphoid cancer deaths for cumulative exposure groups or for the cohort as a whole (59 predicted versus 53 observed).



**Table 32: USEPA's Selected Model Statistically Significantly Over-Predicts Lymphoid Cancer Mortalities for All Cumulative Exposure Groups**

Model <sup>1</sup>	Quintile 2*	Quintile 3	Quintile 4	Quintile 5
Observed	11	11	11	11
Background (No Model)	14.4 (8.0, 28.9)	7.9 (4.4, 15.9)	9.1 (5.1, 18.3)	7.4 (4.2, 14.9)
1. S&A – Loglinear – 15-yr lag (MLE)	14.4 (8.1, 28.9)	8.0 (4.5, 16.1)	9.4 (5.2, 18.8)	9.1 (5.1, 18.3)
2. S&A – Loglinear – 15-yr lag (95% UCL) - <b>TCEQ Adopted</b>	14.5 (8.1, 29.0)	8.1 (4.5, 16.2)	9.8 (5.5, 19.6)	15.0 (8.4, 30.0)
3. USEPA - Loglinear - 15-yr Lag (MLE) USEPA Table 4-2	14.4 (8.1, 29.0)	8.0 (4.5, 16.1)	9.5 (5.3, 19.1)	11.0 (6.2, 22.1)
4. USEPA - Loglinear - 15-yr Lag (95% UCL) USEPA Table 4-2	14.5 (8.1, 29.1)	8.2 (4.6, 16.4)	10.0 (5.6, 20.1)	<b>22.2</b> <b>(12.4, 44.6)</b>
5. USEPA - Linear - 15-yr Lag (MLE) USEPA Table D-36	14.5 (8.1, 29.1)	8.2 (4.6, 16.5)	10.2 (5.7, 20.4)	13.2 (7.4, 26.5)
<b>6. USEPA - Linear - 15-yr Lag (95% UCL) USEPA Table D-36</b>	14.8 (8.3, 29.7)	9.0 (5.0, 18.0)	13.1 (7.3, 26.3)	<b>28.9</b> <b>(16.2, 58.0)</b>
<b>EPA Spline Model with Knot at 1,600 ppm-days</b>				
7. USEPA – Loglinear Spline – 15-yr lag (MLE) – USEPA Table 4-4 Knot @ 1,600 ppm-days	<b>19.8</b> <b>(11.1, 39.7)</b>	17.3 (9.7, 34.7)	<b>20.3</b> <b>(11.3, 40.7)</b>	19.4 (10.8, 38.9)
8. USEPA – Loglinear Spline – 15-yr lag (95% UCL) – USEPA Table 4-4 Knot @ 1,600 ppm-days	<b>27.0</b> <b>(15.1, 54.2)</b>	<b>33.5</b> <b>(18.7, 67.3)</b>	<b>38.8</b> <b>(21.7, 77.9)</b>	<b>33.3</b> <b>(18.6, 66.7)</b>
9. USEPA – Linear Spline – 15-yr lag (MLE) – USEPA Table 4-4 Knot @ 1,600 ppm-days	<b>20.9</b> <b>(11.7, 42.0)</b>	17.6 (9.8, 35.2)	<b>20.8</b> <b>(11.6, 41.7)</b>	<b>20.9</b> <b>(11.7, 41.9)</b>
10. USEPA – Linear Spline – 15-yr lag (95% UCL) – USEPA Table 4-4 Knot @ 1,600 ppm-days - USEPA Selected	<b>29.9</b> <b>(16.7, 60.0)</b>	<b>30.5</b> <b>(17.1, 61.2)</b>	<b>35.8</b> <b>(20.0, 71.7)</b>	<b>33.4</b> <b>(18.7, 67.1)</b>
<b>Results using above USEPA two-piece spline models but assuming that slope for RR is zero after the “knot”</b>				
11. USEPA – Loglinear Spline – 15-yr lag (MLE) – USEPA Table 4-4 Knot @ 1,600 ppm-days	<b>19.8</b> <b>(11.1, 39.7)</b>	17.3 (9.6, 34.6)	<b>19.9</b> <b>(11.1, 39.9)</b>	16.2 (9.0, 32.5)

Model <sup>1</sup>	Quintile 2*	Quintile 3	Quintile 4	Quintile 5
12. USEPA – Loglinear Spline – 15-yr lag (95% UCL) – USEPA Table 4-4 Knot @ 1,600 ppm-days	<b>27.0</b> (15.1, 54.2)	<b>33.5</b> (18.7, 67.2)	<b>38.6</b> (21.6, 77.4)	<b>31.3</b> (17.5, 62.8)
13. USEPA – Linear Spline – 15-yr lag (MLE) – USEPA Table 4-4 Knot @ 1,600 ppm-days	<b>20.9</b> (11.7, 42.0)	17.5 (9.8, 35.0)	<b>20.1</b> (11.2, 40.3)	16.4 (9.1, 32.8)
14. USEPA – Linear Spline – 15-yr lag (95% UCL) – USEPA Table 4-4 Knot @ 1,600 ppm-days	<b>29.9</b> (16.7, 60.0)	<b>30.4</b> (17.0, 61.0)	<b>35.0</b> (19.5, 70.2)	<b>28.4</b> (15.9, 57.0)

[**Boldface** values indicate that the model over-prediction of lymphoid cancer deaths for the quintile is statistically significant.]

<sup>1</sup>The models used to calculate the estimated number of lymphoid deaths are the same as those listed in Table 31 and the footnotes to Table 31 apply here also. Except that the assumption of perfect negative correlation of the slopes before and after the knot in Models 8 and 10 (EPA's 95% UCL for the two-piece spline models) do not affect the predictions in quintile 2.

\* Quintile 1 is the control (unexposed lagged-out) group with 9 lymphoid cancer mortalities observed and 11.5 mortalities predicted by all models with a 95% confidence interval of (6.0, 25.2), which includes the observed 9 lymphoid cancer deaths.

### ***A3.3 Calculation of the Expected Number of Case-Specific Deaths in a Cohort Using US Background Hazard Rates***

The SMR is a measure that compares the number of observed case-specific deaths in a study population with the number of case-specific deaths expected in the study population with known case-specific background death rates of a reference population. The case-specific background death rates of the reference population can adjust for calendar year, age, sex, race, and other relevant variables that may influence the case-specific death rates. The SMR is calculated using the following equation:

$$SMR = \frac{\sum_i y_{oi}}{\sum_i p_{oi} \frac{y_{ri}}{p_{ri}}}$$

where  $i$  is the stratum (the stratum is calendar year, age, sex, and race combination),  $y_{oi}$  is the number of observed deaths in the  $i$ -th stratum of the study group,  $p_{oi}$  is the number of observed person-years in the  $i$ -th stratum of the study group,  $y_{ri}$  is the number of deaths in the  $i$ -th stratum of the reference population, and  $p_{ri}$  is the number of person-years in the  $i$ -th stratum of the reference population.

The ratios  $\frac{y_{ri}}{p_{ri}}$  are the stratum-specific mortality rates in the reference population. The SMR is then the ratio of the number of case-specific deaths in the study population ( $\sum_i y_{oi}$ ) to the expected number of case-specific deaths in the study population ( $\sum_i p_{oi} \frac{y_{ri}}{p_{ri}}$ ) estimated using the background case-specific death rates of the reference population. Several references have a more in-depth discussion of SMRs (e.g., Rothman 1986, Breslow and Day 1987, Checkoway, Pearce, and Crawford-Brown 1989).

The numerator in the SMR calculation is the sum of the calendar year, sex, race, and age-specific lymphoid cancer deaths in the NIOSH study ( $\sum_i y_{oi}$ ) and is equal to the number of observed lymphoid cancer deaths. The denominator in the SMR calculation is the expected number of lymphoid cancer deaths in the NIOSH workers assuming that lymphoid was the only cause of death by using the US background lymphoid cancer mortality rates. The calendar year, sex, race, and age-specific lymphoid cancer mortality rates ( $y_{ri}/p_{ri}$ ) for the US populations and the calendar year, sex, race, and age-specific person-years in the NIOSH study ( $p_{oi}$ ) were used to calculate the expected number of the lymphoid cancer deaths in NIOSH workers.

An SMR greater than 1 (or 100%) implies that the number of observed deaths in the cohort is more than would be expected in a population with the same demographic characteristics as the cohort, except for potential exposures on the job. In contrast, an SMR less than 1 (or 100%) implies that the number of observed deaths in the cohort is less than would be expected in a population with the same demographic characteristics as the cohort, except for potential exposures on the job. The point estimate of the SMR cannot be used to derive statistically relevant conclusions indicating whether the observed number of deaths is greater or less than the expected number of deaths with a specific degree of confidence. Breslow and Day (1987) present the following equations that can be used to derive 100(1- $\alpha$ )% confidence intervals for the SMR.

$$SMR_{LCL} = \frac{Obs}{E} \times \left( 1 - \frac{1}{9 \times Obs} - \frac{Z_{\alpha/2}}{3 \times \sqrt{Obs}} \right)^3$$

and

$$SMR_{UCL} = \frac{(Obs + 1)}{E} \times \left( 1 - \frac{1}{9 \times (Obs + 1)} + \frac{Z_{\alpha/2}}{3 \times \sqrt{Obs + 1}} \right)^3$$

where  $SMR_{LCL}$  is the 100(1- $\alpha/2$ )% lower confidence limit on the SMR,  $SMR_{UCL}$  is the 100(1- $\alpha/2$ )% upper confidence limit on the SMR,  $Obs$  is the number of observed cause-specific deaths (e.g., lymphoid cancer deaths) in the study (*i. e.*,  $Obs = \sum_i y_{oi}$ ),  $E$  is the expected cause-specific deaths (e.g., lymphoid cancer deaths) derived from the reference population background rates

(i.e.,  $E = \sum_i p_{oi} \frac{y_{ri}}{p_{ri}}$ ), and  $Z_{\alpha/2}$  is the  $100(1-\alpha/2)\%$  percentile of the standard normal distribution.

The  $100(1-\alpha)\%$  confidence interval for an SMR is given by the interval ( $SMR_{LCL}$ ,  $SMR_{UCL}$ ). Thus, if the  $SMR_{LCL}$  of a  $100(1-\alpha)\%$  confidence interval is greater than 1 (or 100%), then the SMR is statistically significantly different (greater) than 1 (or 100%) implying that the number of observed cause-specific deaths (e.g., lymphoid cancer deaths) in the cohort is more than the number of expected cause-specific deaths (e.g., lymphoid cancer deaths) in the general population with similar demographics as the cohort. On the contrary, if the  $SMR_{UCL}$  of a  $100(1-\alpha)\%$  confidence interval is less than 1 (or 100%), then the SMR is statistically significantly different (less) than 1 (or 100%) implying that the number of observed cause-specific deaths (e.g., lymphoid cancer deaths) in the cohort is less than the number of expected cause-specific deaths (e.g., lymphoid cancer deaths) in the general population with similar demographics as the cohort.

The US lymphoid cancer mortality rates used for the calculations of the expected number of lymphoid cancer deaths are given in Tables 33-37.

### ***A3.4 Calculating the Expected Number of Cause-Specific Deaths in a Cohort Assuming that the Death Rate in the Cohort Increases with Cumulative Exposure***

The SMR is the ratio of observed to expected number of deaths in a cohort. The expected number of deaths is calculated assuming that the hazard rate is the background hazard rate of the reference population. However, if the background hazard rate is assumed to be affected by exposure to a carcinogen via a multiplicative function, then the expected number of deaths can be calculated assuming that the hazard rate is the product of the background hazard rate of the reference population multiplied by the exposure-response function that modifies the background rates. That is, the expected number of cause-specific deaths in a cohort can be calculated as:

$$\sum_i p_{oi} \times RR(d_i) \times \frac{y_{ri}}{p_{ri}}$$

where  $p_{oi}$  is the number of observed person-years in the  $i$ -th stratum of the study group,  $y_{ri}$  is the number of observed deaths in the  $i$ -th stratum of the reference population,  $p_{ri}$  is the number of person-years in the  $i$ -th stratum of the reference population, and  $RR(d_i)$  is the exposure-response function (rate ratio function) evaluated at cumulative exposure  $d_i$ .

Using this expected number of cause-specific deaths in a cohort, an  $SMR^*$  and bounds on the  $SMR^*$  can be calculated as follows:

$$SMR^* = \frac{\sum_i y_{oi}}{\sum_i p_{oi} \times RR(d_i) \times \frac{y_{ri}}{p_{ri}}}$$

Similarly, the lower and upper limits of the 100(1- $\alpha$ )% confidence interval can be calculated as follows:

$$SMR_{LCL}^* = \frac{Obs}{E^*} \times \left( 1 - \frac{1}{9 \times Obs} - \frac{Z_{\alpha/2}}{3 \times \sqrt{Obs}} \right)^3$$

and

$$SMR_{UCL}^* = \frac{(Obs + 1)}{E^*} \times \left( 1 - \frac{1}{9 \times (Obs + 1)} + \frac{Z_{\alpha/2}}{3 \times \sqrt{Obs + 1}} \right)^3$$

where  $SMR_{LCL}^*$  is the 100(1- $\alpha/2$ )% lower confidence limit on the  $SMR^*$ ,  $SMR_{UCL}^*$  is the 100(1- $\alpha/2$ )% upper confidence limit on the  $SMR^*$ ,  $Obs$  is the number of observed cause-specific deaths (e.g., lymphoid cancer deaths) in the study (i.e.,  $Obs = \sum_i y_{oi}$ ),  $E^*$  is the expected cause-specific deaths (e.g., lymphoid cancer deaths) derived from the reference population background rates multiplied by the exposure response function  $RR(d_i)$  (i.e.,  $E^* = \sum_i p_{oi} \times RR(d_i) \times \frac{y_{ri}}{p_{ri}}$ ), and  $Z_{\alpha/2}$  is the 100(1- $\alpha/2$ )% percentile of the standard normal distribution.

### A3.5 References

- Breslow, N. E. and N. E. Day (1987). Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies. International Agency for Research on Cancer, Lyon, France.
- Checkoway, H., N. E. Pearce, and D. J. Crawford-Brown (1989). Research Methods in Epidemiology. Oxford University Press, New York, USA
- Rothman, K. J. (1986). Modern Epidemiology. Little, Brown and Company, Boston USA / Toronto Canada

**Table 33: Lymphoid Cancer Mortality Rates in the U.S. Population for Each Calendar Year (1930-1972), Each Race, Each Sex and Each Age Group (number of lymphoid cancer deaths per 100,000)**

Age Group (Years)	1930	1940	1950	1960	1968	1969	1970	1971	1972
<b>White Males</b>									
< 1	0.571574	0.571574	0.571574	0.952897	0.664582	0.193834	0.250050	0.264904	0.436483
1-4	0.889715	0.889715	0.889715	0.905855	2.716523	2.469136	2.639159	2.639196	1.416049
5-9	0.896007	0.896007	0.896007	0.792474	3.181767	3.222868	3.486584	3.365958	3.053435
10-14	0.808974	0.808974	0.808974	0.764426	1.743532	2.089818	1.892907	1.777729	1.573083
15-19	1.173753	1.173753	1.173753	1.302018	2.187854	2.304943	2.062410	1.853147	1.868520
20-24	0.779566	0.779566	0.779566	1.226909	1.853888	1.437771	2.074683	1.564349	1.969677
25-34	1.246367	1.246367	1.246367	1.348092	1.948938	1.826095	1.642713	1.866738	1.436086
35-44	2.822822	2.822822	2.822822	3.369977	4.096598	4.063587	3.427241	3.219945	3.996754
45-54	6.291235	6.291235	6.291235	8.459325	10.379543	10.326954	10.435895	10.292100	9.491327
55-64	13.704865	13.704865	13.704865	18.845992	25.093104	24.651811	25.357608	27.116973	25.569775
65-74	18.092659	18.092659	18.092659	32.706133	53.237410	51.595092	51.896786	51.955307	51.216641
75-84	18.992015	18.992015	18.992015	38.781214	82.331839	88.898757	86.483903	88.585069	91.555937
85+	11.917858	11.917858	11.917858	37.471858	104.761905	101.686747	87.071343	105.399568	117.052632
<b>Other Race Males</b>									
< 1	0.493869	0.493869	0.493869	0.000000	0.342912	0.334609	0.950275	0.958681	1.354541
1-4	0.506669	0.506669	0.506669	0.510781	1.218451	1.163832	1.553219	0.925069	0.722674
5-9	0.875629	0.875629	0.875629	0.460755	1.440733	1.962067	1.107201	1.724138	1.617251
10-14	0.419074	0.419074	0.419074	0.374631	1.760325	1.713909	1.412963	0.949367	1.501877
15-19	0.639471	0.639471	0.639471	0.878770	2.205882	1.334380	1.415189	1.505376	1.782042
20-24	1.159879	1.159879	1.159879	0.798062	2.016607	1.771872	1.024119	1.309635	0.886525
25-34	1.371643	1.371643	1.371643	1.371711	1.282051	1.747997	1.386486	1.828030	1.277139
35-44	2.362183	2.362183	2.362183	3.357051	3.718674	3.658537	4.072298	4.099678	5.229794
45-54	5.984989	5.984989	5.984989	9.095071	11.770245	10.925926	12.172295	10.151380	12.971078
55-64	11.279807	11.279807	11.279807	17.047913	29.750000	31.365314	28.395850	31.578947	26.004728
65-74	11.984811	11.984811	11.984811	22.473431	45.908184	51.185771	46.782908	52.000000	43.314501
75-84	11.892728	11.892728	11.892728	23.349211	61.827957	62.765957	67.857013	57.692308	68.202765
85+	0.000000	0.000000	0.000000	15.943369	58.536585	52.272727	59.543142	80.851064	63.829787
<b>White Females</b>									
< 1	0.372830	0.372830	0.372830	0.466696	0.703416	0.752196	0.595918	0.419701	0.461215
1-4	0.589370	0.589370	0.589370	0.382623	2.033672	1.985371	1.976859	1.656868	1.449532
5-9	0.369624	0.369624	0.369624	0.240952	2.059308	2.331391	2.528940	2.320938	1.828012
10-14	0.231579	0.231579	0.231579	0.417692	1.185724	1.195589	1.110161	1.276644	1.255995
15-19	0.258359	0.258359	0.258359	0.242587	0.965624	0.882056	1.138742	1.116447	1.150775

Age Group (Years)	1930	1940	1950	1960	1968	1969	1970	1971	1972
20-24	0.521598	0.521598	0.521598	0.538865	0.859182	0.643897	0.830949	0.817682	0.823469
25-34	0.792567	0.792567	0.792567	0.695775	0.815707	0.811284	0.990505	0.730055	1.008598
35-44	1.656499	1.656499	1.656499	2.209093	2.610084	2.225193	2.125844	2.257623	2.227040
45-54	3.927054	3.927054	3.927054	5.317963	7.310358	6.770297	6.805298	6.449242	6.650224
55-64	9.581633	9.581633	9.581633	13.184796	16.236934	16.778907	16.683520	16.793724	15.473466
65-74	13.471141	13.471141	13.471141	21.389945	33.714562	34.345683	35.204790	33.589547	36.741455
75-84	13.544646	13.544646	13.544646	28.303572	54.802432	54.652880	56.864558	57.238122	56.749460
85+	11.466575	11.466575	11.466575	23.163091	57.645467	65.772669	57.425086	62.057522	59.322034
<b>Other Race Females</b>									
< 1	0.490851	0.490851	0.490851	0.649642	0.000000	0.343348	0.327084	0.659039	0.695476
1-4	0.255302	0.255302	0.255302	0.425917	0.788782	1.171171	1.564646	1.022305	0.545455
5-9	0.373279	0.373279	0.373279	0.153607	0.524246	0.721311	1.050270	1.136364	0.814664
10-14	0.000000	0.000000	0.000000	0.281193	1.222826	0.991408	0.837986	1.144310	0.629327
15-19	0.302773	0.302773	0.302773	0.122783	0.642055	1.078582	0.663027	0.921986	0.679348
20-24	0.572140	0.572140	0.572140	0.142154	1.020408	0.287632	0.898678	0.583333	0.960769
25-34	0.686160	0.686160	0.686160	0.906197	1.654997	1.175015	0.652594	0.694444	0.986842
35-44	1.574455	1.574455	1.574455	3.092078	2.105978	2.642276	2.321355	2.675585	2.514891
45-54	4.516905	4.516905	4.516905	7.099807	9.083333	9.046455	8.699902	8.268934	8.308157
55-64	7.848951	7.848951	7.848951	10.717328	20.000000	16.902944	18.750576	20.582121	16.276704
65-74	5.746153	5.746153	5.746153	12.368748	30.629139	27.597403	28.920872	31.981279	33.027523
75-84	4.880954	4.880954	4.880954	16.111612	37.500000	33.333333	32.715935	35.000000	34.437086
85+	0.000000	0.000000	0.000000	12.414341	29.508197	33.846154	22.881259	42.465753	36.842105

**Table 34: Lymphoid Cancer Mortality Rates in the U.S. Population for Each Calendar Year (1973-1981), Each Race, Each Sex and Each Age Group (number of lymphoid cancer deaths per 100,000)**

Age Group (Years)	1973	1974	1975	1976	1977	1978	1979	1980	1981
<b>White Males</b>									
< 1	0.908058	0.224475	0.528294	0.300067	0.500615	0.358533	0.273877	0.132507	0.132064
1-4	2.244898	1.937849	1.833031	1.491692	1.211771	1.370124	1.234337	0.999559	1.346066
5-9	3.192572	3.142184	2.786254	3.041926	2.701618	2.013605	2.703456	2.514574	2.153795
10-14	2.131166	2.046687	1.720841	1.787372	2.181993	1.920932	1.734473	1.758458	1.563759
15-19	1.934907	1.908439	1.957140	1.817788	1.691974	1.677743	1.720171	1.719677	1.542872
20-24	1.456249	1.256932	1.508621	1.205242	1.383173	1.537081	1.481645	1.646638	1.395948
25-34	1.559640	1.639344	1.467136	1.432200	1.456079	1.578878	1.322802	1.543315	1.499603

Age Group (Years)	1973	1974	1975	1976	1977	1978	1979	1980	1981
35-44	3.285860	3.206107	3.239279	2.932876	2.984485	3.414495	3.156437	3.505926	3.005275
45-54	9.415647	10.002913	9.567420	9.625196	9.086395	9.480337	9.692479	9.433185	9.489925
55-64	24.776732	24.812299	25.402042	24.272853	24.671202	24.745497	24.588897	25.549930	25.109082
65-74	52.533589	52.720450	50.549249	52.758868	52.749171	53.199113	54.677339	54.513390	52.882396
75-84	91.595563	91.298812	90.050167	92.269737	90.846216	96.881248	98.868072	98.827567	99.726331
85+	109.183673	109.126214	119.074074	116.333938	119.789842	125.252525	135.008104	135.478217	128.314866
Other Race Males									
< 1	0.000000	0.350064	0.000000	0.686344	0.000000	0.952922	0.604677	0.000000	0.000000
1-4	0.890472	1.334520	1.432408	1.648352	0.925926	0.915751	0.896057	0.867085	1.145101
5-9	1.717033	1.670146	1.742160	1.098901	2.105978	1.683502	1.346801	0.799939	1.551788
10-14	1.607916	1.411909	0.973828	1.039755	1.363918	1.322418	0.890019	1.453699	1.239236
15-19	1.851852	1.726343	1.179392	1.390568	1.014925	1.410106	1.567034	1.377656	1.363956
20-24	1.528014	1.383238	1.242236	1.187825	1.275691	1.709986	1.058901	1.480282	1.175116
25-34	1.333333	1.145475	1.243243	1.379663	1.699854	1.661283	1.179554	1.310302	1.284428
35-44	3.903201	2.773498	3.506098	3.048327	3.537906	3.778866	3.653586	3.462009	4.639626
45-54	9.490940	13.356164	10.365336	10.867734	10.067114	9.468439	11.367381	10.689003	10.210284
55-64	27.570093	29.633867	29.319955	30.363036	28.862661	25.991649	29.183673	29.668996	26.891935
65-74	56.880734	54.821429	53.739130	53.962901	54.545455	58.582677	50.844854	58.720972	54.042417
75-84	73.991031	76.855895	66.115702	74.806202	81.992337	76.226415	78.651685	85.585907	93.874677
85+	64.583333	76.000000	75.925926	60.000000	82.142857	108.620690	106.779661	80.643834	104.987699
White Females									
< 1	0.559929	0.396269	0.479311	0.555150	0.302594	0.455050	0.361702	0.210232	0.139542
1-4	1.087926	1.337486	1.087164	1.130952	1.031553	1.022044	0.964947	0.643648	0.888346
5-9	2.089711	1.931242	1.779013	1.525870	1.558551	1.671667	1.377491	1.181182	1.282891
10-14	1.010913	1.042753	0.977275	0.935829	1.054746	0.896104	0.828655	0.922761	1.031858
15-19	1.049838	0.888990	0.972081	0.705803	0.887341	0.700328	0.797176	0.818234	0.945110
20-24	0.683717	0.843359	0.774256	0.900794	0.672464	0.716642	0.628578	0.724198	0.705556
25-34	0.861660	0.811775	0.928295	0.739332	0.837019	0.936504	0.798198	0.855556	0.724416
35-44	2.267551	2.112676	2.106728	1.792044	1.865996	1.696495	1.630139	1.887533	1.727053
45-54	6.246017	6.551095	6.287809	6.452209	6.487905	6.471816	6.256618	6.115654	5.936539
55-64	16.013353	16.622439	15.990803	16.423433	16.627989	16.348638	16.209867	16.803601	17.030421
65-74	34.125587	34.821812	32.178287	34.755847	34.549814	35.034501	35.199592	37.603777	35.889455
75-84	58.124174	58.643892	57.581864	61.363079	61.298077	61.771617	63.731992	67.535625	68.589388
85+	67.239636	66.761364	67.724868	67.617450	76.367962	76.519130	75.692964	84.172570	83.353422
Other Race Females									
< 1	0.718184	0.000000	0.000000	0.000000	0.000000	0.654986	0.311744	0.000000	0.000000
1-4	0.898473	0.450045	1.364877	0.372439	0.753296	0.279851	0.547445	0.795146	0.583260
5-9	0.966851	0.629811	1.190476	0.968188	0.959561	0.886767	0.752394	0.407426	1.169315



Age Group (Years)	1973	1974	1975	1976	1977	1978	1979	1980	1981
10-14	0.623053	0.992556	0.802965	0.745805	0.693569	0.960307	0.774693	0.642377	0.757866
15-19	0.786885	0.571429	0.803461	0.422705	0.774732	0.587544	0.815376	0.864307	0.402981
20-24	0.538462	0.591716	0.283487	0.683060	0.654879	0.758534	0.612745	0.654753	0.634340
25-34	0.677083	0.935961	0.836431	0.924296	0.962343	0.558659	0.833018	1.034294	0.828562
35-44	2.156863	2.450032	1.977041	2.114428	2.238355	2.231356	2.103468	2.399917	2.864034
45-54	9.830007	6.540698	9.305655	6.770099	8.432056	6.662088	8.316430	8.035665	6.734315
55-64	18.818819	17.543860	19.038643	20.702403	19.516562	20.555074	18.891688	19.739761	18.660537
65-74	37.037037	34.240688	32.088520	34.087883	32.101911	32.885086	35.924617	32.425347	40.174421
75-84	31.761006	36.445783	44.067797	45.212766	48.041775	45.641026	47.727273	57.289609	57.167055
85+	46.250000	54.117647	41.935484	43.877551	45.192308	50.000000	63.157895	65.743449	70.517392

**Table 35: Lymphoid Cancer Mortality Rates in the U.S. Population for Each Calendar Year (1982-1990), Each Race, Each Sex and Each Age Group (number of lymphoid cancer deaths per 100,000)**

Age Group (Years)	1982	1983	1984	1985	1986	1987	1988	1989	1990
<b>White Males</b>									
< 1	0.000000	0.462407	0.000000	0.192266	0.064567	0.512302	0.000000	0.244261	0.118477
1-4	0.897367	1.310122	0.781290	0.830986	0.877404	0.739505	0.737235	0.663349	0.708275
5-9	2.366171	1.846937	1.510829	1.428039	1.366221	1.467699	1.225459	1.297239	0.913484
10-14	1.583212	1.360994	1.426616	1.285190	1.274476	1.210121	1.201909	1.428199	1.352777
15-19	1.796605	1.780555	1.689925	1.682906	1.512290	1.333880	1.353366	1.212178	1.409300
20-24	1.343823	1.284539	1.270779	1.324499	1.419361	1.497749	1.274751	1.514134	1.248516
25-34	1.527609	1.570647	1.584635	1.706365	2.154965	1.607166	1.992268	1.977337	2.268786
35-44	3.607424	3.210907	3.607591	3.900018	3.907493	3.733309	3.744332	4.073447	3.925666
45-54	10.320582	9.492029	9.475140	9.981628	10.353269	10.305775	10.121232	10.454357	11.342008
55-64	25.740401	25.933995	26.359149	27.642635	26.093181	28.162326	28.577168	29.628210	29.421239
65-74	55.446249	58.683266	58.006916	60.547081	63.379973	61.768858	60.894609	63.835855	64.680548
75-84	102.512985	103.269530	102.903810	113.797884	111.957418	110.325657	117.539257	121.572182	124.689270
85+	141.091466	154.657919	146.182157	158.545624	152.478016	146.762825	171.258407	163.709977	185.700410
<b>Other Race Males</b>									
< 1	0.282407	0.000000	0.560626	0.544009	0.265887	0.513383	0.243094	0.231537	0.000000
1-4	0.950552	0.843139	0.898864	0.815968	0.584038	0.359246	0.352241	0.545662	0.529965
5-9	1.544365	1.263091	1.035059	1.065461	1.635687	1.002256	0.802618	0.847424	0.838924
10-14	1.101152	1.094825	1.341328	1.465289	1.305275	0.991744	0.674730	1.075256	0.990555
15-19	1.544260	1.214203	1.108428	0.701977	0.978176	1.531826	1.121842	1.232062	0.892218

Age Group (Years)	1982	1983	1984	1985	1986	1987	1988	1989	1990
20-24	0.848498	1.603323	1.108261	1.322919	1.200467	0.919044	1.446631	1.389804	1.442548
25-34	1.840239	1.941467	1.637358	1.906600	1.752430	1.457848	1.865610	2.782049	2.290311
35-44	3.630473	3.495188	4.120332	4.426983	4.713920	4.554605	4.972986	4.699949	5.240313
45-54	12.753297	11.795082	11.153652	10.804774	11.090469	11.424834	12.745138	13.021074	13.059052
55-64	27.441584	33.281437	30.656579	29.982650	30.277039	26.602320	29.171684	30.098894	33.984171
65-74	57.237298	55.381074	50.838187	61.469040	67.722773	64.142203	60.374990	60.402824	65.684984
75-84	99.028610	108.712639	94.311838	97.257155	112.593187	106.228728	99.871509	110.026091	109.071026
85+	110.976140	120.734757	82.336687	113.366296	106.579982	137.074874	121.273370	148.091471	159.703198
<b>White Females</b>									
< 1	0.412871	0.418804	0.207705	0.338393	0.204025	0.337325	0.397082	0.450230	0.062415
1-4	0.740887	0.943464	0.464971	0.714428	0.693092	0.601971	0.653006	0.419260	0.451249
5-9	1.294763	0.911457	0.835611	0.988693	0.757493	0.627520	0.559821	0.641137	0.623382
10-14	0.811883	0.631763	0.881446	0.834117	0.803605	0.716906	0.557631	0.640258	0.556603
15-19	0.816159	0.870140	0.723414	0.626600	0.838982	0.794999	0.644126	0.647127	0.788964
20-24	0.873275	0.679190	0.641055	0.778479	0.804127	0.708784	0.656806	0.791296	0.786603
25-34	0.743563	0.696736	0.814677	0.906247	0.940198	0.770082	0.829128	0.869329	0.884170
35-44	1.741456	1.859996	2.115381	1.992830	1.956782	1.717332	2.159311	1.856792	1.787279
45-54	6.734416	6.563147	6.457907	6.609959	6.253106	6.042936	6.355324	6.076045	6.084263
55-64	16.917034	17.085084	17.960658	18.684330	17.474939	17.735989	17.586514	18.798277	17.622023
65-74	37.596194	39.177268	39.824889	39.607408	41.121751	40.965889	41.342613	43.020215	43.082987
75-84	69.543091	70.552506	72.529403	71.315776	76.337351	76.845877	77.916555	80.989763	81.092049
85+	92.412534	89.912880	93.843998	94.727554	100.448726	104.084539	103.516519	109.816269	114.634887
<b>Other Race Females</b>									
< 1	0.292722	0.000000	0.868817	0.563369	0.553598	0.000000	0.252484	0.239977	0.468898
1-4	0.726035	0.546679	0.611366	0.454753	0.298587	0.515052	1.010791	0.699719	0.476427
5-9	0.548698	1.087145	0.198370	0.640049	0.804902	0.421807	0.645421	0.520951	0.458591
10-14	0.812410	0.622286	0.437587	0.752269	0.382603	0.509268	0.377932	0.490451	0.477840
15-19	0.580762	0.764674	0.593717	0.298791	0.471507	0.640464	0.461812	0.519634	0.748110
20-24	0.853074	0.561540	0.501356	0.221421	0.554927	0.671071	0.564213	0.510058	0.851649
25-34	0.731149	0.674739	0.950363	1.008959	0.926506	0.903771	1.071554	0.710502	0.963634
35-44	2.213313	2.192893	2.291606	2.543862	2.321505	2.242482	2.132750	2.326151	2.652870
45-54	7.298407	7.121108	7.312326	6.550464	8.025120	7.634042	7.331957	7.589449	8.253123
55-64	18.533248	17.381368	20.156957	19.876547	18.758072	18.216235	19.695708	19.588978	19.595873
65-74	37.355813	38.276541	36.088017	38.533843	40.391660	39.156632	40.894103	41.773392	41.612207
75-84	59.725264	61.003109	58.979590	72.662063	61.616938	61.855941	67.427820	70.322620	71.910686
85+	64.834220	66.926697	64.149876	77.144586	79.929917	83.506794	81.033922	81.645237	83.769867

**Table 36: Lymphoid Cancer Mortality Rates in the U.S. Population for Each Calendar Year (1991-1999), Each Race, Each Sex and Each Age Group (number of lymphoid cancer deaths per 100,000)**

Age Group (Years)	1991	1992	1993	1994	1995	1996	1997	1998	1999
<b>White Males</b>									
< 1	0.120549	0.304542	0.309342	0.250062	0.125911	0.126229	0.381286	0.313145	0.261647
1-4	0.598010	0.634873	0.641730	0.483114	0.597917	0.525628	0.322071	0.389179	0.520896
5-9	1.077332	1.046375	0.842215	0.869082	1.071523	0.627185	0.728541	0.635617	0.535847
10-14	1.069727	0.922609	1.018617	0.953443	0.855020	0.884591	0.804178	0.847763	0.589373
15-19	1.394160	1.411226	1.281312	1.131257	1.049657	1.046720	0.934061	1.187142	0.880738
20-24	1.486628	1.485252	1.049435	1.532901	1.098601	1.291260	1.508268	1.552742	1.398208
25-34	2.153514	2.230164	2.090814	2.252798	2.244475	2.011220	2.201578	1.773869	1.305571
35-44	4.716193	4.434700	4.386889	4.381832	4.635446	4.322717	3.891075	3.694620	2.936410
45-54	11.299132	10.765887	10.498471	11.240728	10.956518	10.384872	10.941259	10.085568	9.264970
55-64	28.990578	28.964490	28.869688	30.789233	30.267561	29.977605	29.599598	28.278056	27.768360
65-74	65.820142	67.437957	67.622686	70.574494	70.831434	69.983251	72.455585	71.013446	69.063573
75-84	123.244041	128.192453	129.169255	130.541394	132.139030	135.097298	134.542905	135.014407	136.039499
85+	184.620012	182.774888	186.482519	202.084388	203.049861	205.679170	195.813850	199.761637	200.496795
<b>Other Race Males</b>									
< 1	0.000000	0.000000	0.231198	0.000000	0.490283	0.492542	0.242734	0.476757	0.000000
1-4	0.251040	0.180786	0.291989	0.172394	0.286071	0.287824	0.233362	0.352567	0.176170
5-9	0.706327	0.689215	0.565082	0.492402	0.520381	0.819514	0.572628	0.430521	0.256131
10-14	0.775427	0.641820	0.568414	0.759836	1.047504	0.733418	0.767420	0.561479	0.813209
15-19	1.191880	1.185346	0.500675	0.864956	1.198790	0.553187	0.731660	0.662851	1.070727
20-24	1.124612	1.642354	1.785301	1.508855	0.972847	1.313934	2.015238	0.645289	0.993891
25-34	2.237519	2.484545	2.407845	2.206208	2.567098	2.425574	2.111731	1.761624	1.717844
35-44	5.264830	5.221627	4.846035	4.669117	5.130747	5.026924	5.259584	4.383872	3.907748
45-54	12.192547	12.871079	12.740362	12.099461	12.981341	12.574332	13.039173	11.972081	9.760551
55-64	31.597492	34.051901	28.743845	34.058142	31.510938	32.051830	30.667501	30.433409	31.292855
65-74	67.516141	61.893730	69.133246	62.181494	62.604246	67.819297	64.586214	62.510594	61.446247
75-84	118.346204	108.465272	111.503892	101.134128	110.952607	117.171986	116.895856	108.432653	108.149986
85+	131.534134	140.571056	164.607271	156.009507	161.524956	154.217709	152.287127	162.763360	161.416252
<b>White Females</b>									
< 1	0.189610	0.128216	0.260841	0.394373	0.198615	0.463996	0.600393	0.328510	0.206611
1-4	0.544654	0.484663	0.362290	0.393668	0.231834	0.268299	0.322384	0.375495	0.411102
5-9	0.617083	0.712038	0.651712	0.505619	0.510744	0.422820	0.559046	0.412139	0.282375
10-14	0.420396	0.650159	0.510683	0.558181	0.525734	0.507201	0.530655	0.539522	0.375783
15-19	0.791386	0.689823	0.563043	0.653104	0.495588	0.564889	0.605686	0.474534	0.521361

Age Group (Years)	1991	1992	1993	1994	1995	1996	1997	1998	1999
20-24	0.719853	0.647753	0.577305	0.783432	0.732804	0.840555	0.913694	0.930414	0.701500
25-34	0.928258	0.984040	0.944766	1.037638	0.882957	1.072279	0.822517	0.832823	0.824799
35-44	1.920846	1.937426	1.865423	2.084310	2.097702	1.968226	1.983071	1.727557	1.672751
45-54	6.500862	5.997125	5.912764	6.459897	6.114375	6.139397	5.639134	5.577498	5.202266
55-64	19.178724	18.330817	19.220898	19.593339	19.239323	19.268723	19.531043	17.763069	17.363737
65-74	44.670651	45.063962	46.706389	46.334466	47.634353	46.662600	47.170072	45.873513	46.282577
75-84	85.652607	85.539274	87.768235	88.536784	89.289949	90.527655	89.550870	91.065418	91.226321
85+	118.035157	115.502420	120.620701	117.264248	125.040442	121.648591	124.871721	121.364315	122.155611
<b>Other Race Females</b>									
< 1	0.234086	0.000000	0.000000	0.000000	0.254598	0.254855	0.504694	0.000000	1.249619
1-4	0.193747	0.434289	0.180589	0.415097	0.472506	0.356208	0.300468	0.120879	0.181199
5-9	0.502308	0.109141	0.688359	0.355915	0.489020	0.376693	0.364674	0.178399	0.221088
10-14	0.340783	0.658581	0.265457	0.260343	0.718685	0.604677	0.148552	0.193467	0.420867
15-19	0.760147	0.290665	0.629617	0.667091	0.589240	0.516753	0.551219	0.243356	0.478619
20-24	0.552215	0.701958	0.744932	0.369962	0.529128	0.641656	0.371187	0.574389	0.811758
25-34	1.250760	1.161703	1.074879	0.969668	1.282122	1.191926	1.034714	1.221072	0.860489
35-44	2.631571	2.695297	2.201742	2.072282	2.737377	2.480527	2.904835	2.831665	2.114252
45-54	7.433460	7.524094	7.964662	7.841874	7.423539	6.577967	6.862564	6.910658	6.250333
55-64	20.877164	19.463921	21.271408	20.568934	23.617713	21.535597	20.943180	21.726642	21.037674
65-74	46.704315	41.136051	43.407193	39.603040	41.951707	46.011816	43.479905	44.474852	41.977259
75-84	81.049219	72.227947	77.173631	76.716888	75.573071	76.119672	72.954561	78.245435	76.115208
85+	87.337153	99.305842	94.501598	94.680398	94.904241	99.516750	98.701031	99.677092	95.995562

**Table 37: Lymphoid Cancer Mortality Rates in the U.S. Population for Each Calendar Year (2000-2008), Each Race, Each Sex and Each Age Group (number of lymphoid cancer deaths per 100,000)**

Age Group (Years)	2000	2001	2002	2003	2004	2005	2006	2007	2008
<b>White Males</b>									
< 1	0.524806	0.250750	0.381423	0.126342	0.125603	0.063462	0.378854	0.433816	0.375811
1-4	0.390715	0.311593	0.340849	0.547846	0.383588	0.428761	0.414535	0.207105	0.460199
5-9	0.647961	0.536133	0.544783	0.809098	0.738830	0.586288	0.440868	0.721561	0.485417
10-14	0.836564	0.644528	0.792704	0.683952	0.508571	0.705677	0.615860	0.597909	0.405742
15-19	1.143733	1.118192	1.005208	0.941732	1.015803	0.933706	0.867502	0.827787	0.838181
20-24	1.424321	1.262936	1.335348	1.160621	1.051160	1.247020	1.314343	1.043871	1.270049
25-34	1.207456	1.325997	1.292035	1.232081	1.287954	1.026088	1.180857	1.123533	1.249620

Age Group (Years)	2000	2001	2002	2003	2004	2005	2006	2007	2008
35-44	2.951331	2.947883	2.787913	2.719071	2.445056	2.470472	2.151277	2.365903	2.161794
45-54	8.736368	8.658735	8.160044	7.522465	7.274624	6.838794	6.861847	6.613099	6.164806
55-64	26.024599	25.768249	24.602045	24.337611	22.290379	21.443948	20.815903	20.218269	20.093016
65-74	68.210725	66.846157	66.754466	63.724138	59.058038	59.772839	55.443301	55.225882	52.210701
75-84	137.861646	131.603614	132.026187	129.571266	125.750437	126.843740	126.655258	125.431566	123.714919
85+	202.953378	206.959834	212.138265	213.290538	201.174047	212.220517	195.502713	202.949122	202.726728
<b>Other Race Males</b>									
< 1	0.235491	0.000000	0.448970	0.000000	0.000000	0.211882	0.207428	0.000000	0.389636
1-4	0.232676	0.174487	0.114159	0.281887	0.388513	0.436998	0.324330	0.529700	0.359809
5-9	0.426663	0.433151	0.350934	0.177529	0.536648	0.669715	0.307361	0.432344	0.255016
10-14	0.352086	0.844244	0.697316	0.803100	0.437740	0.359507	0.481909	0.444312	0.486827
15-19	0.920683	1.076046	0.792248	0.602980	0.459569	0.604006	0.779758	0.720078	0.890076
20-24	1.679528	1.056120	0.877657	1.167735	1.357733	1.165263	1.232959	1.051449	0.744980
25-34	1.363152	1.404313	1.538684	1.551104	1.403061	1.602819	1.098655	1.126761	1.266334
35-44	2.835120	3.817562	3.392236	3.049851	2.553021	2.602693	3.074193	3.089058	2.116457
45-54	10.717689	9.866223	8.851983	9.939288	9.058168	9.391368	8.899028	8.540407	7.925244
55-64	26.363186	29.985785	26.175855	23.212888	23.481933	23.096876	24.894886	21.742272	21.917414
65-74	61.467682	61.255497	57.822519	52.268589	57.715894	54.302768	52.212361	49.404447	51.758535
75-84	102.947245	104.276589	99.069233	95.457067	100.239504	96.713415	94.921776	97.159675	93.011377
85+	145.308316	142.557723	134.973258	143.433958	145.190271	126.514193	152.502927	143.278205	131.946501
<b>White Females</b>									
< 1	0.483682	0.131239	0.332853	0.596126	0.263276	0.199731	0.198550	0.324862	0.327583
1-4	0.376789	0.310412	0.392293	0.388978	0.217928	0.199665	0.334287	0.317396	0.216318
5-9	0.425186	0.446824	0.547368	0.446350	0.436685	0.356507	0.299872	0.379088	0.375590
10-14	0.486294	0.377656	0.561295	0.397890	0.411565	0.441312	0.381939	0.540134	0.375560
15-19	0.492428	0.502412	0.435949	0.420339	0.629975	0.422781	0.479903	0.488373	0.438460
20-24	0.606969	0.729405	0.791141	0.676381	0.607536	0.555826	0.530911	0.682503	0.390786
25-34	0.751260	0.854954	0.782482	0.621166	0.630221	0.725255	0.731735	0.641508	0.582598
35-44	1.522875	1.588986	1.609632	1.453520	1.243847	1.286495	1.359781	1.251519	1.204327
45-54	5.326357	4.737304	4.630905	4.389539	4.295574	3.898529	3.933733	3.694953	3.534546
55-64	17.389128	16.335271	15.009996	13.676430	13.322191	13.352400	12.130725	11.797667	11.197640
65-74	44.010466	41.752191	40.585987	37.403030	36.937724	35.289786	35.434227	33.258375	31.591145
75-84	90.119912	87.396791	84.699781	84.711257	82.164651	81.038234	78.777329	78.024018	75.235482
85+	128.513697	128.834098	129.776449	128.647982	124.750168	125.342160	126.731086	123.320293	121.223154
<b>Other Race Females</b>									
< 1	0.244260	0.000000	0.464279	0.000000	0.000000	0.000000	0.000000	0.000000	0.000000
1-4	0.359362	0.179663	0.176290	0.232051	0.114423	0.000000	0.000000	0.164215	0.053145
5-9	0.309062	0.402679	0.271573	0.228525	0.459707	0.000000	0.135214	0.266130	0.261604

Age Group (Years)	2000	2001	2002	2003	2004	2005	2006	2007	2008
10-14	0.227928	0.174845	0.254859	0.499492	0.206140	0.289557	0.373864	0.083534	0.377093
15-19	0.520827	0.465908	0.824630	0.536728	0.260194	0.208961	0.283326	0.236140	0.231250
20-24	0.838657	0.702065	0.770675	0.398600	0.393036	0.650290	0.687329	0.466475	0.581676
25-34	1.000629	1.272210	1.020700	0.869944	0.899656	0.752461	0.696625	0.664100	0.611427
35-44	2.317793	2.049276	1.899200	1.862371	1.737403	2.008196	1.872617	1.809375	1.348465
45-54	6.319216	6.213190	6.929462	5.666120	5.479445	5.300950	5.361658	5.400012	4.546107
55-64	17.592975	18.765077	17.788091	14.672254	15.503902	15.881942	14.640494	14.890397	13.472998
65-74	40.580024	41.223164	41.278055	41.797987	36.900825	36.086683	34.291068	34.010516	31.508649
75-84	74.119505	74.499069	70.453876	77.651645	71.641475	61.796102	62.880913	66.641937	62.963260
85+	115.616309	97.336673	86.333420	98.078476	99.450371	89.589566	92.445974	88.253258	86.059963

#### Appendix 4 Hypothetical Example of Appearance of Supra-Linearity in the Absence of Truly Low-Dose Data

USEPA acknowledges that “the actual exposure-response relationship at low exposure levels is unknown” (pp. 4-61 and 4-74 of USEPA 2016). The inability to observe sublinearity in the NIOSH cohort might be explained by the lack of dose-response data at low air concentrations (e.g., a few ppb) that would allow total internal exposures (endogenous + exogenous) to remain in/near the normal endogenous range (e.g., see Figures 3 and 6). Where available dose-response data are predominated by exposures above the area in the dose-response expected to be sublinear (i.e., within/near/below the normal endogenous range in the present case), if the doses are sufficiently high to be in the area of the dose-response where disproportionately increased risk occurs, then the dose-response observed based on the data available might appear supra-linear overall. As a hypothetical example, Figure 14 below is similar to Figure 4-2 of USEPA (2016) for lymphoid cancer.






Figure 14: Seemingly Supra-linear Dose-Response for Lymphoid Cancer

The dose-response as presented (not based on the individual data or additional exposure groups) may appear overall supra-linear in nature, as noted by USEPA (2016). However, examination of the dose axis reveals that there are no truly low-dose data to characterize the shape of the dose-response at low exposures (e.g., a few ppb), especially within/near/below the endogenous range where USEPA (2016) expects sublinearity. Hypothetical dose-response data in the range of endogenous exposures and below were used to produce Figures 15 and 16 (see below).



**Figure 15. Hypothetical Sublinear Dose-Response at Truly Low Doses Plotted with Available High-Dose Data for Lymphoid Cancer**






**Figure 16: Hypothetical Sublinear Dose-Response at Truly Low Doses Plotted with Available High-Dose Data for Lymphoid Cancer – Expanded Low-Dose View**


The availability of adequate, truly low-dose data in this hypothetical example reveals the existence of sublinearity in the overall dose-response at doses corresponding to the endogenous range (and significantly lower doses corresponding to 1E-06 to 1E-04 excess risk based on USEPA 2016). However, simple removal of these truly low-dose data results in a graph

depicting a seemingly supra-linear dose-response (Figure 17) with a steep low-dose slope down to a relative risk of 1 at 0 dose (similar to Figure 4-9 in USEPA 2016). At the same time, it should be realized that use of a different (e.g., higher) number of cumulative exposure intervals provides a different visual impression (e.g., see Figure 6S of Valdez-Flores et al. 2013).



**Figure 17: Seemingly Supra-linear Dose-Response from Removal of Hypothetical Low-Dose Data for Lymphoid Cancer**

Figure 18 also depicts the possibility of a downward shift in the apparent dose-response curve in the absence of truly low-dose data, where the dose range for the apparent supra-linear curve on the left could be similar to that in Figure 14.



Sublinearity expected in the endogenous range (as opposed to a steep low-dose slope from an overall supra-linear model), but in the absence of truly low-dose data and dose-response data only being available in the higher-dose region, the full dose-response would not be apparent and the dose-response would shift to the left, with only the portion defined by higher-dose data being defined and appearing supra-linear in nature.

**Figure 18: Seemingly Supra-linear Dose-Response from Removal of Hypothetical Low-Dose Data**

These examples simply demonstrate the hypothetical possibility of the appearance of an overall supra-linear dose-response, despite an underlying true dose-response that is sublinear at truly low doses, *when available data are at relatively high doses* above the sublinear portion of the curve and into the steep slope portion wherein high response per unit dose is induced.

To help put the high occupational EtO exposures into perspective, the environmental-to-occupational level corresponding to 1E-04 excess risk based on USEPA (2016) is 0.777 ppm-days (i.e.,  $0.00001 \text{ ppm (environmental at 1E-04 excess risk)} \times 70 \text{ years} \times 365 \text{ days/year} \times 20 \text{ m}^3/10 \text{ m}^3 \times 365 \text{ days/240 days} = 0.777 \text{ ppm-days occupational}$ ). By comparison, the midpoint of the lowest exposure group for lymphoid cell lineage cancer in Steenland et al. (2004) is almost 800 times lower ( $\approx 600 \text{ ppm-days}$ ; 15-year exposure lag) and had an odds ratio of only 0.90. Even today the OSHA PEL (1 ppm) is 222 times the air concentration corresponding to the 95<sup>th</sup> percentile of the normal endogenous background range (4.5 ppb; Table 4 of Kirman and Hays

2017), and around 294,000-417,000 times higher than central tendency environmental levels (i.e., background and environmental exposure means  $\approx 0.0044$ - $0.0062 \mu\text{g}/\text{m}^3$  ( $0.0024$ - $0.0034$  ppb) per USEPA 2016).

The TCEQ has not evaluated the hypothetical above further as it is somewhat beyond the scope of this DSD.

## Appendix 5 Corrected p-Values and Akaike Information Criterion (AIC) for the Two-Piece Spline Model and Other Models

### A5.1 Lymphoid Cancer:

#### A5.1.1 Corrected p-value example for the log-linear spline model with knot at 1,600 ppm-days

The likelihood ratio test is used to test whether a fitted model significantly improves the fit of the data by estimating parameters instead of just assuming a baseline (null) model for the data. The likelihood ratio test is evaluated by comparing the likelihood of the model with the estimated parameters and the likelihood of the null model. If the likelihood of the model with the estimated parameters is equal to the likelihood of the null model, then the natural logarithm of the ratio of these likelihoods multiplied by two follow a Chi-Square distribution with as many degrees of freedom as the number of parameters estimated for the fitted model. Thus, if the fit of the baseline (null) model and the model with estimated parameters are not different,

$$\text{Chi-Square}(k) = \chi_k^2 = -2 \ln \left( \frac{\text{likelihood for null model}}{\text{likelihood for fitted model}} \right)$$

This can also be written as follows,

$$\chi_k^2 = -2\text{LogL}(\text{null model}) + 2\text{LogL}(\text{fitted model})$$

Here  $k$  is the number of degrees of freedom ( $k$  is the number of parameters that were estimated in excess of the parameters estimated for the null model or nested model).

For the log-linear spline model with knot at 1,600 ppm-days for lymphoid cancer (Table D-33 on p. D-46 of USEPA 2016), the  $\chi_k^2$  value was equal to 5.2722 (463.912-458.640) and  $k$  was set to 2. This resulted in a p-value of 0.0716. That is, the fitted model was assumed to have two parameters; namely, the slope below the knot and the slope above the knot. The results are from a Statistical Analysis System (SAS) output for the model specified. The two-piece log-linear model specified included a knot. This knot was determined so that the likelihood of the spline model was maximized. That is, the knot is another parameter that was searched for outside SAS. Because the estimation of the knot was done outside SAS, the SAS program did not count the knot as a parameter and, consequently, the Chi-Square test SAS reported does not reflect the fact that the knot was also estimated. The correct Chi-Square that accounts for the fact that the knot was estimated outside SAS should then be 5.2722, but  $k$  (the degrees of freedom) should be three. This corrected calculation would result in a p-value of 0.1529. That is, the corrected p-value indicates that the likelihood of the log-linear spline model with knot at 1,600

ppm × days is not different from the likelihood of the null model at the 5% significance level. In plain words, there is not enough evidence indicating that the fitted two-piece log-linear spline model explains the variability in the data any better than the null model. The same is true for the linear two-piece spline model with a “knot” at 1,600 ppm × days selected by USEPA (p-value of 0.14).

#### **A5.1.2 Corrected AIC value example for the log-linear spline model with knot at 1,600 ppm-days**

The AIC is equal to  $2k - 2\text{LogL}$  where  $k$  is the number of parameters estimated for the model and  $\text{LogL}$  is the logarithm of the likelihood. Table D-33 in USEPA (2016) lists the  $-2\text{LogL}$  as 458.640 and the AIC as 462.640. That is:

$$462.640 = 2k + 458.640$$

*The AIC and  $-2\text{LogL}$  implies that  $k$  equals 2. That is, the spline model was assumed to have estimated two parameters; namely, the slope below the knot and the slope above the knot. The results in Table D-33 (p. D-46 of USEPA 2016) consist of SAS output for the two-piece log-linear spline model specified. The model specified included a knot. This knot was pre-assigned (i.e., previously estimated using a separate optimization procedure outside the SAS run), so the likelihood of the model was maximized only *conditional on* the estimated knot-value used for that calculation. Consequently, the knot must be treated as an additional parameter that was estimated outside SAS. Because the estimation of the knot was done outside SAS, the SAS run performed by USEPA did not count the knot as a model parameter and, consequently, the resulting AIC value it obtained does not reflect that the knot was in fact estimated. USEPA could have requested SAS to account properly for the extra degree of freedom properly associated with its estimated knot value, but USEPA evidently elected not to make this request of SAS.*

The correct AIC, which accounts for the fact that the knot was estimated outside SAS, should instead be:

$$\text{AIC} = 464.640 = 2 \times 3 + 458.640$$

*Correct AIC values and p-values for all models in Table 4-6 of USEPA (2016) are summarized in the corrected USEPA Table 4-6 below, which is Table 38 of this DSD (i.e., the p-values and AIC values have been corrected to reflect the degree of freedom for the knot in the two-piece spline models and to reflect the likelihood difference between SAS procedures used for linear and log-linear models).*

**Table 38: Corrected USEPA Table 4-6 - Models Considered for Modeling the EtO Exposure-Response Data for Lymphoid Cancer Mortality in Both Sexes in the NIOSH Cohort for the Derivation of Unit Risk Estimates**

Model <sup>a</sup>	p-value <sup>b</sup>	AIC <sup>c</sup>	USEPA Comments
<b>Two-piece spline models</b>			
Linear spline model with knot at 1,600 ppm × days	0.14	464.5	<b>SELECTED.</b> Adequate statistical and visual fit, including local fit to low-exposure range; linear model; AIC within two units of lowest AIC of models considered.
Linear spline model with knot at 100 ppm × days	0.11	463.8	Good overall statistical fit and lowest AIC of two-piece spline models, but poor local fit to the low-exposure region, with no cases below the knot.
Log-linear spline model with knot at 1,600 ppm × days	0.15	464.6	Linear model preferred to log-linear (see text above).
Log-linear spline model with knot at 100 ppm × days	0.11	463.8	Good overall statistical fit and tied for lowest AICc of two-piece spline models, but poor local fit to the low-exposure region, with no cases below the knot.
<b>Linear (ERR) models (<math>RR = 1 + \beta \times \text{exposure}</math>)</b>			
Linear model	0.13	463.6	Not statistically significant overall fit and poor visual fit.
Linear model with log cumulative exposure	0.02	460.6	Good overall statistical fit, but poor local fit to the low-exposure region.
Linear model with square-root transformation of cumulative exposure	0.053	462.2	Borderline statistical fit, but poor local fit to the low-exposure region.
<b>Log-linear (Cox regression) models (<math>RR = e^{\beta \times \text{exposure}}</math>)</b>			
Log-linear model (standard Cox regression model)	0.22	464.4	Not statistically significant overall fit and poor visual fit.
Log-linear model with log cumulative exposure	0.02	460.4	Good overall statistical fit; lowest AIC <sup>c</sup> of models considered; low-exposure slope becomes increasingly steep as exposures decrease, and large unit risk estimates can result; preference given to the two-piece spline models because they have a better ability to provide a good local fit to the low-exposure range.
Log-linear model with square-root transformation of cumulative exposure	0.08	462.8	Not statistically significant overall fit and poor visual fit.

<sup>a</sup> All with cumulative exposure as the exposure variable, except where noted, and with a 15-yr lag.

<sup>b</sup> p-values from likelihood ratio test, except for linear regression of categorical results, where Wald p-values are reported.  $p < 0.05$  considered “good” statistical fit;  $0.05 < p < 0.10$  considered “adequate” statistical fit if significant exposure-response relationships have already been established with similar models.

<sup>c</sup> AICs for linear models are directly comparable and AICs for log-linear models are directly comparable. However, for the lymphoid cancer data, SAS proc NLP (where NLP = nonlinear programming) consistently yielded –2LLs and AICs about 0.4 units lower than proc PHREG for the same models, including the null model, presumably for computational processing reasons, and proc NLP was used for the linear RR models. Thus, AICs for linear models

are equivalent to AICs about 0.4 units higher for log-linear models. No AIC was calculated for the linear regression of categorical results. *In order to make the AICs comparable for different models, the AICs for the linear models have been increased by 0.4 to reflect the discrepancy in the -2LogL values reported by the SAS proc NLP and by SAS PHREG (as italicized in this table).*

Table 38 shows that *neither the linear two-piece spline model with a “knot” at 1,600 ppm × days selected by USEPA (2016) nor the standard Cox regression model fit the data statistically significantly better than the null model (zero slope).* Additionally, the AIC values are very similar. *However, as use of a supra-linear model (i.e., the steep lower-dose slope) is not scientifically justified for low-dose extrapolation (see Section 3.4.1.4.1), the two-piece spline models are not considered for adoption;* nor are other models that have an inherently supra-linear dose-response over the exposure range (i.e., log-linear or linear models with log cumulative exposure or with square-root transformation of cumulative exposure). As for the linear model, it neither fits the data statistically better than the null model (at the 5% significance level) nor is consistent with USEPA’s/TCEQ’s expectation of sublinearity in the endogenous range, while the standard Cox regression model is consistent. Lastly, *no superior model fit is readily apparent visually based on accurate depictions of model fit to the actual underlying data* (Appendix 6). Thus, based on these and other considerations discussed in this DSD, *the TCEQ selects the standard Cox regression model for lymphoid cancer mortality.*

## **A5.2 Breast Cancer Incidence**

### **A5.2.1 Corrected AIC example for the linear spline model with knot at 5,750 ppm-days**

Similar to Table 38 above for lymphoid cancer, correct AIC values and p-values for all breast cancer incidence models in Table 4-14 of USEPA (2016) are summarized in the corrected USEPA Table 4-14 below, which is Table 39 in this DSD (i.e., the p-values and AIC values have been corrected to reflect the degree of freedom for the knot in the two-piece spline models and to reflect the likelihood difference between SAS procedures used for linear and log-linear models).



**Table 39: Corrected USEPA Table 4-14 - Models Considered for Modeling the EtO Exposure-Response Data for Breast Cancer Incidence in Females in the Subcohort with Interviews from the NIOSH and Health Incidence Study Cohort for the Derivation of Unit Risk Estimates**

Model <sup>a</sup>	p-value <sup>d</sup>	AIC <sup>b</sup>	USEPA Comments
<b>Two-piece spline models</b>			
Two-piece linear spline model (knot at 5,750 ppm × days)	0.0367	1,956.360 <sup>e</sup>	<b>SELECTED.</b> Good overall statistical fit and good visual fit, including local fit to low-exposure range; linear model; AIC within two units of lowest AIC of models considered.
Two-piece log-linear spline model (knot at 5,800 ppm × days)	0.0384	1,956.485	Good overall statistical fit and good visual fit, including local fit to low-exposure range; preference given to the two-piece linear spline model primarily because it has the advantageous property of linearity, but it also has a marginally better statistical fit (lower AIC).
<b>Linear (ERR) models (<math>RR = 1 + \beta \times \text{exposure}</math>)</b>			
Linear model with square-root transformation of cumulative exposure	0.0038	1,952.501	Good overall statistical fit and lowest AIC; low-exposure slope becomes increasingly steep as exposures decrease, and large unit risk estimates can result; preference given to the two-piece spline models because they have a better ability to provide a good local fit to the low-exposure range.
Linear model with untransformed cumulative exposure	0.0114	1,954.526	Good overall statistical fit but poorer local fit to low-exposure range than the two-piece spline models; higher AIC than selected model.
<b>Log-linear (Cox regression) models (<math>RR = e^{\beta \times \text{exposure}}</math>)</b>			
Log-linear model with square-root transformation of exposure	0.0049	1,953.028	Good overall statistical fit; low-exposure slope becomes increasingly steep as exposures decrease, and large unit risk estimates can result; preference given to the two-piece spline models because they have a better ability to provide a good local fit to the low-exposure range.
Log-linear model with (natural) log cumulative exposure	0.0302	1,956.176	Good overall statistical fit but poor local fit to low-exposure range; low-exposure slope becomes increasingly steep as exposures decrease, and large unit risk estimates can result; higher AIC than selected model.
Log-linear model (standard Cox regression)	0.0404	1,956.675	Good overall statistical fit but poor local fit to low-exposure range (too shallow); AIC exceeds that of selected model by >2.
<b>Linear regression of categorical results</b>			
Linear regression of categorical results, excluding the highest exposure quintile	---	--- <sup>c</sup>	Not statistically significant, as one might expect because the approach, which is based on categorical data, has low statistical power; preference given to models that treated exposure as a continuous variable and that also provided reasonable representations of the low-exposure region.

<sup>a</sup> All with cumulative exposure as the exposure variable, except where noted, and with a 15-yr lag, and all with exposure as a continuous variable except for the linear regression of categorical results.

<sup>b</sup> AIC = 2p-2LL, where *p* = number of parameters and LL = ln(likelihood), assuming two exposure parameters for the two-piece spline models.

<sup>c</sup> Not calculated.


<sup>d</sup> *p-values were calculated from EPA's Table D-2.*

<sup>e</sup> *AIC values for the two-piece spline models were adjusted to reflect the degree of freedom for the knot.*

Table 39 shows that *both the linear two-piece spline model with a "knot" at 5,750 ppm × days selected by USEPA (2016) and the standard Cox regression model selected by the TCEQ fit the data statistically significantly better than the null model (zero slope).* Additionally, the AIC values are very similar. *However, as use of a supra-linear model (i.e., the steep lower-dose component) is not scientifically justified for low-dose extrapolation (see Section 3.4.1.4.1), the two-piece spline models are not considered for adoption; nor are other models that have an inherently supra-linear dose-response over the exposure range (i.e., log-linear or linear models with log cumulative exposure or with square-root transformation of cumulative exposure).* While the linear model is not consistent with USEPA's/TCEQ's expectation of sublinearity in the endogenous range, the standard Cox regression model is consistent. Thus, based on these and other considerations discussed in this DSD, *the TCEQ will consider standard Cox regression modeling results for breast cancer incidence.*

## Appendix 6 Visual Fit to the Underlying NIOSH Data

Visual fit to the data was used by USEPA (2016) as a criterion for model selection. However, no appropriate visual comparison of model fit to the lymphoid cancer mortality data can be made based on Figure 4-3 (p. 4-21 of USEPA 2016) since the data shown are not even the data to which the models were fit. As such, USEPA Figure 4-3 (shown below as Figure 19 of this DSD) misrepresents model fit.



$e^{(\beta \cdot \text{exp})}$ :  $RR = e^{(\beta \cdot \text{exposure})}$ ;  $e^{(\beta \cdot \log \text{exp})}$ :  $RR = e^{(\beta \cdot \ln(\text{exposure}))}$ ;  $e^{(\beta \cdot \sqrt{\text{exp}})}$ :  $RR = e^{(\beta \cdot \sqrt{\text{exposure}})}$ ; categorical:  $RR = e^{(\beta \cdot \text{exposure})}$  with categorical exposures, plotted at the mean cumulative exposure; linear reg: weighted linear regression of categorical results, excluding highest exposure group (see text);  $1 + \beta \cdot \text{exp}$ :  $RR = 1 + \beta \cdot \text{exposure}$ ;  $1 + \beta \cdot \log \text{exp}$ :  $RR = 1 + \beta \cdot \ln(\text{exposure})$ ;  $1 + \beta \cdot \sqrt{\text{exp}}$ :  $RR = 1 + \beta \cdot \sqrt{\text{exposure}}$ ; spline100(1,600): Two-piece log-linear spline model with knot at 100 (1,600) ppm x days (see text); linspline100(1,600): Two-piece linear spline model with knot at 100 (1,600) ppm x days (see text). (Note that, with the exception of the categorical results and the linear regression of the categorical results, the different models have different implicitly estimated baseline risks; thus, they are not strictly comparable to each other in terms of RR values, i.e., along the y-axis. They are, however, comparable in terms of general shape.)

Source: Steenland reanalyses for males and females combined; see Appendix D (except for linear regression of categorical results, which was done by EPA).


Figure 4-3. Exposure-response models for lymphoid cancer mortality vs. occupational cumulative exposure (with 15-year lag).

### Figure 19: USEPA (2016) Figure 4-3


More specifically, the actual data underlying the model fits are the individual data, not the less refined categorical data shown in USEPA Figure 4-3. *Thus, because the model fits shown in USEPA (2016) Figure 4-3 are those to the individual data (and not the categorical data depicted), the figure does not actually indicate model fit to the modelled data at all.*

**Categorical rate ratios (RRs) should not be used for visually comparing models fit to individual data, particularly when appropriate statistical model fit criteria are available.** More specifically, estimated nonparametric RRs are calculated with respect to an underlying background hazard rate that is also estimated nonparametrically. The RRs of parametric models fit to the individual data are defined with respect to an underlying background hazard rate estimated by the model. However, the underlying background hazard rates estimated by the nonparametric RRs and the parametric model are generally different. A better comparison of models fit to the observed data is to use the predictiveness of the model; that is, the capability of the model to estimate the observed number of deaths with a certain degree of confidence (see Appendix 3). Moreover, visual interpretation of the consistency of categorical RRs with the shape/slope of a modelled dose-response can change as the number of exposure categories changes. For example, Figures 1-3 of Valdez-Flores and Sielken (2013) demonstrate, among other things, how the dose-response (i.e., dose-RR) slope for breast cancer mortality in the NIOSH cohort appears very steep when compared to only four exposure categories but seems more shallow when additional categories are added (i.e., up to 20 and 61 categorical RRs). In the present case, the overall dose-response appears ill represented by only a few categorical RRs, whether for breast cancer (see Figures 1-3 of Valdez-Flores and Sielken 2013) or lymphoid cancer (see below and supplementary material for Valdez-Flores and Sielken 2013).


The visual presentation of only a few exposure categories can blind the data user to the variability in the underlying dose-response data, and by corollary, preclude an appropriate visual assessment/comparison of model fit to the actual individual data. For example, in looking at all lymphoid cancer death RRs for the NIOSH cohort in the Figures 20-22 below (e.g., as opposed to a few categorical RRs represented by the red dots), objective examination of the model fits to the underlying data reveals no readily apparent superior fit by any particular model. What is most readily apparent is the loss of visualized information that results from only using the five grouped RRs (represented by the red dots) as in Figure 4-3 of USEPA (2016). The nonparametric rate ratios for individual cases (categorical) represented by the black circles in Figure 22 below form no discernable pattern that appears most consistent with any specific model (i.e., visual fit cannot be used to readily identify a model fit most representative of the actual data). In fact, other dose-responses could be added that would appear equally plausible and/or consistent with these high-dose occupational data.



**Figure 20: Lymphoid Cancer Death Categorical Rate Ratios (RRs) and Various Fitted Models for 15-Year Lagged Occupational Doses  $\leq 150,000$  ppm  $\times$  days (NIOSH cohort)**



**Figure 21: Lymphoid Cancer Death Categorical RRs and Various Fitted Models for 15-Year Lagged Occupational Doses  $\leq 40,000$  ppm  $\times$  days (NIOSH cohort)**



**Figure 22: Lymphoid Cancer Death Categorical RRs and the Cox Proportional Hazards and Two-Piece Spline (“knot” at 1,600 ppm × days) Fitted Models for 15-Year Lagged Occupational Doses ≤150,000 ppm × days (NIOSH cohort)**

The TCEQ contends that no defensible model fit conclusions may be drawn based on these more elucidating, transparent, and accurate depictions of model fit other than no superior model fit is readily apparent (e.g., see the three figures above and Figure 3 of Valdez-Flores and Sielken 2013). Appropriate statistical model fit criteria are evaluated elsewhere in this DSD (Section 3.4.1.3 and Appendix 5).

[Note: In these graphs, the dotted light blue line approximates the correct visual representation of the log-linear model (standard proportional hazards model) fit to the full NIOSH dataset after adjusting for the difference in baseline risks between the rate ratios and the log-linear model, thereby addressing USEPA’s following footnote to Figure 4-3 (p. 4-21 of USEPA 2016) concerning the visual incomparability of model fit to the data, “Note that, with the exception of the categorical results and the linear regression of the categorical results, the different models have different implicitly estimated baseline risks; thus, they are not strictly comparable to each other in terms of RR values, i.e., along the y-axis.” The model “ $RR_o * e^{(B * exp)}$ ” is an approximation of the log-linear model ( $e^{(B * exp)}$ ) adjusted through multiplying by the ratio of the underlying baseline hazard rate of the model to the underlying baseline hazard rate the nonparametric estimates.]